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ABSTRACT 
 
 
 
Alzheimer’s disease is characterized by the presence of amyloid plaques, made up 
primarily of Aβ peptides, and neurofibrillary tangles, containing hyperphosphorylated 
tau.  Aβ is generated by sequential proteolysis of the amyloid precursor protein (APP) by 
β- and γ-secretases.  The leading hypothesis of Alzheimer’s disease pathogenesis is the 
amyloid cascade hypothesis, which suggests that amyloid is central to the disease 
process.  However, tau pathology correlates more closely with cognitive dysfunction and 
follows a predictable anatomical course through the brain.  We hypothesize that if Aβ is 
upstream of tau pathology and tau pathology follows this predictable course through the 
brain, Aβ production may also propagate through the brain in an anatomical fashion.  In 
order to investigate this possibility, we examined two broad cellular processes induced in 
cells when exposed to Aβ, p53-dependent apoptosis and cell cycle activation.  We report 
that p53-dependent apoptosis is associated with a decrease in the Aβ and sAPPα and an 
increase in an alternative, caspase-cleaved fragment of APP, resulting from an apparent 
cleavage in the near extracellular domain of APP.  Mitosis is associated with the 
phosphorylation of both tau and APP, and increased production of Aβ.  Our results 
indicate that while p53-dependent apoptosis is not associated with increased 
amyloidogenesis, cell cycle activation increases Aβ production and may play a role in 
disease propagation.  Together, these findings suggest various treatment approaches, 
including cell cycle inhibition and disruption of APP endocytosis, which may decrease 
xi 
amyloidogenic processing.  Continued research into these potential approaches, coupled 
with earlier detection of the disease process, could lead to promising treatments for 
Alzheimer’s disease. 
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CHAPTER 1:  INTRODUCTION TO ALZHEIMER’S DISEASE 
 
 
 
1.1. Chapter Synopsis 
Here, we briefly discuss the long history of age-related dementia, from its early 
descriptions in the Greco-Roman period to the modern era.  A persisting theme in the 
history of dementia has been a debate as to whether dementia should be considered part 
of normal aging or a pathological state.  The initial description of the neuropathology of 
what would come to be known as Alzheimer’s disease (AD) began to set this disease 
apart from normal aging, and a further understanding of the specific pathology as well as 
the genetics of AD helped to solidify this distinction.  Today, much of what we 
understand about the pathological progression of AD still centers upon the pathological 
hallmarks first described by Alois Alzheimer  [1], namely the extracellular plaques and 
neurofibrillary tangles.  As the genetics of AD came to be better understood, amyloid-β 
(Aβ), the primary constituent of these extracellular plaques, emerged as a major player in 
the pathogenesis of AD.  Aβ  is produced via proteolysis of the amyloid precursor protein 
(APP).  Therefore, a complete understanding of the proteolysis of APP is central to our 
understanding of AD pathogenesis.  The studies in the chapters that follow aim to further 
this understanding through an investigation of how various pathological cellular states 
alter APP proteolysis.  In the course of these studies, we will discuss the identification of 
a novel proteolytic site, examine more closely the way in which this proteolytic event 
occurs, and examine the function of the fragments generated by this proteolytic cleavage. 
2 
1.2. A Brief History of Dementia from the Greco-Roman Period to the 19th 
Century 
The conceptualization of AD as it is currently understood has historical roots 
extending as early as the Greco-Roman period. These early scholars, not unlike scholars 
of more recent times, appear divided in their opinion as to whether dementia can be 
considered pathological as opposed to a normal part of aging. For example, Pythagoras 
described the end stage of life as the time when “the scene of mortal existence closes, 
after a great length of time, to which, very fortunately, few of the human species arrives. 
The system returns to the imbecility of the first epoch of the infancy [3].”  Here, 
Pythagoras implies that “imbecility” with advanced age is a natural facet of life’s 
progress, a view that seems to be shared by Aristotle, who suggests that elderly 
individuals be excluded from high administrative positions because  
There is not much left of the acumen of the mind which 
helped them in their youth, not of the faculties which served 
the intellect, and which some call judgment, imagination, 
power of reasoning and memory. They see them gradually 
blunted by deterioration and see that they can hardly fulfill 
their function [3]. 
The view that dementia is a natural part of aging, shared by Aristotle and 
Pythagoras, stands in contrast to that of Cicero, who in his essay De senectute states  
As wantonness and licentiousness are faults of the young 
rather than of the old, yet not of all young men but only the 
3 
depraved, so the senile folly called dotage is characteristic 
nor of all old men but only of the frivolous [4]. 
Galen, who in his “On Anatomical Procedures” (c. 200) described atrophy of the 
brain in very old animals such that “the brain is much too small to fill the cavity of the 
skull,” also shared Cicero’s view, describing patients  
In whom the knowledge of letters and other arts are totally 
obliterated; indeed they can’t even remember their own 
names … Even now it is seen, that on account of extreme 
debility in old age, some are afflicted with similar 
symptoms [4]. 
While it’s clear from these early writings that age-related cognitive decline was 
recognized even before the Common Era, it is also apparent that a conflict in thought 
exists, one side believing dementia to be a normal part of aging, and the other side 
recognizing it as a pathological state.  This conflict continued for centuries, and can be 
found in the writings of Chaucer and Shakespeare, with the latter making distinctions 
between “senile decay” and “plain madness” [3].  Progress in the conceptualization of 
dementia in the Middle Ages, the Renaissance, and in the centuries that followed was 
greatly hampered by a lack of understanding of the function of the brain – the 
predominant thought of most of this period was that mental functions were seated in the 
heart, not the brain.  It was not until the end of the 18th century that neuropathology was 
connected to disease, and with it the first description, made by William Cullen in 1776, of 
senile dementia as a medical entity involving “decay of perception and memory, in old 
age” [as quoted in 3].  In the following century, French psychiatrist Jean-Étienne 
4 
Dominique Esquirol, a student of Phillipe Pinel, established a formal distinction between 
“dementia” and “amentia”, the former being associated with disease and the latter being 
developmental in origin [3]. 
The classification of dementia as a disease paved the way for pathologists to take 
an interest in the brain and begin to assess the physiological changes associated with 
dementia.  With the vast advances in microscopy made during the 19th century and the 
concomitant development of several new staining methods, including the silver stain 
discovered by Camillo Golgi in 1873 and later improved by Max Bielschowsky in 1903 
[3], the stage was set for Alois Alzheimer’s landmark work identifying a new disease of 
the cerebral cortex.  
1.3. Initial Description of Alzheimer’s Disease Neuropathology:  The Case of 
Auguste D 
On November 4, 1906, Alois Alzheimer presented a case study in a lecture at the 
37th Conference of South-West German Psychiatrists in Tübingen [1].  In 1907, an 
original case report entitled “Über eine eigenartige Erkrankung der Hirnrinde” 
(translation: “A peculiar Disease of the Cerebral Cortex”), authored by Alois Alzheimer, 
was published in the Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche 
Medizin, a German journal for psychiatric and psychological medicine [See 5 for original 
German, 6 for translation to English].  This landmark case study marks the starting point 
in our understanding of the specific type of dementia which would later come to be 
known as “Alzheimer’s disease.” 
The case study presents the case of 51 year old Auguste D, who in 1901 was 
admitted to an insane asylum in Frankfurt after presenting with “ideas of jealousy toward 
5 
her husband” and “memory weakness” which rapidly progressed to the point that she 
could “no longer negotiate her way around her dwelling” [6].  The report proceeds to 
describe a woman “entirely disoriented to time and place,” occasionally mistrustful of 
doctors fearing they would assault her physically or sexually, apparently suffering from 
auditory hallucinations, and often loudly yelling [6].   
Physically, Frau D was largely normal, able to walk with a normal gait, use both 
hands well and had normal papillary and patellar reflexes.  However, she often spoke 
awkwardly, evidently unable to name common objects and often forgetting their purpose.  
As she deteriorated over the four and a half years of her illness, she ultimately became 
“completely dull, lying in bed with legs pulled up,” suffering from incontinence and 
ultimately succumbing to septicemia due to decubitus on April 8, 1906 [1, 6].   
The medical file of Auguste D, lost for nearly 90 years, was finally located in an 
archive in Frankfurt on December 21, 1995, 2 days after the 80th anniversary of Alois 
Alzheimer’s death.  As Alzheimer had left Frankfurt in 1903, the later stages of disease 
progression and her ultimate demise were not directly observed by Alzheimer.  Her file 
notes a “Tendency to develop a decubitus since the beginning of 1906.  Ulcerations at the 
sacral and left trochanteric area with a size of about 5 cm.  Very weak, high fever up to 
40°C within the last days.  Pneumonia in both inferior lobes” [1]. Upon her autopsy in 
Frankfurt, it was noted that she had moderate hydrocephalus, cerebral atrophy, 
arteriosclerosis of the small cerebral vessels, pneumonia in both inferior lobes, and 
nephritis [1].  Following her death and initial autopsy, Alois Alzheimer requested that her 
brain and medical records be sent to the Royal Psychiatric Clinic in Munich, where 
Alzheimer worked under the clinic’s director Emil Kraepelin.   
6 
Alzheimer’s description of the histopathology found in the brain of Auguste D, 
included in his 1907 paper, marks some of the most seminal writings on the subject of 
AD.  Alzheimer described an “evenly atrophic brain” with evidence of atherosclerosis, 
consistent with the changes observed at autopsy.  Sections of Frau D’s brain were silver 
stained using Bielschowsky’s method, leading to the first descriptions of the 
neurofibrillary tangles now deemed characteristic of the disease.  Alzheimer’s description 
states: 
Initially, through their particular thickness and particular 
stainability, a single one or a few fibrils come to prominent 
on the inside of an otherwise still “normal” appearing cell.  
Then, during further progression, many such fibrils 
running next to each other show changes in the same way.  
They subsequently fold together into dense bundles and 
move toward the cell surface.  Eventually, the nucleus and 
the cell disintegrate, and only a tangled bundle of fibrils 
indicates the place which had formerly been occupied by a 
ganglion cell [6]. 
This description defines multiple facets of what we now understand to be tau 
pathology, initial changes to the neuropil and formation of paired helical filaments, which 
ultimately accumulate into neurofibrillary tangles.  Upon the ultimate death of the cell, 
these tangles may remain as “ghost” or “tombstone” tangles, marking the site where the 
neuron had been.  Tau pathology was more recently and further described by Heiko 
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Braak, and, as the progression of this pathology follows a distinct anatomical path 
through the brain, is used today for neuropathological staging of disease progression [7].1 
Alzheimer also noted that “since these fibrils are stainable with other dyes than 
normal neurofibrils, a chemical transformation must have taken place; which appears to 
be the cause for the fibrils’ persistence after the demise of the cell [6],” reflecting on the 
changes to tau, now understood to be hyperphosphorylation and misfolding, that cause it 
to become stable and accumulate in sufficient quantity and conformation for silver 
staining.2 
In addition to his description of neurofibrillary tangles, Alzheimer also described 
“dispersed over the entire cortex and especially numerous in the upper layers … miliary 
foci; which are due to storage of a peculiar matter into the cortex.  It can be detected even 
without staining, but remains very refractory to dyes [6].”  This is consistent with the 
characteristic amyloid plaques, now considered central to the pathology of AD. 
It is worth noting that Alois Alzheimer was not the only individual to study the 
histopathology of dementia cases including Auguste D. In addition to Alzheimer, 
Gaetano Perusini, Oskar Fischer, and Francesco Bonfiglio also described 
histopathological changes in dementia.  The eponym “Alzheimer’s disease” was coined 
by Emil Kraepelin and first published in the 8th edition of his Handbook of Psychiatry in 
1910, four years after Alzheimer’s initial description at the conference in Tübingen [1].  
The conferring by Kraepelin, the most influential psychiatrist of the time and considered 
the father of modern scientific psychiatry, and his inclusion of “Alzheimer’s disease” in 
this important text ensured the longevity of the moniker.   
                                                 
1 For further discussion of tau pathology, see section 1.4.2. 
 
2 For further discussion of amyloid pathology, see section 1.4.1. 
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Following the description by Alois Alzheimer in 1906 and inclusion of 
“Alzheimer’s disease” in the Handbook of Psychiatry in 1910, AD gained recognition as 
a psychiatric disease with an organic basis, but it would be nearly three-quarters of a 
century before the composition of the “miliary foci” described by Alzheimer would be 
understood, enabling further study into AD pathogenesis. 
1.4. The Neuropathology of Alzheimer’s Disease 
As is often the case in science, the initial observation of the pathological 
hallmarks of AD came long before the technology was available to further understand 
them.  Technological advances in proteomics and genomics of the mid-twentieth century 
enabled determination of the amino acid sequence of individual proteins, as well as 
mapping these proteins to specific genes.  Application of these technologies during the 
1980s and 1990s has resulted in vast progress in understanding AD neuropathology, and 
consequently AD pathogenesis. 
1.4.1. Amyloid Plaques 
In 1984, the constitutive protein of senile plaques was isolated using high 
performance liquid chromatography, and the protein sequenced for the first time [8].  The 
sequence obtained from this initial sequencing was: 
NH2-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln3-Val-
His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val---
COOH [8]  
                                                 
3 The sequence published by Glenner and Wong in the paper cited here identifies the eleventh amino 
acid of Aβ as Gln.  Subsequent work from the same lab and others has resulted in a consensus of 
Glu at this position. 
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This sequence is now appreciated to be the first 24 amino-acids of the amyloid-β 
peptide (Aβ), a proteolytic fragment of the amyloid precursor protein (APP) which varies 
in length but is most commonly 40 or 42 amino acids long.  Upon its sequencing, there 
was no homology found with any of the proteins that had been sequenced up until that 
point.  The discovery of this novel protein as specifically aggregated in AD brain raised 
the hope that antibodies might be generated against it, potentially enabling detection of 
the disease state by the presence of these proteins in the patients sera by 
radioimmunoassay [8].   This, however, did not prove to be a viable approach, as it was 
not appreciated at the time that the peptide isolated and sequenced as the constituent of 
amyloid plaques was in fact a proteolytic fragment of a larger protein expressed 
throughout the body.4 
In addition to Aβ, the primary component of plaques, many proteins have been 
observed to be associated with Aβ plaques.  Aβ is notoriously “sticky”, and deposits of 
Aβ proteins tend to also contain a variety of other proteins.  A 2004 study utilizing laser 
capture microdissection of postmortem AD brain tissue found 26 proteins enriched 
specifically in amyloid plaques.  These included collagen, tau, glial fibrillary acidic 
protein, vimentin, 14-3-3, dynein, phosphofructokinase, and Ubiquitin-activating enzyme 
E1, among others [9].  It is not clear from this study, however, whether these proteins are 
aggregated extracellularly along with Aβ within the plaque, or if these protein are in fact 
contained within the surrounding cells and represent a cellular response to the presence of 
the plaque.  Indeed, dystrophic neurites and activated astrocytes are often found in the 
vicinity of these plaques, and plaques are often decorated with microglia [10]. 
                                                 
4 The proteolysis of the amyloid precursor protein will be discussed further in section 1.7. 
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1.4.1.1. Factors that Promote Amyloid Deposition 
Of particular interest in understanding the formation of amyloid plaques are 
factors that promote oligomerization of Aβ peptides to form fibrils and ultimately deposit 
into amyloid plaques.  The fibrillization of Aβ is controlled by many factors in the local 
microenvironment including pH, temperature, and the presence of metal ions.  
Immunoreactivity of Aβ to certain antibodies, specifically antibodies that recognize Aβ9-
14 or Aβ17-21 (6F/3D and 4G8, respectively) are less able to detect Aβ at lower pHs, 
suggesting that the accessibility of the antibody to its epitope on the Aβ peptide is 
reduced due to changes in Aβ conformation.  Susceptibility to degradation by proteinase 
K is also reduced at lower pHs, suggesting that low pHs are associated with an 
oligomeric state [11]. The immunoreactivity of Aβ using these same antibodies is also 
sensitive to temperature – they are most reactive at normal body temperatures and 
reactivity tends to decrease at febrile temperatures [12], suggesting that Aβ may have an 
increased propensity for aggregation at higher body temperatures.   
1.4.1.1.1. Metal Ions 
The contribution of metal ions to the oligomerization of Aβ has been well 
established, but its importance in the disease process has been somewhat controversial.  
Copper ions have been shown to bind with high affinity to histidine and tyrosine residues 
(potentially involved residues from the Aβ peptide include H6, H13, H14, and Y10) [13].  
This facilitates crosslinking of Aβ peptides via their tyrosine residues and promotes 
oligomer formation [14].  Interestingly, Aβ also is capable of catalyzing the reduction of 
Cu(II) and Fe(III), which results in the production of H2O2 and potentially contributes to 
oxidative stress [15, 16].  While copper appears to be capable of cross-linking peptides 
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into oligomers, it also, somewhat incongruously, has been shown to prevent the 
formation of thioflavin T positive, β-sheet rich aggregates of Aβ, but enhances 
neurotoxicity.  This suggests that copper promotes the formation of small oligomers of 
Aβ, but not plaque deposition.  These small oligomers, however, seem to be particularly 
toxic [17, 18].  
In addition to copper, zinc has been shown to promote the aggregation of Aβ, 
which has been hypothesized to result in a localized disruption in zinc homeostasis [19, 
20].  Indeed, levels of zinc present in the cortices and hippocampi of Tg2576 transgenic 
mice are elevated as compared to controls.  Aβ plaques may effectively sequester zinc 
extracellularly, reducing intraneuronal zinc and impairing microtubule stability. 
 The role of aluminum in AD has also been a subject of some controversy, which 
has garnered some attention from the media and worked its way into mainstream culture, 
leading to concerns regarding exposure due to use of deodorants, anti-perspirants, 
aluminum cookware, and aluminum cans.  A potential connection between aluminum and 
AD first became apparent in the 1960s, when Igor Klatzo described the induction of 
cerebral neurofibrillary degeneration, similar to that seen in AD, by aluminum [21].  
Aluminum has been shown to induce conformational changes in Aβ that reduce the α-
helical content of the peptide and may enhance its aggregation [22].  Aluminum has also 
been shown to cause apoptotic cell death in neurons and glia as well as inhibit LTP in 
vitro. A lack of a significant difference in aluminum levels between AD patients and 
controls, among other problems, resulted in significant debate over the importance of 
aluminum in AD [23].  In support of aluminum as a potential disease modifier, studies in 
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transgenic mice overexpressing APP (Tg2576) suggest that there is increased plaque 
deposition in mice who are fed an aluminum-enriched diet as compared to controls [24]. 
1.4.1.1.2. Aβ Associated Proteins 
In addition to metal ions, deposition of amyloid can also be affected by protein-
protein interactions.  Proteins that bind Aβ and stabilize a β-pleated sheet conformation 
can facilitate its aggregation into plaques [25].  Such proteins include α1-
antichymotrypsin, ApoE, C1q complement factor, and GM-1 gangliosides. α1-
Antichymotrypsin is an acute-phase serine protease inhibitor secreted by activated 
astrocytes in response to stimulation by IL-1β [26].  It has been shown to be associated 
with amyloid plaques in AD [27], but is not found in other amyloidoses that do not 
involve the Aβ peptide [28].  α1-Antichymotrypsin has been shown to promote 
fibrillization of Aβ [29], as well as promote deposition of Aβ into plaques, as transgenic 
mice that express both human APP(V717F) and α1-antichymotrypsin have increased 
plaque load as compared to transgenic mice that express APP(V717F) without α1-
antichymotrypsin [30].  ApoE4 acts similarly to α1-antichymotrypsin in that it also binds 
to and promotes the fibrillization of Aβ in vitro [29] and is associated with higher plaque  
loads in older mice, with synaptic deficits occurring even in younger mice.  ApoE4 is 
also the most common and significant genetic risk factor for sporadic AD, which will be 
discussed later in this chapter.5 
Another protein which has been shown to localize to amyloid plaques is the 
complement factor C1q [31].  This protein is part of the C1 complex, and the C1q subunit 
itself binds to a ligand and, provided there are no inhibitors of the process also present, 
                                                 
5 Genetic risk factors for sporadic AD are discussed in section 1.6.4. 
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activate the complement cascade [32].  C1q can bind to amyloid, activating an immune 
response to the aggregated peptides.  It has also been show to promote the aggregation of 
Aβ both in vivo and in vitro. Incubation of amyloid in the presence of C1q results in 7x 
more aggregation than amyloid incubated alone.  Further, injection of C1q into the brains 
of APP+PS1 transgenic mice leads to an increase in Congo red-positive fibrillar amyloid 
deposits in vivo [33]. 
GM-1 gangliosides are also elevated in AD and have been shown to both bind Aβ 
and localize to Aβ plaques in AD.  The binding of GM1 gangliosides to Aβ results in the 
conversion from a predominately random-coil tertiary structure to a structure rich in β-
sheet, which facilitates oligomerization.  GM1 gangliosides are generally appreciated for 
their neuroprotective functions; while they are not neurotrophic in and of themselves, 
they do appear to potentiate neurotrophic effects [34].  The binding of GM1 gangliosides 
in amyloid plaques may result in the sequestration of these molecules in plaques, 
preventing them from mediating neurotrophism.  GM1 gangliosides are also associated 
with certain immune responses – cholera toxin binds specifically to GM1 gangliosides, 
and antibodies against GM1 gangliosides are upregulated in the autoimmune disease 
Guillain-Barré syndrome.   
1.4.1.2. Factors that Impair Aβ Clearance 
In addition to factors that affect its deposition, the amount of Aβ present in the 
brain is also modulated by Aβ clearance.  Aβ clearance is modulated predominately by 
microglia, phagocytic cells capable of phagocytosing and degrading Aβ.  Aβ can be taken 
up into cells through scavenger receptors such as SRA, CD36, and RAGE, and degraded 
by Aβ degrading enzymes such as insulysin, neprilysin, and MMP9.  This is thought to 
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be more efficient in unaffected individuals, but as the disease progresses these microglia 
enter a more pro-inflammatory state associated with increased production of IL-1β and 
TNF-α, and the expression of genes associated with Aβ clearance decreases, while 
expression of genes associated with aggregation increases.  This state of “malactivation” 
results in impaired amyloid clearance and shifts the balance of amyloid dynamics toward 
plaque deposition [35]. 
Plaque load is ultimately determined by the balance of factors affecting Aβ 
production via proteolysis, oligomerization and deposition, and clearance.  When factors 
that increase Aβ production or oligomerization outweigh those mediating degradation and 
clearance, amyloid plaques form.  The formation of plaques, however, may not correlate 
directly with toxicity – the plaques may actually serve to sequester more toxic forms of 
amyloid. The dichotomy apparent in data regarding Aβ toxicity in the presence of copper, 
for example, illustrates this phenomenon.  Copper can cross-link peptides into oligomers 
and confer neurotoxicity, but the formation of thioflavin T positive, β-sheet rich 
aggregates is actually decreased.  This suggests that it is the small oligomers that confer 
this copper-mediated toxicity [17, 18].   
Further support for the notion that small oligomers, and not plaques per se, are 
responsible for the deficits seen in AD comes from the observation that the addition of 
clusterin, another protein that can bind Aβ and associate with amyloid plaques, to PC12 
pheocromocytoma cells in culture reduces amyloidogenesis while, seemingly conversely, 
increasing cell toxicity [36, 37].  The case for small oligomers as toxic agents also 
extends to in vivo models, as synapse loss in transgenic mice expressing human APP in 
the absence of amyloid deposits [38], and memory loss in transgenic mice can be 
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reversed even when amyloid is not removed [39, 40].  This evidence has led to the 
oligomer hypothesis, which suggest that memory loss early in the disease process can be 
attributed to oligomer-induced destruction of synapses, with later stages of the disease 
associated with oligomer-induced cellular degeneration and death [For review, see 41].  
This places small oligomers of Aβ at the center of disease pathogenesis, with plaques 
acting, potentially, as a means of sequestration of these toxic oligomers.  The hypothesis 
that amyloid is central to the disease process of AD will be discussed further in section 
1.5. 
1.4.2. Neurofibrillary Tangles 
The other major histopathological hallmark of AD are neurofibrillary tangles, the 
“tangled bundles of fibers” [5] that appear, eventually overtaking the neurons until only 
“ghost” or “tombstone” tangles remain.  The formation of neurofibrillary tangles (NFTs) 
involves the hyperphosphorylation of the microtubule associated protein tau.  When tau 
becomes hyperphosphorylated, it falls off of microtubules and forms fibrils – a 
conformation referred to as a paired helical filament (PHF) [42].  PHF accumulates 
intracellularly, forming neurofibrillary tangles.  The dissociation of tau from 
microtubules and subsequent  formation of NFTs may ultimately result in destabilizing 
changes to the microtubules that can impair axonal transport, leading to synaptic 
dysfunction and ultimately to neurodegeneration [43]. 
The normal physiological function of tau is the stabilization of microtubules.  The 
ability of tau to bind to microtubules is regulated by serine/threonine directed 
phosphorylation [44], though it may also be affected by glycosylation and other post-
translational modifications [45-47].  The phosphorylation of tau is typically higher during 
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development, and is generally low in the differentiated cells of the adult brain.  However, 
in the case of some tauopathies, including AD, the tight regulation suppressing tau 
phosphorylation is lost, and tau becomes aberrantly hyperphosphorylated.   
Factors that directly affect the phosporylation of tau may include, naturally, the 
upregulation or aberrant activation of kinases responsible for phosphorylation of tau as 
well as the downregulation of phosphatases responsible for dephosphorylation.  At least 
30 different serine/threonine residues on tau may be phosphorylated by a number of 
different kinases, including proline directed kinases such as mitogen activated protein 
kinase (MAPK), glycogen synthase kinase 3 (GSK3), cyclin dependent kinase 5 (cdk5), 
Jun N-terminal kinases /stress-activated protein kinase (JNK/SAPK), and p38 mitogen-
activated protein kinase (p38 MAPK), and non-proline directed kinases such as cyclic 
AMP-dependent protein kinase, protein kinase C (PKC), microtubule affinity regulating 
kinase (MARK) and calcium/calmodulin-dependent protein kinase (CaMK) [43].  The 
phosphatases implicated in regulating the phosphorylation state of tau include protein 
phosphatases 1, 2A, 2B, and 2C [43, 48].   
In addition to phosphorylation, other covalent modifications to tau also occur, 
though their relevance to the pathological state of tau is not clear.  These modifications 
include gycosylation, glycation, ubiquitinylation, sumoylation, and nitration [49].  
Furthermore, tau may also undergo proteolysis by calpain, cathepsin-L, or caspase-3, and 
the cleaved forms of tau generated seem to be particularly toxic to cells [50, 51].  
Cleavage of tau by calpains generates a 17 kD species that in some studies seems to be 
associated with toxicity, but is not prone to aggregation.  Tau cleaved by caspase-3 or 
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degraded by lysosomal proteases, however, does show a greater propensity towards 
aggregation [52-55]. 
The specific mechanism of tau-mediated neurotoxicity has not been fully 
established.  Some mechanisms that have been proposed and garnered support include the 
hypothesis that an increase in bound tau can inhibit the attachment of motor proteins 
resulting in a slowing of axonal transport and ultimately impeding cellular function.  
Further, cleavage of tau by caspases and lysosomal proteases result in the generation of a 
fragment in which the repeat domain of tau is exposed [51].  This fragment is particularly 
prone to aggregation, and may result in the formation of toxic neurofibrils [51].  The 
accumulation of tau is also dependent on a failure of cytosolic chaperones to facilitate tau 
clearance [56].  Of course, there may also be other, as-yet-unidentified mechanisms 
contributing to tau toxicity.   
The complex interactions between phosphorylation, ubiquitinylation, and tau 
proteolysis are still being elucidated.  It does appear that the phosphorylation of tau at 
specific sites, such as S262/S356, impedes proteasomal degradation, as the CHIP/Hsp90 
complex does not recognize and ubiquitinylate this form [57].  The failure of tau turnover 
can lead to an increase in the accumulation of phospho-tau species, which ultimately 
aggregate within the cell.   
1.5. The Amyloid Cascade Hypothesis 
The relative importance of Aβ and tau, historically, has been the focus of much 
debate within the field.  The most widely accepted hypothesis regarding AD pathogenesis 
is the amyloid cascade hypothesis, and this hypothesis has dominated AD research for the 
past 20 years [58, 59].  According to this hypothesis, the production and/or accumulation 
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of Aβ is central to disease pathogenesis.  The major support for the amyloid cascade 
hypothesis is in the genetics of familial AD, which will be discussed in detail in section 
1.6.  Mutations in APP and the presenilins (the catalytic portion of the γ-secretase 
enzyme complex, one of the enzymes responsible for the cleavage of APP into Aβ, as 
discussed in section 1.7) result in an increase in the production of Aβ42 throughout life.   
In individuals without familial disease-causing mutations, failures in Aβ clearance lead to 
elevated levels of Aβ. This results in the accumulation of oligomerized Aβ throughout the 
parenchyma, which has delirious effects on synaptic function.  The Aβ aggregates into 
plaques, resulting in microglial activation and astrocytosis.  The ensuing inflammatory 
responses lead to oxidative injury.  This oxidative stress is also associated with altered 
kinase and phosphatase activity that leads to the hyperphosphorylation of tau, eventually 
causing the formation of neurofibrillary tangles and ultimately cell death. [60] 
1.5.1. In Vivo Evidence in Support of the Amyloid Cascade Hypothesis 
Central to the amyloid cascade hypothesis is the notion that amyloid production 
precedes tangle formation.  This notion has been difficult to show conclusively, as most 
models of AD utilize overexpression of amyloid, tau, or both in order to induce disease-
like conditions.  One important study addressing the question of whether amyloid does 
indeed precede tau deposition utilized triple transgenic mice (carrying mutations in PS1, 
APP, and tau) and carefully assessed the mice at different ages, finding that amyloid 
deposits in the cortex were visible before the first evidence of tau pathology [61].  
Further, while mutant tau expressing animals develop tau pathology in the absence of Aβ 
overexpression, when these mice are crossed with APP transgenic mice pathology is 
enhanced [62].  Injection of Aβ42 fibrils into the brains of mutant tau transgenic mice also 
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induces enhanced tau pathology, with five times more amygdalar neurons containing 
neurofibrillary tangles in Aβ42-injected mutant tau mice as compared to those not injected 
with Aβ [63].  Finally, clearing Aβ using passive immunotherapy in triple transgenic 
mice results in first a decrease in Aβ followed by a decrease in early phospho-tau species 
[64].  Taken together, the evidence from these transgenic mouse models suggests that Aβ 
can indeed induce changes in tau pathology, with increased levels of Aβ enhancing 
pathology and decreased levels of Aβ associated with a decrease in some species of 
phospho-tau [65]. 
While the evidence from these in vitro models offers significant support for the 
amyloid cascade hypothesis, the major limitation is that the models utilize gross 
overexpression of wild type human or mutant human protein in the brains of transgenic 
mice.  While they are particularly useful for examining the downstream effects of 
increased levels of these proteins on other systems, they do not address many aspects of 
the human condition, especially anything that may be upstream of Aβ pathology.  
Further, in the case of doubly or triply transgenic mice expressing both tau and APP, each 
pathology would develop in the absence of the other gene.  While use of these models 
allow us to study the interaction between the two pathologies to some extent, because 
these pathologies are essentially driven by the overexpression or mutation present the 
external validity of the models are somewhat questionable.  Finally, with the exception of 
the htau mice developed by Karen Duff and Peter Davies [66], most models of tau 
pathology used in AD research utilize mutations in tau, such as those seen in tauopathies 
like frontotemporal dementia.  These mutations are not found in AD patients, so the 
20 
specific mechanisms of aggregation of tau may be very different in these transgenic 
models than in the human condition. 
1.5.2. In Vitro Evidence in Support of the Amyloid Cascade Hypothesis 
While they do not completely solve the problem of external validity and 
applicability to the human condition, in vitro models are often more appropriate for 
working out specific intracellular mechanisms with regard to how Aβ may induce tau 
pathology.  In vitro studies have been seminal in showing that tau is essential for Aβ-
induced neurotoxicity – neurons expressing either human or mouse tau are susceptible to 
Aβ induced degeneration, while neurons from tau-knockout mice are not [67].  Two 
proposed mechanisms by which Aβ may mediate its toxicity are via oxidative stress 
and/or via receptors on the neuronal membrane [48].  As discussed earlier in section 
1.4.1.1.1, Aβ oligomerization, when stabilized by binding to metals such as copper and 
zinc, can result in the formation of H2O2.  H2O2 and other reactive oxygen species induce 
oxidative stress on cells, including peroxidation of lipids, oxidation of amino acids in 
proteins, DNA damage, and disruption of mitochondrial respiration [48].  Mitochondrial 
disruption starves cells of energy and results in internal generation of additional free 
radicals, which can also ultimately result in the induction of apoptosis.   
While the oxidative stress pathway places Aβ clearly upstream of cell death, the 
connection to hyperphosphorylated tau is less clear. Reactive oxygen species may induce 
activation of JNK and p38 MAPK, which may be involved in the phosphorylation of tau, 
though the specific pathway by which oxidative stress results in increased tau 
phosphorylation requires further investigation. 
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In addition to oxidative stress related pathways, some evidence exists that the 
effect of Aβ on tau phosphorylation may occur via a receptor-mediated transduction 
pathway.  Aβ can bind receptors on the cell surface and induce signaling via multiple 
cellular pathways.  For example, binding of Aβ to amylin receptor 3 can induce activation 
of PKA, MAPK, Akt, and cFos pathways [68].  APP can also bind to death receptor 6, 
triggering cell death during trophic factor deprivation (which also induces proteolysis via 
an amyloidogenic pathway) [69].  Further, Aβ exposure can induce the activation of 
GSK-3.  GSK-3 inhibition prevents Aβ induced cell death, and GSK-3 is a known tau 
kinase [70].  Though the specific pathways involved in this activation have not yet been 
entirely mapped out, Aβ does seem to be effective in inducing both cell death and 
activating tau kinases.  Therefore, both the in vivo work presented in the previous section 
and the in vitro work presented here strongly support the notion that Aβ may indeed be 
the instigator of further disease pathology, as suggested by the amyloid cascade 
hypothesis. 
1.6. The Genetics of Alzheimer’s Disease 
While the in vitro and in vivo evidence presented above provides strong support 
for this hypothesis, the longest standing and perhaps strongest support for the amyloid 
cascade hypothesis comes from the evidence that suggested the hypothesis in the first 
place – the genetics of familial AD.  Familial AD (FAD) is an early-onset form of AD 
that accounts for about 10% of cases.  FAD involves the presence of at least one of 
several genetic mutations that result in the development of AD.  Importantly, all FAD 
cases result from either mutation or duplication of the APP gene, or gain of function 
mutations in one of the enzymes responsible for the generation of Aβ from APP, 
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specifically presenilin 1 or presenilin 2 [71].  The fact that no mutations have been 
identified in the NFT-associated protein tau in the brains of AD patients, while mutations 
in APP that confer both increased and decreased risk, as will be discussed in this section, 
have been identified, stands in strong support of the amyloid cascade hypothesis. 
1.6.1. Trisomy 21 and APP Duplication 
The gene for APP is located on chromosome 21.  Down’s syndrome (DS) arises 
from missegregation of chromosome 21 in the fertilized ovum, resulting in trisomy 21 in 
every cell of the body.  This results in a duplication and consequent overexpression of 
APP and an increase in the proteolytic fragment Aβ, leading to plaque formation and 
development of AD pathology.  All adults with trisomy 21 over the age of 40 years 
develop neuropathology similar to AD [72], thought to be primarily due to the extra 
“gene dosage” and consequent overexpression of APP.   
It should be noted, that while individuals with complete trisomy 21 always 
present with AD like pathology, there are individuals with most major clinical features of 
DS without trisomy of the entire chromosome but rather a duplication of a small part of 
the chromosome.  The smallest region thus far identified that results in clinical features 
reminiscent of DS is a 4.3 Mb region spanning 21q22.13-21q22.2 [73], a region which 
does not include APP  (located at 21q21.2) but does include the kinase Dyrk1A, which is 
known to phosphorylate APP and tau.  This family, thus far mother and daughter, 
presents with facial features reminiscent of DS, speech deficits, and mild intellectual 
disability [73].  Due to the rarity of the genetic anomaly and the young age of the patients 
identified as carriers, it is not yet clear if individuals with partial trisomy present with 
progressive neurodegeneration, though cognitive dysfunction is evident.   
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A large genetic screening of a UK population found that APP duplication was 
significantly associated with early onset dementia as well as an increased risk of seizures.  
This screen did identify one family in which two individuals were identified as affected 
or probably affected with early onset dementia where the region duplicated included the 
APP gene but not the so-called “DS critical region” identified in individuals presenting 
with DS-like phenotype due to partial trisomy 21 [74].  Another screening of a Swedish 
population identified an individual with AD who also had a duplication of a very small 
portion of chromosome 21 that included the APP gene but not the DS critical region [75].  
Though duplication of such a small locus is very rare, the type of early onset dementia 
seen in patients with APP duplication in the absence of DS critical region strongly 
suggest that APP is central to the pathogenesis of individuals with AD as well as the 
progressive neurodegeneration observed in DS individuals. 
1.6.2. Mutations in APP that Increase Risk for AD 
In addition to duplication of the APP gene, various pathogenic mutations which 
result in early onset AD have been identified along the APP gene.  These include 25 
mutations, shown in Table 1.1 [2], which are mostly aggregated in two regions along the 
peptide – in the vicinity of amino acid 671 or in the vicinity of amino acid 717 (according 
to the 770 isoform).  Importantly, as will be discussed later in this chapter (section 1.7), 
these locations are the points at which APP is cleaved in order to form the Aβ peptide.  
These mutations increase the propensity for APP to be cleaved to form Aβ or, as is the 
case for many of the mutations at amino acid 717 (the γ-secretase site mutations) increase 
the ratio of the more toxic form Aβ42 to the less toxic Aβ40.  Particularly notable is the 
Austrian mutation, T714I, which results in an 11-fold increase in the Aβ42:Aβ40 ratio [76]. 
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Table 1.1.  Mutations in APP resulting in early onset AD. 
 
Mutation Name First Reported 
KM670/671NL Swedish Mullan et al., 1992 
D678N Tottori Wakutani et al., 2004 
E682K Leuven Browers et al., 2008 
A692G Flemish Hendriks et al., 1992 
E693K Italian Tagliavini et al., 1999 
E693Q Dutch Levy et al., 1990 and Van Broeckhoven et al., 1990 
E693Δ - Tomiyama et al., 2008 
E693G Arctic Kamino et al., 1992 
D694N Iowa Grabowski et al., 2001 
L705V - Obici et al., 2005 
A713T - Giaccone et al., 2002 
T714A Iranian Pasaler et al., 2002 
T714I Austrian Kumar-Singh et al., 2000 
V715A German De Jonghe et al., 2001 
V715M French Ancolio et al., 1999 
I716T - Terrini et al., 2002 
I716V Florida Eckman et al., 1997 
I716F - Clarimón et al., 2008 
V717F Indiana Murrell et al., 1991 
V717G - Chartier-Harlin et al., 1991 
V717I London Goate et al., 1991 
V717L - Murrell et al., 2000 
T719P - Ghidoni et al., 2009 
L723P Australian Kwok et al., 2000 
K724N Belgian Theuns et al., 2006 
 
  Twenty-five mutations, listed here, have been identified as resulting in early onset 
AD.  Importantly, these mutations are located predominately in the vicinity of amino 
acid 671 and amino acid 717, the two sites at which APP is cleaved in order to form the 
Aβ peptide.  This list has been compiled from the AD Mutations database accessible at 
http://www.molgen.vib-ua.be/ADMutations [2]. 
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The plaques in the brains of these individuals are diffuse, predominately consist of Aβ42, 
and do not contain detectable levels of Aβ40.  As diffuse, non-fibrillar, small oligomeric 
Aβ is thought to be the most toxic form; this strongly implicates Aβ42 as a particularly 
pathogenic species, and places considerable focus on the enzyme responsible for its 
production, γ-secretase. 
1.6.3. Mutations in Presenilins that Increase Risk for AD 
The γ-secretase complex is made up of four proteins:  presenilin, nicastrin, 
anterior pharynx defective 1 (Aph1), and presenilin enhancer 2 (Pen2) [77].  The catalytic 
subunit of the γ-secretase complex is presenilin.  Vertebrates have two presenilin genes 
encoding two different presenilins, PS1 and PS2, either of which may be incorporated 
into the γ-secretase complex [78].  A total of 185 mutations have been identified in PS1 
and 13 in PS2, making presenilin mutations far and away the most common mutations 
seen in early onset familial AD.    The mutations tend to cluster in exon 8, which forms 
the long acidic loop between the sixth and seventh transmembrane domains, suggesting 
that this structural feature is likely important in the enzyme’s function  [79]. 
Other notable mutations in presenilin include the delta 9 mutation, a mutation that 
affects mRNA splicing such that exon 9 is deleted [80].  This mutation results in a unique 
phenotype similar in some ways to the Austrian mutation in APP described above, in 
which there is an increase in the Aβ42:Aβ40 ratio, resulting in diffuse plaques [81]. 
1.6.4. Mutation in APP that Decreases Risk for AD 
To date, only one genetic mutation has been identified which renders protection 
against AD.  This very rare mutation, APP(A673T) was identified from a population of 
1,795 Icelanders and is located adjacent to the β-secretase cleavage site, which is 
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involved in Aβ production. This mutation decreases the production of Aβ by 40% in 
vitro, and confers decreased risk for developing AD.  This strongly supports both the 
amyloid cascade hypothesis as well as the notion that inhibition of β-secretase activity 
should prevent disease progression [82]. 
1.6.5. Genetic Mutations in Tauopathy 
Importantly, there are known genetic mutations in tau that yield an AD 
phenotype.  However, transgenic mice overexpressing APP or mutant APP is not 
generally sufficient to produce tau pathology in mice.  While hyperphosphorylation of tau 
is sometimes seen, formation of neurofibrillary tangles and neurodegeneration is rare, 
most likely due to differences in tau between mice and humans.  Mice tend to produce 
more 3R tau than 4R tau in adulthood, while in humans the pattern is reversed.  4R tau 
has a higher propensity for aggregation as compared to 3R tau, making human tau more 
prone to forming neurofibrillary tangles when phosphorylated as compared to mouse tau.   
Mutations in tau, while not associated with AD in humans, have been associated 
with frontotemporal dementia, which, like AD, features hyperphosphorylated tau, 
neurofibrillary tangles, and progressive neurodegeneration.  Because the tau pathology 
observed in frontotemporal dementia is similar to that observed in AD and AD mice do 
not develop tau pathology with expression of human wild-type or mutant APP, mutations 
in tau have been “borrowed” from frontotemporal dementia for use in AD mouse models.  
The tau mutation most commonly used in animals for the study of AD is the P301L 
mutation.  This mutation results in the formation of neurofibrillary tangles as well as 
significant neuron loss in the hippocampus, gross atrophy of the forebrain, and decreased 
brain weight [83]. 
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1.6.6. Genetic Risk Factors for Sporadic AD 
Importantly, 90% of AD cases are not associated with known genetic mutations.    
This is intriguing as it suggests that mechanisms other than those directly related to APP 
and its proteolysis may contribute to the production, deposition, or impaired clearance of 
Aβ in the majority of AD cases.  There have been many genetic polymorphisms which, 
through genome wide association studies, have been shown to result a modestly increased 
risk of AD.  These include the genes encoding bridging integrator 1, clusterin, 
complement receptor 1, ABCA7, phosphatidylinositol binding clathrin assembly protein, 
and CD33, among others.  Together these implicate mechanisms including endocytosis 
and complement system, which likely influence Aβ generation6 and clearance, 
respectively.  
The most important genetic risk factor for late onset AD, however, is the 
apolipoprotein E4 allele, which confers a three times greater risk of developing AD.  The 
specific mechanism by which ApoE4 increases the risk is still not entirely clear.    Some 
candidate mechanisms include inflammation-induced vascular damage [84], increased Aβ 
levels [85, 86], changes in Aβ fibrilization [87], brain hypometabolism independent of 
Aβ [88], and impaired Aβ clearance [89]. 
1.7. Understanding APP Proteolysis 
1.7.1. Classical Processing of APP:  Amyloidogenic and Non-Amyloidogenic 
Pathways 
Altered proteolysis of APP is a central event in AD pathogenesis.  APP is cleaved 
sequentially by β- and γ-secretases to generate Aβ fragments that are 38-43 amino acids 
                                                 
6 The role of endocytosis in Aβ generation is further discussed in section 1.7.1.2. 
28 
in length.  These fragments, as described in section 1.4.1., are the primary component of 
amyloid plaques and the initiators of the amyloid cascade [90, 91]. β-secretase cleaves 
APP between amino acids 671 and 672, while γ-secretase cleaves in the vicinity of amino 
acids 711-714 (based on APP770).  It is the γ-secretase cleavage that determines the length 
of the Aβ fragment and thus its propensity for aggregation.  Cleavage of APP by β- and 
γ-secretases is referred to as amyloidogenic processing because it results in the formation 
of amyloid-β (Figure 1.1, amyloidogenic pathway).  The major β-secretase in the brain is 
β-site APP cleaving enzyme 1 (BACE) [92], while γ-secretase, as described above in 
section 1.6.3, is comprised of a multiprotein complex including presenilin 1 or 2, 
presenilin enhancer 2, nicastrin and anterior pharynx defective 1, with the catalytic 
subunit being the presenilin [77].  The initial cleavage is thought to be performed by 
BACE, generating the APP C-terminal fragment C99 as well as the N-terminal fragment 
sAPPβ.  C99 is then cleaved by γ-secretase to generate Aβ and the APP intracellular 
domain (AICD). 
APP can also be cleaved by α-secretases between amino acids 687 and 688.  This 
cleavage occurs at the extracellular surface of the plasma membrane and is within the Aβ 
domain, thereby precluding the formation of Aβ.  Because this cleavage precludes the 
formation of Aβ, it is known as non-amyloidogenic processing (Figure 1, non-
amyloidogenic pathway).  α-Secretases are members of the ADAM (a disintegrin and 
metalloprotease domain) family of proteins, ADAM-10, ADAM-17 (also known as 
TACE), ADAM9, and ADAM19 have all been shown to have α-secretase activity [93].  
In this pathway, full length APP is cleaved by α-secretase to generate the C-terminal 
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Figure 1.1.  Classical processing of APP via the non-amyloidogenic and 
amyloidogenic pathways.  Aβ is produced through sequential cleavage of the APP 
peptide by β- and γ-secretases via the amyloidogenic pathway.  Aβ can aggregate to 
form amyloid plaques, one of the histopathological hallmarks of AD.  Alternatively, 
APP may be cleaved by α-secretase to form sAPPα, a neuroprotective proteolytic 
fragment. 
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fragment C83 as well as the N-terminal fragment sAPPα.  C83 can also be cleaved by γ-
secretase to generate the small peptide p3 as well as AICD. 
Importantly, sAPPα has been shown to have neuroprotective properties.  sAPPα 
can inhibit calcium currents and increase potassium currents, stabilizing membrane 
potentials and protecting cells against excitotocity [94-96].  It has also been shown to 
have neurotropic properties, promoting neurite outgrowth, synaptogenesis, and cell 
adhesion [97, 98]. Intracerebroventricular sAPPα administration in rats results in 
enhanced learning and memory performance, increased long-term potentiation, and 
enhanced N-methyl D-aspartate receptor mediated currents [99].  Further, sAPPα can 
increase the proliferation rates of neural stem cells [100].  Taken together, this indicates 
that sAPPα can be considered to have both neurotropic and neurotrophic properties [101].   
1.7.1.1. Phosphorylation Dependent Changes in Processing 
APP can be phosphorylated at T654, S655, and T668, with the phosphorylation at 
T668 resulting in the most pronounced conformational change to the C-terminus [102].  
In neurons, this phosphorylation is primarily performed by cyclin-dependent kinase 5 
(cdk5) [103]. Increased expression of the cofactors that regulate cdk5 activity, namely 
p25 and p35, results in increased APP phosphorylation as well as increased production of 
various proteolytic fragments of APP, including Aβ, sAPPβ, and sAPPα [104].  The 
phosphorylation of APP at T668 has been associated with an increase in the translocation 
of AICD to the nucleus, localization of APP to the centrosome, and enhancement of 
neurodegeneration [105, 106].   
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1.7.1.2. Effect of Trafficking on APP Proteolysis 
Trafficking of APP also seems to be important for Aβ production.  The 
cytoplasmic domain of APP contains an endocytosis signal (YENP740), and mutating or 
deleting this region results in decreased production of Aβ [107].  When APP at the 
surface of the cell is labeled, endocytosis can be observed and labeled Aβ is produced 
[108-110].  Depletion of cellular potassium prevents clathrin-mediated endocytosis and 
effectively lowers Aβ production [109, 110].  Taken together, these data illustrate that 
endocytosis is important for the production of Aβ.   
Depleting proteins important in the early multivesicular body pathway result in 
accumulation of APP in the early endosomes, but reduce Aβ production.  Depleting 
proteins that act later in this pathway result in an accumulation of APP in the trans-Golgi 
network and enhanced APP processing and production of Aβ, suggesting that APP 
processed into Aβ is first endocytosed then routed to the trans-Golgi network.  APP 
recycled from the early endosomes into the trans-Golgi network creates a pool of APP 
from which Aβ is produced [111].   
1.7.2. Alternative Processing of APP by Other Proteases 
In addition, other proteases such as calpains and caspases are also known to 
cleave APP [112-117]. For example, APP is cleaved by caspase-3 at three distinct sites in 
apoptotic cells [113, 118].  Two of these sites, DNVD*S198 and DYAD*G220 are located 
near the N-terminus of APP, while a third site, VEVD*A740, is located near the C-
terminus.  Since the cleavage at VEVD*A740 could be prevented with the small peptide 
inhibitor DEVD-FMK, this cleavage of APP has been attributed to caspase-3 [113].   
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Caspase activation, DNA fragmentation, and apoptosis are associated with 
neurodegeneration in AD brains [112, 119-121]. Studies in post mortem AD brain tissues 
have shown increased levels of caspases, specifically caspase-1 and -7, prior to exhibition 
of other signs of apoptosis [122]. Induction of caspases in AD brain, along with the 
observation that caspases can cleave APP, suggests that caspase-mediated processing of 
APP may contribute to pathology development in AD. Caspase-3, -6, and -8 have all 
been implicated in APP cleavage [113, 123].  The studies presented in later chapters here 
will also provide evidence for caspase-7 mediated cleavage of APP [124].  
1.8. Closing Remarks 
In this chapter, we have discussed the history of age-related dementia and the 
earliest descriptions of AD, first described by Alois Alzheimer in 1906.  A certain 
dichotomy has existed throughout history, with some believing memory impairment and 
cognitive dysfunction to be a normal part of aging, while others recognizing that, at least 
in some cases, there appears to be something more at work.  The case of Auguste D, who, 
at 51 years of age, was relatively young for the degree of impairment she experienced, 
marks the first investigation into the neuropathology of what would come to be known as 
AD. 
Since the very beginning, our understanding of AD has been driven by its 
neuropathology.  Understanding what these histopathologically characteristic plaques and 
tangles are made of, how they form, why they persist, how they may be removed, and 
what affect they have on the brain have been the major questions the AD field has faced 
for the last 40, if not 100, years.  The discovery of the Aβ peptide, its parent protein, and 
the genetic work that followed provided the foundation for the amyloid cascade 
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hypothesis, which has largely driven AD research for nearly 25 years.  The notion that 
Aβ is at the center of the disease process is well supported, through genetics, in vitro, and 
in vivo work.  However, the specific mechanisms underlying its production, beyond 
which secretases cleave the parent protein at which locations, is still under investigation.  
Only recently have we begun to appreciate the importance of endocytosis in the 
production of Aβ. 
Many facets of the AD brain contribute to its dysfunction.  There are impairments 
in the blood brain barrier, impaired circulation, inflammation, the presence of protein 
aggregates both inside and outside of cells, and cell death.   In the chapters that follow, 
we will discuss cellular processes that are activated in the AD brain, namely cell cycle 
activation and activation of apoptotic pathways, and the effect these processes have on 
both classical and alternative processing of APP. 
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CHAPTER 2:  THE ANATOMICAL CASCADE, CELL CYCLE ACTIVATION,  
 
AND CELL DEATH1 
 
 
 
2.1. Chapter Synopsis 
Our understanding of the pathogenesis of AD has been largely driven by the 
amyloid cascade hypothesis for nearly 20 years.  Given the strong genetic evidence and 
the large body of in vitro and in vivo evidence presented in chapter 1, the fixation the AD 
field has had on Aβ seems quite appropriate.  However, somewhat of a dichotomy exists 
between disease severity as determined by cognitive function and amyloid load.  While 
tau pathology can be rather closely correlated to cognitive function, amyloid pathology 
correlates only weakly.  This can be explained by the identification of small oligomers as 
the toxic species.  However, this leads to an interesting question – if small oligomers of 
Aβ are upstream of tau pathology, and tau pathology follows a predictable, anatomical 
progression through the brain which correlates with disease severity, do the production of 
Aβ and its small oligomers may also follow a predictable pattern through the brain?  This 
question led to the hypothesis that certain facets of microenvironment present in the AD 
brain may in fact beget Aβ production, allowing pathology to propogate through the 
brain.  Here, we present evidence of cell cycle dysregulation in the AD brain, and 
describe how this dysregulation ultimately leads to cell death.  We also present the 
                                                 
1 Portions of this chapter have been previously published (Fiorelli and Padmanabhan, 2010, 2011) 
and are utilized with the permission of the publishers.  See Appendices B and C. 
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hypothesis and supporting evidence from the literature that these aberrant cell cycle 
related events and the cell death that follows may in fact lead to altered proteolytic 
processing of amyloid precursor protein, and that this altered proteolytic processing may 
set off the anatomical progression of disease-related pathology in the AD brain.  In the 
chapters that follow, we will present our experiments designed and performed to address 
the hypothesis that aberrant cell cycle related events and apoptosis alter APP processing 
and promote AD pathogenesis. 
2.2. The Alzheimer’s Disease Dichotomy 
While the evidence discussed in chapter 1 presents a strong case for the 
importance of Aβ in AD pathogenesis, the fact that Aβ-related plaque pathology does not 
correlate well with disease severity has historically been somewhat of a “thorn in the 
side” of the amyloid cascade hypothesis.  Plaque pathology seems to develop over the 
decades-long preclinical phase of AD, and is likely present long before cognitive 
dysfunction is severe [1].  Some individuals with moderate to advanced plaque pathology 
never show cognitive dysfunction [2, 3].  Further, plaque pathology is observed broadly 
throughout cortical regions of the brain, with no apparent specificity for regions 
functionally associated with spatial or associative memory.  The severity of amyloid 
plaque pathology in the brain has very little to no predictive value in determining the 
degree of cognitive dysfunction in the AD patient. 
2.2.1. Anatomical Progression of Tau Pathology 
Tau pathology, on the other hand, is much more tightly correlated with cognitive 
dysfunction.  Tau pathology progresses in a distinctive, predictable, anatomical pattern 
through regions of the brain specifically associated with memory.  In fact, the correlation 
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between tau pathology and AD severity is so well established that staging of tau 
pathology is perhaps the most widely recognized neuroanatomical measure of disease 
severity.  The formation of argyrophilic NFTs in AD follows a predictable, nonrandom 
course throughout the hippocampus, neocortex and subcortical nuclei [4]. This 
predictable anatomical pattern of progression was first defined by Heiko Braak in 1991, 
and its use has become common practice in staging the progression of AD.  
2.2.1.1. Braak Staging of Alzheimer’s Disease 
According to Braak’s method of neuropathological staging, six distinct stages of 
disease progression can be distinguished based on the localization and severity of tau 
pathology [4, 5].  In Braak stage I, very slight pathology may be seen in the 
transentorhinal cortex, specifically in layer Pre-α.  As the disease progresses into stage II, 
pathology in the transentorhinal cortex becomes somewhat more severe.  Pathology is 
largely confined to the transentorhinal cortex, but some mild pathology may be detected 
in the CA1 region of the hippocampus, the entorhinal cortex, and the temporal isocortex 
in stage II.  Because the pathology of Braak stages I and II is largely isolated in the 
transentorhinal cortex, these are sometimes referred to collectively as the transentorhinal 
stages. 
In Braak stage III, the transentorhinal cortex is heavily burdened with tangle 
bearing neurons, and increasing pathology can be seen in the hippocampus, entorhinal 
cortex, and temporal isocortex, though pathology of the neocortex is minimal at this 
point.  In addition, mild pathology may be seen in the other layers of the transentorhinal 
and entorhinal cortices; in addition to layer Pre-α pathology is seen in layers Pri-α and 
Pre-β as well.  Stage IV is the first stage in which pathology is pronounced in layers 
52 
outside of Pre-α, as pathology in Pri-α and Pre-β advances.  In stage IV, there is marked 
destruction of the transentorhinal and entorhinal cortices, as well as marked damage in 
the CA1 region of the hippocampus, and increasing damage throughout the hippocampal 
formation.  There is still little involvement of the neocortex at this point.  The losses seen 
in stage III and IV within the external and internal principle strata result in significant 
impairments in the transfer of information between the hippocampus and the neocortex, 
thereby disrupting the limbic circuits.  Because of this disruption, stages III and IV 
together are referred to as the limbic stages. 
In the most advanced pathological stages of AD, Braak stages V and VI, 
extensive damage can be seen throughout the hippocampal formation, entorhinal and 
transentorhinal cortices, and the temporal isocortex.  The significant damage in the 
temporal isocortex gives stages V and VI their collective name – the isocortical stages.  
There is also significant pathology in the neocortical association areas.  Interestingly, the 
conventionally used criteria for the diagnosis of AD require extensive pathology in the 
neocortical regions.  Therefore, only pathology of at least Braak stage V or VI would be 
definitively diagnosed as AD based on conventional neuropathological criteria [4]. 
2.2.1.2. Correlation of Tau Pathology with Cognitive Function 
Overall, the correlation between Braak stage and clinical dementia rating (CDR) 
of individuals with probable AD is high (ρ=0.66, P<0.01) according to Gold et al. [6]), 
though the Braak stages are not particularly useful for distinguishing individuals with 
normal (CDR score of 0 on a scale of 0 to 3) cognition from those with mild cognitive 
changes (CDR score of 0.5) [6]. 
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According to Braak and Braak [4], the transentorhinal stages of the disorder are 
considered cognitively silent.  However, some studies have found that these stages are 
often associated with clinical pathology:  71% of individuals in Braak stage I and 75% of 
individuals in Braak stage II showed at least mild cognitive changes according to CDR 
score [6], and 22% of individuals in Braak stage I or II were considered clinically 
demented according to the CAMDEX criteria [7]. 
While a thorough analysis of the types of neuropsychological testing involved in 
these studies is beyond the scope of this text, it must be noted that both the CDR and 
CAMDEX assessments address global cognitive function.  It is, therefore, not surprising 
that such a gross approach to neuropsychological analysis results in significant overlap 
across different neuropathological stages.  When individual modalities of cognitive 
functions are examined independently, it appears that the transentorhinal stages are 
associated with deficits in episodic memory [8].  Neuroanatomically, the transentorhinal 
cortex receives inputs from the isocortical association areas, and project to the 
hippocampal formation via the entorhinal cortex [4].  Based on these neuroanatomical 
substrates, damage to the transentorhinal cortex characteristic of Braak stage I and II 
would result in the deficits in episodic memory observed in these early stages.  This is 
also consistent with the observation that episodic memory is typically impaired very 
early, during the preclinical course of the disease [8]. 
The limbic stages, Braak stages III and IV, are particularly interesting.  While 
stage III is quite ambiguous, with 43% of individuals in stage III clinically demented 
according to CAMDEX criteria [7] and CDR scores covering the full range of possible 
scores [6], conversion to stage IV is quite significant.  On the basis of CDR scores, all the 
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individuals reaching stage IV neuropathology were at least mildly demented [6], while on 
the basis of the CAMDEX criteria 67% of individuals at stage IV were considered 
clinically demented, the first stage at which significantly more individuals were demented 
than not (χ2=6.31, P=0.01) [7].   
The limbic stages, as described above, are associated with severe pathology in the 
transentorhinal cortex, moderate pathology in the hippocampal formation, and only very 
slight pathology in the temporal isocortex.  The increasing severity of neuropathology is 
also associated with progressions in clinical pathology, including deficits in verbal 
abilities, visiospatial function, attention, and executive functions [8].  Interestingly, the 
neuroanatomical regions associated with these cognitive functions are largely neocortical, 
including association, frontal, and prefrontal cortices.  While the loss of connections 
between the association cortex and the hippocampal formation due to destruction of the 
transentorhinal and entorhinal regions may partially account for these clinical 
manifestations, the clinical pathology suggests more neocortical involvement than is seen 
in the limbic stages. 
Considering the statistically significant conversion from stage III to stage IV, and 
the vast extent of neuropathology seen at these advanced stages, it is not surprising that 
progression into the neocortical stages is associated with severe dementia.  On the basis 
of CDR score, 88% of individuals at stage V were severely demented [6], and on the 
basis of CAMBREX score 70% of individuals at Braak stage V or higher were 
considered clinically demented [7].  Clinically, these stages are associated with 
increasing severity in the same types of deficits seen in the previous stages.  In addition, 
deficits are also seen in primary memory – the fluid, working memory required for 
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performance of everyday tasks.  Such deficits are associated with intermediate and late 
stages of AD [8]. 
Even in individuals with deficits in primary memory, as is associated with Braak 
stage V and VI, little deficit is observed in tasks that require sensory-motor performance 
[8].  The end stages of AD can involve aphasia, loss of the ability to control movement, 
inability to perform activities of daily living, and unresponsiveness.  These are somewhat 
beyond the scope of the Braak staging classifications, as stage VI can be associated with 
advancing intermediate clinical stages of the disorder and are not specific to end stage 
disease [8].  The spatiotemporal progression of neuropathological changes proposed by 
Braak and Braak [5] are, therefore, more useful in setting forth the progression of the 
early stages of the disease, which are dominated by allocortical pathology.  As the 
progression continues and neocortical pathology dominates, the Braak stages are less 
indicative of clinical manifestations. 
2.2.2. Oligomeric Amyloid and the Anatomical Cascade 
The apparent dichotomy between the vital importance of amyloid in the disease 
pathogenesis, so strongly supported by genetic evidence, and the lack of correlation 
between amyloid plaque pathology and disease severity (while tau pathology, which is 
thought to be downstream of amyloid pathology, correlates rather well with disease 
severity especially in the intermediate phase of the disease) can be largely explained by 
the recent evidence that small oligomers of Aβ act as the toxic species.  These small 
oligomers are not evident in gross neuropathological assessments aimed at examining 
amyloid pathology, such as thioflavin-S and Congo Red staining, as these dyes 
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specifically stain β-pleated sheet structures and therefore require much larger Aβ 
aggregates for detection. 
Biochemical analysis, however, does suggest that Aβ42 levels in the brain do 
indeed correlate with disease severity, so while plaque load is not well correlated the 
cognitive function the total levels, inclusive of both Aβ contained in plaques and more 
soluble forms, including small oligomers, does correlate well with cognitive function, 
with individuals with higher levels of soluble Aβ having significantly poorer cognitive 
function [9, 10]. 
If the presence of small oligomers of amyloid is indeed upstream of tau 
pathology, and tau pathology follows a predictable anatomical course through the brain, it 
stands to reason that the presence of small amyloid oligomers may also follow a similar 
anatomical progression through the brain, despite our inability to detect with anatomical 
specificity the presence of small, soluble peptides secreted into the parenchyma.  The 
anatomical progression of tau pathology may serve as a roadmap, heralding the presence, 
or, given the longevity of neurofibrillary tangles, the former presence, of small oligomers 
of amyloid in the extracellular space. 
This hypothesis suggests that amyloid, like tau, follows an anatomical progression 
through the brain, whereby Aβ in the cellular microenvironment causes some change in 
the surrounding cells which result in changes in the processing of amyloid precursor 
protein.  A schematic of this hypothesis is presented in Figure 2.1.  This may ultimately 
result in the production of more Aβ, allowing Aβ production to propogate through the 
brain in a fashion similar to tau pathology.  Aβ has been shown to induce both cell cycle 
activation and apoptosis in cells, both of which are candidates for processes which may 
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Figure 2.1.  Schematic of the anatomical cascade hypothesis.  Aβ has been shown to 
induce phosphorylation of tau and has also been proposed to act as a mitogenic 
signal.  Furthermore, the phosphorylation of tau can occur in a cell cycle dependent 
manner.  Tau pathology is also known to propagate through the brain in a predictable 
manner.  If amyloid is upstream of tau and tau propagates through the brain, it stands 
to reason that Aβ production may also propagate through the brain in a similar 
fashion.  In this schematic, Aβ elicits cell cycle activation in the cell on the left, 
which may lead to p53-dependent apoptosis.  Alternatively, the cell may progress 
further into the cell cycle, resulting in the phosphorylation of tau.  This research is 
aimed to address the hypothesis that cell cycle activation and/or p53-dependent 
apoptosis may be associated with altered APP processing, including an increase in 
the production of Aβ.  This Aβ can then affect surrounding cells, allowing pathology 
to propagate through the brain.  
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alter APP proteolysis.  Cell cycle activation is associated with posttranslational 
modifications to APP which may alter its trafficking and processing throughout the cell.   
Apoptosis is associated with the activation of caspases, some of which have been 
shown to directly cleave APP, though the contribution of these alternative proteolytic 
events to the production of Aβ is not clear.  In the rest of this chapter, we discuss the 
evidence for cell cycle activation and apoptosis occurring in the AD brain, as well as the 
evidence that cell cycle activation and apoptosis may be induced by the presence of Aβ.  
In the chapters that follow, we will present our experimental studies designed to assess 
whether cell cycle activation and apoptosis result in alterations in APP processing. 
2.3.  Cell Cycle Activation 
AD is a neurodegenerative disease, and neurons are typically thought of as 
terminally differentiated, post-mitotic cells that do not enter the cell cycle.   This idea 
stems from the unique functional architecture of neuronal networks.  During 
development, neural progenitor cells migrate to their destination, undergo terminal 
differentiation, and integrate their axons and dendrites into the neuronal circuitry.  These 
neurons remain integrated in a complex network throughout the life of the organism. 
Although it is known that neural precursor cells can divide and the newly formed 
daughter cells can migrate and differentiate into mature neurons, the ability of mature 
neurons to divide is debatable.  A more widely accepted, and relatively intuitive, view 
suggests that neurons are not able to undergo mitosis, since entry into mitosis and 
subsequent cytokinesis would require cytostructural reorganization that would impair 
neuronal connectivity and function [11]. In fact, there are rare cases in which binucleated 
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neurons have been found in AD brain, suggesting that neurons may attempt to divide but 
fail to undergo cytokinesis [12].   
Neurons constituitively express cell cycle markers, including cyclins D, A, B, and 
E, cyclin dependent kinases (cdks) 1, 2, 4, and 5, as well as cyclin dependent kinase 
inhibitors (cdk inhibitors)  [11, 13].  The expression of these markers in the normal brain 
suggests a non-canonical role of these cell cycle related proteins in normal neuronal 
function, possibly involved in synaptic plasticity or stability [13].  However, under 
cytotoxic stress such as DNA damage, oxidative stress, or trophic factor deprivation, 
cyclins and cdks are expressed in a sequential manner indicative of aberrant cell cycle 
reentry, rather than non-canonical roles for these proteins [11, 14-17].   
The proteins most strongly associated with AD pathology, APP and tau, have both 
been shown to be regulated in a cell cycle dependent manner.  APP is phosphorylated at 
threonine 668 in a cell cycle dependent manner, specifically enhanced during the mitosis 
phase of the cell cycle [18, 19].  Tau has also been shown to be phosphorylated in a 
mitosis specific manner [20-25].  These studies suggest that the cell cycle activation 
associated with AD could result in the modification of AD related proteins.  The 
phosphorylation of these proteins can, in turn, affect their propensity to form aggregates 
and thus contribute to the development of AD pathology.  
In addition to the contribution of these proteins toward the development of AD 
pathology, there is clear evidence for the involvement of AD-related proteins APP, PS, 
and tau in the cell division cycle.  The association of these proteins with the cell cycle 
machinery suggests that they may play a regulatory role in the cell cycle.  For example, 
the presenilins associate closely with centrosomes and the kinetochore, suggesting a role 
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for the presenilins in the modulation of cell cycle [26-29].  Further evidence for a close 
association between presenilins and cell cycle regulation comes from in vitro studies 
showing that overexpression of PS1 leads to G1 arrest, and that this arrest can be 
potentiated by overexpression of PS1 mutants [30]. Knock-in mice expressing mutant 
PS1(M136V) show increased expression of cyclin D1, a G1-associated protein, in 
cortical neurons [31].  Treatment of neurons expressing mutant PS1 with the cell cycle 
inhibitor quercetin, but not a gamma secretase inhibitor, protected these cells from 
undergoing apoptosis [31].  Together, this suggests that expression of mutant PS1 is 
associated with aberrant cell cycle activation, which in turn leads to the induction of 
apoptosis independent of gamma secretase activity. In addition, blocking the cell cycle by 
down regulating cyclin D1 using a small interfering RNA construct also reversed the 
neurodegeneration observed in PS1 mutant neurons [31], further suggesting that the 
apoptosis and neurodegeneration seen in PS1 mutant neurons is mediated by aberrant 
cell-cycle reentry.  Importantly, FAD patients expressing mutated PS1 also show 
abnormal accumulation of cyclin D1 in the temporal cortex, supporting the validity and 
relevance of these models to the study of AD as it occurs in the human patient, as well as 
the hypothesis that aberrant cell cycle reentry may play a significant role in the 
neurodegeneration characteristic of AD. 
Numerous studies have suggested that aberrant cell cycle activation occurs in the 
AD brain.  For example, Ki-67, a DNA binding protein involved in cell division, is 
upregulated in the hippocampus of AD patients [32, 33].  This protein is not usually 
present in cells arrested in G0, but begins to accumulate in G1 and peaks during M phase, 
suggesting that diseased neurons are not maintained in a fully-differentiated state.  In 
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addition, the master regulator of the cell cycle, retinoblastoma protein (Rb), has been 
shown to be phosphorylated in the brains of AD patients [34, 35].  In cycling cells, Rb 
binds to E2F and suppresses transcription of E2F dependent genes required for cell cycle 
progression.  Upon phosphorylation, Rb dissociates from E2F resulting in transactivation 
of genes and cell cycle progression.  The phosphorylation of Rb observed in AD brains 
is, therefore, indicative of cell cycle dysregulation.2   
Other cell cycle associated proteins such as PCNA, cdk4, the cdk-activating 
kinase cdk7, and cyclins D, E, and B have also been reported to be upregulated in AD 
patients, with cyclin B/cdc2 expression associated with tau phosphorylation [36-39].  In 
fact, there has even been one report of binucleated neurons present in AD brains [12], but 
not in normal controls.  This suggests that some cells may progress through the cell cycle 
as far as anaphase, albeit a rare event [40]. 
Cyclin B1/cdc2 complexes have also been shown to be upregulated in the AD 
brain.  These complexes are observed in NFT-containing and NFT-susceptible neurons, 
and have been shown to be capable of phosphorylating tau in vitro at M-phase specific 
phosphoepitopes  [41, 42].  Increased levels of CIP-1-associated regulator of Cyclin B 
(CARB) have also been observed in the tangle-bearing neurons of the AD brain.  CARB, 
through its association with cyclin B and p21, is one of the regulators involved in the 
G2/M phase of the cell cycle [43, 44].  Interestingly, inducing cell cycle activation in 
neurons by adenoviral expression of oncogenes such as c-myc and ras is sufficient to 
induce tau phosphorylation, as well as conformational changes in tau typically seen in 
AD [45]. 
                                                 
2 Rb and E2F regulation of the cell cycle will be discussed further in section 2.4.1.1.1. 
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These conformational changes in tau can be detected using a conformation-
specific antibody, Alz50, which was initially raised against AD brain homogenates.  
Alz50 was, in turn, used to purify PHF from AD brains, which were then used to raise 
seven different antibodies against PHF – the TG and MC series of antibodies from the 
laboratory of Peter Davies (Albert Einstein School of Medicine, NY).  Interestingly, all of 
these antibodies, when used on an asynchronous population of dividing cells from 
multiple lineages, such as MSN cells, HeLa cells, human lymphocytes, human B cells, 
human astrocytes, and mouse or rat fibroblasts, specifically stain mitotic cells and do not 
stain cells in interphase.  This suggests that the epitopes phosphorylated in PHF from 
human AD brains are the same epitopes phosphorylated during mitosis [42], and further 
supports the notion that cell cycle dysregulation may be important in the development of 
tau pathology in AD. 
2.3.1. Aβ-Induced Cell Cycle Activation 
There is extensive evidence of aberrant activation of the mitogen-activated protein 
kinase (MAPK) pathways in AD [For review, see 46].  Since these pathways are typically 
activated by extracellular stimuli, this suggests that both entry into the cell cycle and tau 
phosphorylation can occur downstream of a mitogenic extracellular signal.  One potential 
candidate for a mitogenic signaling molecule that can induce tau phosphorylation and 
apoptosis in neurons is Aβ itself.  
There is some evidence that preparations of oligomeric, but not monomeric, Aβ 
can induce cell cycle events, including DNA synthesis, in dissociated cortical neurons 
[47].  Furthermore, picomolar concentrations of Aβ1-42 induced cyclin D1 expression, 
indicative of the G1 phase of the cell cycle, while micromolar concentrations of Aβ1-42 
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resulted in cyclin B1 expression, indicative of G2.   R1.40 mice, which express human 
APP with a Swedish mutation and show evidence of cell cycle events, do not show 
evidence of cell cycle activation when BACE is not present, indicating that 
amyloidogenic processing of APP may be required to elicit cell cycle activation in these 
mice and further implicating Aβ as a mitogenic signal [47].  
Aβ has also been shown to interact with RAGE receptors, which may provide a 
mechanism for Aβ-induced cell cycle activation [48, 49].  Further evidence suggests that 
stimulation of integrins and activation of focal adhesion kinases may also be involved in 
this process [50].  Given the evidence that Aβ may be able to elicit a mitogenic response 
from cells, the hypothesis that cell cycle activation may play an important role in AD is 
not at odds with the widely accepted amyloid cascade hypothesis, but rather provides a 
mechanism through which Aβ may induce tau phosphorylation and neurodegeneration. 
2.4. Cell Death in Alzheimer’s Disease 
Although loss of neuronal tissue is characteristic of AD, the specific way in which 
cells die in AD is not entirely clear.  There is evidence supporting the induction of 
apoptosis, especially in vitro when cells are treated with Aβ [51-55].  However, while 
some characteristics of apoptosis have been observed in the AD brain, other pathological 
features seem inconsistent with apoptosis as a mechanism of cell death.  For example, the 
so-called “ghost tangles” – extracellular aggregates of tau observed in the AD brain, still 
maintain the shape of the neuron in which they were formed [56, 57].  If the cell had 
broken down into apoptotic bodies as part of the apoptotic process, these ghost tangles 
would not persist.  Additionally, tau is detected in the cerebrospinal fluid of AD patients. 
The presence of this intracellular protein in the extracellular space suggests a breakdown 
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of the cellular membrane.  Such a breakdown is not typically associated with apoptosis, 
but instead is more characteristic of necrotic cell death. 
Furthermore, with the aggregation of Aβ in the extracellular space and the 
formation of intraneuronal neurofibrillary tangles, AD may be considered a protein 
misfolding disorder.  The misfolding of tau, in addition to mitochondrial dysfunction, 
places great stress on the lysosomal pathway, and evidence exists in support of autophagy 
in AD [58-60].  While autophagy is likely induced as a protective response meant to 
degrade misfolded proteins and damaged organelles, it is not clear whether autophagy in 
AD is protective or actually contributes to cell death [59]. 
In this section, we will review the evidence in support of apoptosis, necrosis, and 
autophagy as players in the cell death observed in AD, briefly describing each process 
and presenting evidence evaluating the relative contributions of each process to 
neurodegeneration in the AD brain. 
2.4.1. Evidence for Apoptosis-Mediated Cell Death in Alzheimer’s Disease 
Apoptosis is often described as “programmed cell death” or “cellular suicide.”  It 
is a gene-directed process that is important for the development of adult tissue by 
eliminating cells that are damaged or otherwise unwanted or unneeded [61].  Apoptosis is 
energetically expensive, requiring the production and orchestration of complex molecular 
events and ultimately resulting in the shrinkage and breakdown of the cell into apoptotic 
bodies which may then be phagocytosed by microglia [62].  The entire process is largely 
contained and does not elicit an immune response – an important difference when 
compared to necrotic cell death.   
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The mechanisms by which apoptotic cell death occurs have been and continue to 
be extensively studied.  The process of apoptosis is regulated largely by the sequential 
activation of various cysteine-dependent aspartate-specific proteases, or caspases.  There 
are two pathways through which caspases are activated – an intrinsic and an extrinsic 
pathway [for review, see 63].  The intrinsic pathway is initiated by the mitochondria, 
which, in response to an apoptotic stimulus, release cytochrome c into the cytosol [64].  
The release of cytochrome c is largely regulated by the Bcl-2 family of proteins.  The 
released cytochrome c binds to apoptosis protease activating factor-1 (Apaf-1), inducing 
a conformational change in Apaf-1.  This conformational change allows Apaf-1 to bind to 
ATP, which results in its oligomerization to form an apopotosome.  Procaspase-9 is 
recruited to the apoptosome through interaction of the caspase recruitment domains 
(CARDs) on both enzymes.  This results in the activation of caspase-9, which can then 
cleave and activate downstream executioner caspases such as caspase-3 [65]. This 
process is under tight regulation by inhibitor of apoptosis proteins (IAPs), which are in 
turn regulated by the proapoptotic mitochondrial protein Smac/Diablo [63, 65]. 
The extrinsic pathway is activated by binding of a ligand to a death receptor at the 
cell surface. There are a number of cell surface proteins that contain a “death domain” 
allowing them to signal apoptosis.  These receptors include TNF receptor 1, death 
receptors (DR), and Fas.  Upon binding a ligand, these proteins trimerize and the 
associated conformation change allows the cytoplasmic death domain to bind adapter 
molecules, which in turn bind and activate procaspase-8 or -10.  Active caspase 8/10 can 
then activate executioner caspases such as 3/7, resulting in apoptosis [63]. 
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Apoptosis is characterized by a number of morphological changes to cells, 
including membrane blebbing, chromatin condensation, nuclear shrinkage, and nuclear 
fragmentation.  The plasma membrane, however, remains largely intact until the 
lattermost portion of the apoptotic program [61].  Apoptotic DNA fragmentation is 
characterized by DNA laddering on an agarose gel, with oligonucleosome sized 
fragments (multiples of ~180 base pairs) [61, 66].  Identifying apoptosis in tissue, 
therefore, is generally done by observation of these morphological changes as well as 
examination of the activation states of various caspases and cleavage of target proteins by 
executioner caspases.3  
In the nervous system, apoptosis is particularly important in development.  It is 
the major process through which pruning is achieved and therefore essential for the 
development of the adult brain [for review, see 67].  It has been estimated that half of the 
cells born in the developing nervous system die via an apoptotic pathway [68].  The loss 
of these cells allows for optimization of synaptic connections and pattern formation 
required for the proper “wiring” of the adult brain to develop.  The determination of 
which cells survive and which cells die seems to be dependent on connections to a 
postsynaptic target (the formation of synapses) and competition for neurotrophic factors 
[68].  Only the cells and synapses that form stable, active connections as well as trophic 
support are retained, the others are eliminated or “pruned” from the system.  The 
regulation of apoptosis in the developing nervous system involves complex regulation 
between pro-apoptotic, for example Bax, and anti-apoptotic, for example Bcl-2, proteins 
[67]. 
                                                 
3 The roles of various caspases in the initiation and execution of apoptosis is further described in 
section 3.2.3. 
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2.4.1.1. Aβ-Mediated Induction of Apoptosis via Cell Cycle Activation 
Since neurons do not possess functional cell cycle machinery, this aberrant 
reentry typically results in abortive exit from cell cycle and apoptosis [11].  Incapable of 
undergoing cell division or transformation, neurons undertake apoptosis as an alternative 
mechanism.  The observation that neurons which aberrantly enter the cell cycle undergo 
apoptosis, combined with the upregulation of cell cycle regulators in AD, led to the 
hypothesis that cell cycle deregulation plays a significant role in AD pathogenesis [11]. 
We and others have hypothesized that Aβ acts as a mitogenic signal which 
promotes aberrant cell cycle activation that can lead to both tau phosphorylation and 
neuronal death.  This neuronal death may be mediated by the “guardian of the genome” 
p53, which has been shown to be overexpressed, altered in its conformation, and 
posttranslationally modified in AD.  These alterations in p53 likely reduce its function, 
resulting in increased APP expression and tau phosphorylation that, in addition to 
promoting apoptosis, could also contribute to both major pathological hallmarks of AD.   
Treatment of cells with Aβ induces increased expression of DNA polymerase-β, 
PCNA, and the p49 and p48 subunits of DNA primase, suggesting entry into S-phase and 
upregulation of the DNA replication machinery.  In neurons challenged with Aβ, DNA 
primase, DNA polymerase-β, and DNA polymerase-δ are loaded into the replication fork, 
and p53 expression is increased [69, 70].  P53 is a transcription factor that plays an 
important role in mediating apoptosis in response to DNA damage.  Alternatively, cdc2 
has also been suggested as a potential mechanistic link between aberrant cell cycle 
activation in neurons and apoptosis.  Specifically, cdc2 phosphorylates BAD, the bcl-2 
associated death promoter, and thereby inducing apoptosis [71].  Cell cycle activation 
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associated apoptosis may occur through cdc2/BAD-dependent and/or p53-dependent 
mechanisms. 
It has also been suggested that Aβ-induced apoptosis is APP dependent, as APP 
knockout neurons are less susceptible to Aβ-induced neurotoxicity [72].  Importantly,  γ-
secretase derived fragments of APP have been shown to induce the expression of p53 
[73], and AD-associated mutations in PS1 result in increased expression of p53 [74].  
This suggests that Aβ-induced, APP-dependent apoptosis may be mediated by p53.  The 
importance of p53 in neurodegeneration in AD is further supported by the observation 
that p53 expression is increased in the hippocampi of AD patients [75, 76], and that 
polymorphisms in the gene encoding p53 are associated with increased risk for late-onset 
AD [77].  In fact, two independent groups have suggested that specific conformational 
alterations of p53 may be promising biomarkers that may be useful in the diagnosis of 
AD [78, 79].  In addition to conformational alterations, alterations in the 
glutathionylation of p53 have also been suggested to be involved in AD pathogenesis by 
preventing p53 tetramer formation, which is required for DNA binding and normal p53 
function [80]. 
Interestingly, p53 has been shown to regulate the expression of APP by reducing 
the binding of Sp1 to the APP promoter [81].  The β-secretase enzyme BACE may also 
be regulated in a similar manner, as there is also an Sp1 binding region within the BACE 
promoter [82, 83].  Increases in p53, therefore, are normally associated with decreased 
expression of APP.  In AD, however, p53 function appears to be compromised due to 
glutathionylation and conformational alterations that prevent its normal function.  p53 
dysfunction may, therefore, increase APP expression and contribute to amyloidogenesis. 
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Surprisingly, mice haplodeficient in p73, a member of the p53 family with 
neuronal specific expression, show an age-dependent accumulation of phospho-tau and 
neurodegeneration [84].  This suggests that p53, whose normal function is described as 
the “guardian of the genome” in cell division, could potentially contribute to all three 
major pathological hallmarks of AD – Aβ accumulation, P-tau accumulation, and 
neurodegeneration. 
2.4.1.1.1. Rb and E2F in Cell Cycle Progression 
Expression of cyclin D1 and E are associated with activation of the G1 phase of 
the cell cycle.  Cyclin D1 associates with cdk4 and 6 and cyclin E associates with cdk2, 
all of which have been shown to be upregulated in neurons under cytotoxic stress such as 
DNA damage, oxidative stress, or trophic factor deprivation [11, 14, 16, 17, 85-87].  The 
cyclin D1/cdk4-6 and cyclin E/cdk2 complexes then induce phosphorylation of the 
master regulator of cell cycle, Rb [88-90]. 
In non-cycling cells under normal conditions, Rb binds E2F and thereby inhibits 
the transactivation of genes under the control of E2F.  Upon phosphorylation, Rb 
becomes inactive and dissociates from E2F allowing transcriptional activation of E2F-
dependent genes to occur.  Thus phosphorylation of Rb promotes passage of cells through 
the G1/S checkpoint allowing cell proliferation [88, 91-93]. 
Interestingly, expression of a mutant form of Rb which cannot be phosphorylated 
protected neurons from apoptosis, suggesting that cell cycle related Rb phosphorylation 
may be an important event leading to neuronal apoptosis [94, 95].  In addition to the 
phosphorylation mutant of Rb, in vivo inhibitors of cyclin-dependent kinases (cdkis), 
including p21, p16, and p27, have also been shown to be neuroprotective [96].  Cdk 
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inhibitors function by binding to cdks and inhibiting their interaction with cyclins.  Since 
the coupling of cdks with partner cyclins is essential for cdk activity, the binding of cdk 
inhibitors to cyclins prevents cyclin-dependent phosphorylation and inactivation of Rb.  
In vitro studies utilizing cortical neurons in which apoptosis has been induced using DNA 
damaging agents indicate that overexpression of cdk inhibitors, including p16 and p21, 
can protect neurons from imminent apoptosis [97].  
2.4.1.1.2. Aβ-Induced Aberrations in Rb/E2F 
Apoptosis induced by Aβ treatment of neurons has also been shown to be 
associated with increased cdk4 activity in vitro, as well as hyperphosphorylation and 
inactivation of Rb [98, 99].  Inhibition of E2F by overexpression of a dominant negative 
form of dp1, the dimerization partner of E2F, protected the cells from Aβ-induced 
apoptosis, suggesting that Aβ-mediated apoptosis involves E2F activity and therefore cell 
cycle activation.  Similarly, preventing the phosphorylation of Rb through expression of a 
constitutively active phosphorylation mutant of Rb prevents DNA damage- and axotomy-
induced apoptosis in neurons [94, 95].  
The evidence discussed thus far has suggested that aberrant phosphorylation of 
Rb in neurons is a pathological response to Aβ toxicity and DNA damage.  The 
phosphorylation of Rb, subsequent dissociation of Rb from E2F, and transcriptional 
activation of E2F-regulated genes, are events associated with cell cycle progression.  In 
neurons, these events can lead to apoptosis, supporting the hypothesis that aberrant cell 
cycle activation may be responsible for the neurodegeneration seen in AD.   
This hypothesis is further supported by the observation that there are increased 
levels of phosphorylated Rb in the brains of AD patients as compared to cognitively 
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normal age-matched controls.  In addition, the subcellular localization of Rb and E2F is 
also altered in the AD brain, with hyperphosphorylated Rb found in the nucleus and E2F 
in the cytoplasm.  While these abnormal features were not significantly associated with 
tangle-bearing neurons, they were detected in neurons surrounding Aβ plaques, these 
suggest a role of Rb/E2F mediated cell cycle activation in Aβ-mediated toxicity and 
therefore in AD pathogenesis [100].  Similar to transactivation of genes, E2F-dependent 
de-repression of genes are also associated with induction of neuronal apoptosis.  For 
example, it has been shown that the trophic factor withdrawal and DNA damage-induced 
apoptosis in neurons are associated with de-repression of Myb family of genes, C and B-
Myb [101, 102].  This suggests that the inactivation of Rb by cdks induce pro-apoptotic 
genes by transactivation and de-repression, and an inhibition of inactivation of Rb could 
be significant to the neuron’s survival.  
Interestingly, these effects were not isolated to neuronal populations, as glia also 
showed positive immunoreactivity to E2F and Rb.  In addition to neuronal death, glial 
death has also been shown to be involved in AD, and plaque formation is associated with 
gliosis in transgenic mice expressing the Swedish mutation of APP under a thy1 promoter 
(APP23).  This gliosis is associated with expression of cell cycle regulatory proteins, 
including cyclin D1, E and B1 as well as nuclear translocation of cdk4 [103].   
The apparent involvement of cell cycle related events in the degeneration of both 
neurons and glia support the hypothesis that AD is caused by mitotic defects, and that the 
unwarranted cell cycle activation observed in the AD brain could strongly contribute to 
cellular and neuritic loss, ultimately leading to the cortical atrophy characteristic of AD.   
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2.4.1.2. Other Forms of Cell Death in AD 
2.4.1.2.1. Necrosis 
Necrosis, unlike apoptosis, is a passive process.  Apoptosis is much more active, 
requiring RNA and protein synthesis to progress [66].  Therefore, apoptosis is much more 
energetically taxing.  If a cell does not have the energetic resources to undergo apoptosis, 
it may undergo necrosis.  In necrosis, cells essentially swell and rupture, leaking cellular 
contents into the extracellular space.  One of the most notable differences between 
necrosis and apoptosis is that while in apoptosis membrane integrity is maintained as 
cells fragment into apoptotic bodies, during necrosis membrane integrity is lost.  
Therefore, while apoptosis does not induce an inflammatory response, in necrosis 
inflammation is induced due to cell lysis and spilling of cellular contents [66]. 
Morphological changes associated with necrosis include cellular edema, 
mitochondrial swelling, and breakdown of the nuclei.  Chromatin aggregates, but does 
not condense into regular and definable structures – the condensed chromatin is more 
poorly defined [104].  The major difference between apoptosis and necrosis is the state of 
the membrane and the nature of the DNA fragmentation.  Similar to apoptosis, DNA 
fragmentation also occurs during necrosis, however, the degradation is more random.  
The random cleavages characteristic of necrosis appears as a smear by electrophoresis, 
unlike the laddering pattern observed from apoptotic cells [61, 66]. 
Necrosis occurs when cells are exposed to extreme stress such that they are no 
longer capable of maintaining their integrity.  Examples of necrotic conditions include 
extreme hypoxia, high temperatures, contact with toxic compounds, and mechanical 
strain [105].  Necrosis is typically thought of as a chaotic process without a defined and 
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predictable mechanism, but some specific biochemical pathways can play major roles in 
necrotic cell death.  Unlike in apoptosis, which utilizes a pathway specific for execution 
of the apoptotic process, the biochemistry of necrosis involves cellular pathways involved 
in other cell functions, not necessarily performing aberrantly.  For example, during 
excitotoxic stress such as that seen in stroke, calcium channels open and allow calcium to 
enter the cell.  This response to an excitatory signal is the normal function of these 
channels, however in the presence of too much excitatory stimulus (e.g. glutamate), too 
much calcium enters the cell and leads to calcium overload.  The membrane potential is 
perturbed; both Na+ and Ca++ enter the cell, and the cell swells.  Calcium homeostasis is 
disrupted and may result in mobilization of the Ca++ stores of the endoplasmic 
reticulum, further contributing to the overload of intracellular calcium and ultimately 
leading to necrotic cell death [105].  In addition to disruption of calcium homeostasis, 
magnesium and zinc dysregulation can also lead to necrotic cell death, as can 
perturbations in the intracellular pH. 
Because membranes break down during necrosis, cellular contents are released.  
This is often measured by release of lactate dehydrogenase (LDH).  However, 
morphological degeneration of cells after Aβ treatment is not temporally associated with 
LDH release.  This suggests that membranes remain intact as cells die due to Aβ 
exposure, supporting the argument that in AD cells die from apoptosis rather than 
necrosis, at least in in vitro systems [61].  However, even some of the strongest 
proponents of apoptosis as the primary cause of cell death in AD have observed and 
reported necrotic cell death under certain conditions in neuronal cell culture, suggesting 
that neurons may be susceptible to death via either pathway.  More specifically, it appears 
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that in culture conditions with lower levels of glucose (5 mM), cells are susceptible to 
necrosis, whereas in cultures with higher levels of glucose (25 mM) cells are susceptible 
to death via apoptosis [61].  
Morphological evidence of necrosis is apparent in the AD brain.  In addition to 
DNA fragmentation, which occurs in both apoptosis and necrosis, mitochondrial swelling 
is observed in the AD brain.  Similarly, chromatin forms aggregates but does not form 
well-defined, electron-dense structures as is the case in apoptotic cell death [104].  
Furthermore, neuroinflammation is a well-established component of AD pathology.  
Death by necrosis could be a contributing factor to this neuroinflammation, whereas 
apoptotic cell death would not. 
2.4.1.2.2. Autophagy 
In apoptosis, cells die via a well-defined mechanism purposefully designed for 
cellular death.  In necrosis, we see cellular functions operating in their normal capacities, 
though the stresses placed on the cell exceed the cell’s ability to maintain homeostatic 
function, ultimately resulting in death. Autophagy is an independent mechanism whose 
normal function is to remove and turnover cellular components using the endosomal-
lysosomal system, yet may contribute to an alternative form of programmed cell death.  
Autophagy, unlike apoptosis, does not work exclusively within the realm of cell death – 
this turnover is a normal physiological process. Lysosomal degradation is important to 
remove proteins from the system that are no longer required. Autophagy is involved in 
the cellular response to nutrient deprivation, allowing cells to recycle nutrients when an 
extracellular source is not available.  In addition, autophagy may be important for the 
regulation of cellular metabolism, morphogenesis, differentiation, and cellular defense 
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[58].  Importantly, autophagy is responsible for the removal of accumulated neurotoxic 
aggregates, damaged organelles and membranes, as well as cellular inclusions.  
Autophagy is therefore an important tool in the maintenance of homeostasis.  While 
autophagy is a major contributor to cell survival, in conditions of excess stress or 
activation of this system can lead to autophagic cell death.  
The basic mechanism of autophagy begins with the sequestration of materials to 
be removed in the autophagosome, which fuses with the lysosome to form an autophagic 
vacuole.  The normal, unstressed cell will typically show only basal levels of autophagy.  
This level is upregulated in order to replenish the pool of available amino acids and 
glucose to allow for protein synthesis in the absence of growth factors.  Additionally, 
activation may occur if major organization to the cellular architecture is required [58]. 
The contribution of autophagy to cell death is not as well understood and is 
somewhat controversial.  Autophagy may contribute to cell death either upstream of 
caspase activation or perhaps independent of caspase activation.  The major 
morphological evidence of autophagy is the formation of autophagosomes and 
autophagic vacuoles, microvilli on the cell surface, and chromatin condensation [58]. 
In AD there seems to be extensive dysfunction of the lysosomal system, and 
autophagosomes are evident within dystrophic neurites, though they are not observed in 
axons and dendrites [59].  These vacuoles progressively accumulate, which may be 
reflective of impairment of the lysosomal system and failure of the autophagosomes to 
fuse with lysosomes. Importantly, both APP and the secretases can be found in the 
autophagosome, which may result in the autophagosome being the major intracellular 
pool of Aβ peptide and potentially contributing to plaque formation [59, 106].  
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Interestingly, PS1, one of the subunits of the γ-secretase complex, is enriched in the 
autophagosome.  Mutation of PS1 in familial AD leads to lysosomal pathology and cell 
loss, suggesting that PS1 may be directly involved in the autophagy pathway [59]. 
2.4.1.3. Comments on Cell Death in AD 
One thing to consider is that, although we define these different death pathways as 
distinct pathways, the boundaries between forms of cell death are not clear; there is likely 
significant crosstalk between systems, making our delineation of specific pathways 
somewhat arbitrary [107].  Necrosis and apoptosis, for example, have long been thought 
of as dichotomous.  However, it is plausible that a cell could initiate apoptosis and be 
unable to complete it, and die via necrosis or some other cell death pathway. 
Similarly, we typically categorize neurodevelopment and neurodegeneration at 
opposite sides of a spectrum.  While this categorization is not surprising – one occurs at 
the beginning, the other the end – it is also somewhat arbitrary and potentially incorrect.  
In neurodevelopment, an estimated fifty percent of neurons die during the pruning 
process as the young brain takes its final adult shape.  The cells that are eliminated are 
those that fail to form stable synaptic connections with other cells and do not receive 
trophic support.  In neurodegenerative diseases like AD, there is synaptic degeneration 
and a loss of trophic support.  In the case of the developing brain, the synapses and 
support never existed, in the diseased brain they no longer exist.  Regardless of the 
history behind the circumstances, the neuron’s response is the same – the cell dies.    
In the case of the developing nervous system, the young cell is likely quite 
capable of successfully and efficiently committing suicide.  The aged cell, however, may 
be less well equipped, plagued with chaperone, lysosomal, and metabolic stress, and 
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unable to efficiently complete the energetically taxing process of apoptosis.  The cell 
death observed in AD is, therefore, prolonged, perhaps to the point that apoptosis is 
aborted, a phenomenon sometime referred to as abortosis. 
Aborted apoptosis may be consistent with the observation that although DNA 
fragmentation is observed in the AD brain, other features of apoptosis, including 
chromatin condensation, cell shrinkage, and nuclear fragmentation, are not typically seen. 
Although apoptosis is initiated and parts of the process are completed, others are not.  
Interestingly, the act of cell shrinkage and nuclear fragmentation requires large structural 
changes that would require a dynamic and functional cytoskeletal system.  Evidence of 
microtubule dysfunction is also present in the AD brain [29, 108-110], which may impair 
the cell’s ability to complete the apoptotic process.  In addition, the cytoarchitecture of a 
mature neuron is more complex than that of an immature neuron, and may have been 
maintained that way for decades. The breakdown of such a stable and complex 
architecture may not be possible with an impaired microtubule regulatory system.  
It is interesting to note that the cognitive deficits observed in AD need not be 
caused by loss of neurons.  Loss of synaptic connectivity would be sufficient to result in 
cognitive impairments. It is widely accepted that Aβ can induce the formation of 
abnormalities in the neurites (axons, dendrites, etc) of neurons and result in the 
degeneration of these neurites.  This would disrupt brain circuits in the vicinity of the 
plaques, which can often be observed in the hippocampus and cortex, thereby resulting in 
the dementia observed in AD patients.   
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2.5. Closing Remarks 
In this chapter, we have discussed the correlation between amyloid plaque load, 
tau pathology, and cognitive function.  While amyloid is thought to be central to the 
disease process in AD, it is tau pathology, not amyloid pathology, that correlates more 
closely with cognitive dysfunction.  This can be explained by the presence of small 
oligomers of Aβ.  While amyloid plaque pathology is poorly correlated with cognitive 
dysfunction, the concentration of soluble forms of Aβ correlates more closely.   
Tau pathology follows a predictable course through the brain that is so consistent 
it is commonly used to stage pathology.  Neurofibrillary tangles form first in the 
entorhinal cortex, then progress into the hippocampus and ultimately into the neocortex.  
Here, we present the hypothesis that, if Aβ is upstream of tau pathology and tau 
pathology follows this predictable course through the brain, Aβ production may also 
propogate through the brain in an anatomical fashion. 
Finally, we present two broad cellular processes induced in cells when exposed to 
Aβ, apoptosis and cell cycle activation.  As we will discuss in subsequent chapters, both 
of these processes could contribute to alterations in processing of the amyloid precursor 
protein.  APP has been previously shown to be directly cleaved by caspases, though the 
contribution to amyloidogenesis is not entirely clear. Further, phosphorylation of APP 
occurs in a cell-cycle dependent manner, though whether cell cycle activation results in 
changes in APP proteolysis is also not clear.  In the chapters that follow, we will also 
present a series of experiments designed to characterize the proteolysis of APP during 
apoptosis and cell cycle activation. 
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CHAPTER 3:  CLASSICAL PROCESSING OF APP DURING P53-DEPENDENT  
 
APOPTOSIS1 
 
 
 
3.1. Chapter Synopsis 
In the preceding chapters we have discussed the pathological hallmarks of AD 
including amyloid plaques, neurofibrillary tangles, and cell death, as well as discussed 
some of the prevailing hypotheses of AD, including the amyloid cascade hypothesis, the 
anatomical cascade hypothesis, and the cell cycle hypothesis of AD.  We have reviewed 
the literature regarding evidence of both cell cycle activation and various forms of cell 
death in AD, including apoptosis. 
We have also presented a hypothesis that describes an intersection of the three 
hypotheses mentioned above.  We predict that, given the observation that tau pathology 
progresses in a predictable pattern through the brain, and that Aβ can elicit cell cycle 
activation and, consequently, phosphorylation of tau at epitopes associated with both 
mitosis and AD, Aβ may also progress in a similar pattern.  Further, we hypothesize that 
p53-induced apoptosis and/or cell cycle activation may provide a mechanism for this 
progression. 
In the current chapter, we first review the mechanism behind p53-dependent 
apoptosis, and present our model concerning changes in APP processing during p53-
dependent apoptosis.  We then present our findings concerning the processing of APP 
                                                 
1 Portions of this chapter have been previously published (Fiorelli et al., 2013) and are utilized 
with the permission of the publisher.  See Appendices B and C. 
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during p53-depedent apoptosis, and discuss the relevance of these findings for AD 
pathogenesis in the context of our hypothesis. 
3.2. P53-Dependent Apoptosis 
As described in section 2.4.1.1 in chapter 2, Aβ is capable of inducing activation 
of p53 and p53-dependent apoptosis.  In this section, we will describe the function of p53 
and its role in apoptosis. 
3.2.1. Function of P53 
P53 was initially identified as an oncogene, due in part to the fact that it tends to 
be overexpressed in many different tumor-derived cell lines.  Later, however, it was 
shown that the oncogenic potential of p53 actually derives from mutation of the gene, 
typically within its DNA-binding region, and often exerting dominant-negative effects on 
wild-type p53 [1].  In fact, wild-type p53 acts as a potent tumor suppressor due to its role 
both in allowing DNA repair and in initiating apoptosis in cells in which DNA damage is 
irreparable [1]. 
P53 performs these two important functions through its activity as a transcription 
factor.  P53 transcriptionally regulates genes involved in cell cycle arrest and apoptotic 
cell death.  The levels of p53 under normal conditions are quite low, but when cells are 
under stress from DNA damage, oxidative stress, or other cellular stressors p53 is post-
translationally modified by phosphorylation and/or acetylation.  This stabilizes the 
protein and allows it to accumulate in the nucleus [1].  If p53 levels in the nucleus are 
sufficiently elevated, transactivation of pro-apoptotic genes can occur. 
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3.2.2. Mechanism of P53-Dependent Apoptosis Induction 
P53 transcriptionally regulates many proapoptotic genes, including Bax.  Bax can 
form heterodimers with other pro-apoptotic members of the bcl-2 family of proteins, 
which interact with the mitochondrial voltage-dependent anion channel (VDAC), leading 
to a loss of membrane potential across the mitochondrial membrane.  A loss of 
mitochondrial membrane potential leads to the release of cytochrome c from the 
mitochondria, an important step in the induction of apoptosis [2].  Cytochrome c, once in 
the cytoplasm, can bind to Apaf-1 [2], leading to the formation of a multi-subunit protein 
complex referred to as the apoptosome [3].  Caspase-9 is recruited to the apoptosome 
complex, resulting in the activation of caspase-9 – an initiator caspase.  Caspase-9 can 
then cleave and activate other downstream caspases. 
3.2.3. Downstream Effectors of Apoptosis 
Following initiation of apoptosis through cytochrome c release, assembly of the 
apoptosome, and activation of caspase-9, an initiator caspase, occurs.  Caspase-9 can then 
cleave and activate caspase-3 and caspase-7, executioner caspases, which act on cellular 
targets and execute the apoptotic process.  Executioner caspases cleave a variety of 
intracellular targets, including nuclear lamins, poly-(ADP ribose) polymerase (PARP), 
and inhibitor of caspase-activated DNase (ICAD).   
Nuclear lamins are the proteins that form the structural framework for the nucleus 
and are essential for proper function of the nucleus.  Nuclear lamins are known to 
associate with chromatin, specifically interacting with the tail domains of core histones 
[4].  Thus, nuclear lamins provide the nucleoplasmic scaffold for organizing chromatin in 
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the nucleus [5].  Degradation of nuclear lamins by caspases results in the breakdown of 
the nuclear architecture, leading to nuclear fragmentation characteristic of apoptosis. 
PARP is another nuclear protein involved in DNA repair.  Its major function is to 
detect single-strand DNA breaks, binding to DNA at the site of breakage and 
synthesizing a poly (ADP-ribose) chain at the site.  This chain acts as a signal for the 
enzymatic machinery involved in DNA repair [6].  During apoptosis, however, PARP is 
cleaved by executioner caspases, leading to its inactivation [7].  Through this elegant 
system, DNA repair, an energetically costly endeavor, is halted when DNA damage is 
very extensive, allowing caspase-dependent degradation of chromosomal DNA to 
proceed without untoward investment in DNA repair. 
ICAD functions as a chaperone for caspase-activated DNase (CAD), binding to 
CAD during transcription and complexing with CAD after transcription is complete.  
Upon cleavage by executioner caspases, however, ICAD dissociates from CAD, allowing 
CAD to enter the nucleus and resulting in the degradation of chromosomal DNA [8], 
perpetuating the process of p53-dependent apoptosis. 
3.3. Intrinsic vs. Extrinsic Apoptosis 
It is important to note that DNA damage and activation of p53 is not the only way 
in which apoptosis can be induced.  The induction of apoptosis involving cytochrome c 
release from the mitochondria, assembly of the apoptosome, and activation of initiator 
caspase-9 is referred to as intrinsic apoptosis.  Apoptosis can also be initiated via 
extrinsic, receptor-based pathways.  This involves the binding of a death ligand to a death 
receptor.  A common example of this is the binding of Fas Ligand (FasL) to the death 
receptor Fas.  This results in the formation of a complex that, like the apoptosome, 
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recruits other proteins, including an initiator caspase.  This complex is referred to as the 
death-inducing signaling complex, and assembly of this complex results in the activation 
of caspase-8, an initiator caspase that, like caspase-9, can proceed to activate executioner 
caspases, resulting in degradation of cellular targets and “execution” of apoptosis as 
described in section 1.2.3. 
3.4. Modeling P53-Dependent Apoptosis with Camptothecin 
As described at the end of chapter 2, we hypothesize that Aβ production may 
propogate through the brain in a feed-forward manner, and we focus our investigation on 
cellular processes which are both induced by and have the potential to result in 
production of Aβ.  For our investigations regarding apoptosis we chose to focus on p53-
dependent apoptosis since, as described in section 2.4.1.1., Aβ-mediated apoptosis 
appears to involve p53-dependent mechanisms. 
3.4.1. Mechanism of Action of Camptothecin 
In order to model p53-dependent apoptosis in vitro, we used the DNA-damaging 
agent camptothecin (CPT).  CPT is a topoisomerase-I inhibitor, which stabilizes the 
interaction of topoisomerase-I with DNA, specifically inhibiting the religation of DNA 
by topoisomerase.  During DNA synthesis, the stabilization of topoisomerase-1 on the 
DNA results in the collision of the advancing replication fork with the 
topoisomerase/DNA complex.  Since the DNA has already been nicked by 
topoisomerase, synthesis stops as the replication forks reaches the broken DNA, 
essentially resulting in double-strand DNA breaks [9].  The extensive DNA damage 
resulting from CPT-induced topoisomerase-I inhibition leads to p53-dependent apoptosis.  
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Because this damage occurs during DNA synthesis, CPT-induced apoptosis occurs as the 
cells attempt to progress through S-phase. 
In addition to induction of double strand breaks in DNA, RNA synthesis is also 
halted by a similar mechanism.  The transcriptional machinery can also collide with the 
stabilized topoisomerase/DNA complex, resulting in a halting of transcriptional function 
and single-stranded DNA breaks. 
3.4.2. H4-APP Cells 
In the studies described here, we utilized H4 neuroglioma cells overexpressing 
human wild-type APP (H4-APP cells).  These cells were obtained as a kind gift from Dr. 
Todd Golde from the Mayo Clinic in Jacksonville, FL.  Generation of this cell line has 
been previously described [10].  Briefly, H4 cells, neuroglioma cells from the brain of a 
37 year old Caucasian male (ATCC HTB-148), were grown to 70% confluency in 6-well 
plates and tranfected with 1 µg plasmid DNA containing the human wild-type APP gene 
preincubated with 3 µL FuGene 6 transfection reagent in serum-free OptiMEM.  Cells 
were selected for 10-14 days using 800 µg/mL Hygromycin B in OptiMEM with 10% 
fetal bovine serum.  After initial selection, the concentration of Hygromycin B was 
reduced to 200 µg/mL [10].  Once received in our laboratory, cells were maintained in 
OptiMEM containing 10% fetal bovine serum, 200 µg/mL Hygromycin B, 100 U/mL 
Penicillin and 100 µg/mL Streptomycin.  
3.4.3. Induction of Apoptosis in H4-APP Cells 
Since CPT, as discussed above, is most efficient at inducing apoptosis in S-phase, 
in order to achieve a homogeneous population of apoptotic cells we synchronized cells by 
serum starvation for 48 hours in DMEM containing 100 U/mL Penicillin and 100 µg/mL 
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Streptomycin.  After serum starvation, cells were serum stimulated and treated 
simultaneously with 10 µM CPT and analyzed as they progressed into apoptosis. 
3.4.3.1. Morphological Characteristics of Apoptosis 
As shown in Figure 3.1, treatment of cells for three to six hours with 10 µM CPT 
results in morphological changes indicative of apoptosis.  These include detachment from 
the plate, cell shrinkage, and membrane blebbing.  The cells also show DNA 
fragmentation (data not shown).  Our initial morphological observation of CPT-treated 
cells indicate that apoptosis is evident at three hours post treatment, with significant 
apoptosis evident at six hours. 
3.4.3.2. Quantification of Apoptosis with Propidium Iodide 
In order to quantify the number of cells undergoing apoptosis, cells were 
harvested at each time point and fixed in 70% ethanol.  Following fixation, cells were 
washed and resuspended in PBS containing 5 μg/mL propidium iodide, 0.1% Triton X-
100, and RNaseA in PBS and incubated at room temperature for 45 minutes.  Cells were 
then analyzed using a BD LSR II flow cytometer.2 Results were modeled for cell cycle 
progression and apoptosis using ModFit LT. 
Propidium iodide stains nucleic acid and is often used to characterize the cell 
cycle profile of a population of cells.  Normal diploid cells in G1 phase will have a given 
DNA content, while cells that have replicated their DNA and are in G2/M phase of cell 
cycle will have twice that amount, and cells in the process of replicating their DNA, those 
in S-phase, will have DNA content that falls somewhere between these two peaks (Figure 
                                                 
2 These experiments were performed with the kind help of Karoly Szekeres of the USF Health 
Morsani College of Medicine Flow Cytometry Core. 
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Figure 3.1.  CPT induces apoptosis in H4-APP neuroglioma cells . (A) H4-APP cells 
were exposed to 10 μM CPT for zero to six hours and examined using brightfield 
microscopy.  Morphological changes indicative of apoptosis, including cell detachment 
and shrinkage, were noted after three hours of treatment and were most pronounced at 
six hours. 
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3.2A).  Apoptotic cells, however, which are undergoing fragmentation of the DNA, 
appear as a sub-G1 peak (Figure 3.2B). 
The percentage of cells in each phase of the cell cycle and in apoptosis can be 
modeled by software, such as ModFit LT or FloJo, that applies these characteristics to 
map a series of functions, one for each phase and one for apoptosis, which overly the 
curve described by plotting the number of cells against the amount of propidium iodide 
staining detected.  This modeling software then integrates these functions, allowing us to 
determine the relative number of cells that fall within each peak.   
When this modeling algorithm is applied to the data for cells treated with CPT we 
find that, with regard to the cell cycle profile, there is a significant increase in the cells in 
S-phase after six hours of treatment (Figure 3.2C).  This is consistent with the mechanism 
of action of CPT, as described in section 3.4.1.  Given that CPT is most effective during 
S-phase, the accumulation of cells in S phase is indicative of an inhibition of progression 
through this phase of the cell cycle.  With regard to apoptosis, there is a significant 
induction of apoptosis in cells treated with CPT after three hours, reaching a maximum 
degree of cell death after six hours, with 80% of cells in apoptosis.  This suggests that 
CPT effectively induces apoptosis in our cellular system. 
3.4.3.3. Biochemical Characteristics of Apoptosis 
P53-dependent apoptosis, as described in section 3.2, involves a dramatic increase 
in the levels of P53 in the nucleus, followed by sequential activation of caspase-
dependent cleavage of cellular targets including PARP.  In order to verify that apoptosis 
was actually occurring in the H4 cells, lysates were prepared in RIPA lysate buffer, 
loaded on to 10-20% tricine gels, and proteins separated by polyacrylamide gel 
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Figure 3.2.  CPT induces apoptosis in H4-APP neuroglioma cells after three to six 
hours. (A) H4-APP cells growing asynchronously in culture were fixed and DNA 
stained with propidium iodide.  DNA content of cells was determined by flow 
cytometry.  Untreated cells show a typical cell cycle profile, with a major peak at G1, 
elevated through S phase, and a minor peak for the G1/M phases.  (B) Cells treated 
with CPT for 6 hours prior to collection show a sub-G1 population indicative of 
apoptosis.  (C)  The cell cycle profile of cells treated with 10 µM CPT for 0.5-12 hours 
indicates that at the six hour and 12 hour time points, time points associated with 
extensive apoptosis, cells accumulate in S-phase (asterisks indicates significant 
difference from untreated, p<0.001).  (D) Quantification of the number of cells 
undergoing apoptosis with CPT treatment shows that apoptosis is significantly induced 
with a three hour CPT treatment, and six hour treatment results in approximately 80% 
of cells in apoptosis.  
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electrophoresis (PAGE).  Protein in gels were transferred to 0.2 µm nitrocellulose and 
immunobloted for P53 and PARP.  As shown in Figure 3.3A, p53 was significantly 
induced after treatment with CPT for three to six hours – the same time frame which 
identified apoptosis by both morphological assessment of cells in culture (Figure 3.1) and 
by propidium iodide staining and flow cytometry (Figure 3.2).  The induction of P53 by 
CPT is quantified in Figure 3.3B.   Further, PARP is also cleaved at these time points, 
suggesting activation of executioner caspases. 
 Taken together, the results presented here suggest that CPT effectively induces 
P53-dependent apoptosis in H4-APP cells after three to six hours of treatment.  
Therefore, further experiments investigating the effects of P53-dependent apoptosis were 
performed using 10 µM CPT for three to six hours. 
3.5. Processing of APP During P53-Dependent Apoptosis 
The goal of this set of experiments is to determine whether P53-dependent 
apoptosis has an effect on processing of APP.  As described in section 1.7, Aβ is 
generated from sequential cleavage of APP by β-secretase and γ-secretase.  Jin el al have 
described an increase in γ-secretase activity with P53-dependent apoptosis [11].  Here 
they treated CHO cells overexpressing the C99 fragment of APP with CPT and showed a 
dose-dependent increase in γ-secretase activity as determined by a luciferase-based assay.  
Further, as γ-secretase activity increased, C99 levels decreased, suggesting that the γ-
secretase activity may be resulting in the cleavage of C99 to generate Aβ, though the 
generation of Aβ was not assessed in this model [11].  In a separate model in which both 
human APP with the Swedish mutation (APP(KM670/671NL) and β-secretase is 
overexpressed, the CPT-dependent increase in γ-secretase activity did result in an 
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Figure 3.3.  P53 induction and PARP cleavage in H4-APP cells treated with CPT for 
three to six hours. (A) Representative blot from three independent experiments 
performed to determine the levels of p53 and PARP upon treatment with 10 µM CPT 
for zero to six hours. CPT-induced apoptosis is associated with a time-dependent 
induction in p53 (A, top panel) and cleavage of PARP (A, middle panel). Reprobe of 
p53 blot with an antibody against β-actin shows equal protein loading (A, bottom 
panel). (B) Quantification of p53 blot shows a significant induction after one hour, 
p<0.001. Post hoc analysis reveals that each group is significantly different from all 
other groups. 
 
 
 
 
 
 
 
 
 
 
104 
increase in Aβ generation [11].  The authors did not, however, assess whether β-secretase 
or α-secretase activity were altered with CPT treatment.   
It is also worth noting that while this work was being performed in our laboratory, 
another group reported that p53 is capable of regulating the expression of APP in 
neuroblastoma cells and primary neuronal cultures [12].  This seems to be mediated by a 
p53-dependent reduction in the binding of Sp1 to the APP promoter.  When p53 is 
overexpressed or cells are treated with CPT, the binding of Sp1 to the APP promoter is 
suppressed and APP expression is reduced. 
3.5.1. Assessing α- and β-Secretase Activity  
Although the activity of γ-secretase is known to increase during p53-dependent 
apoptosis, the α- and β-secretase cleavage steps are the rate limiting enzymatic steps in 
APP proteolysis, and also the steps that dictate amyloidogenic vs. non-amyloidogenic 
processing.  Therefore, we decided to assess the activity of α- and β-secretase to 
determine whether APP processing is indeed shifted toward amyloidogenesis in our 
model.   
3.5.1.1. FRET-Based Assays 
In order to assess the relative activities of α- and β-secretase, we first attempted to 
utilize commercially available fluorescence resonance energy transfer (FRET)-based 
assays.  A schematic depicting these assays is shown in Figure 3.4. In these assays, the 
portion of the APP peptide cleaved by the enzyme of interest is conjugated to 5-(2′-
aminoethyl) aminonapthalene-1-sulfonic acid (EDANS) and 4-(4′-dimethylamino-
phenylazo) benzoic acid (DABCYL).  The EDANS moiety has an excitation wavelength 
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Figure 3.4.  Assessing β-secretase activity using an EDANS/DABCYL reporter system. 
Peptide fragments representing the portion of APP cleaved by β-secretase are 
conjugated to EDANS and DABCYL molecules. If the peptide is not cleaved, 
DABCYL efficiently absorbs fluorescent emissions from EDANS, quenching the 
signal. However, when the peptide is cleaved EDANS is physically separated from 
DABCYL, allowing a fluorescent signal to be emitted. This signal is proportionate to 
the amount of substrate cleaved. 
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of 336 nm and emits at a wavelength of 490 nm.  This acts as a fluorescence donor for the 
DABCYL moiety, which absorbs light at the same wavelength, effectively quenching 
fluorescence from the EDANS moiety.  When the substrate is cleaved by the secretase, 
however, the EDANS and DABCYL moiety are physically separated from one another 
and the DABCYL moiety can no longer quench the light emitted by the EDANS moiety.  
The 490 nm light emitted by EDANS can be measured using a plate reader capable of 
exciting at around 336 nm and reading fluorescent light at around 490 nm.  The amount 
of fluorescence measured is directly proportional to the amount of substrate cleaved by 
the secretases in the assays. 
3.5.1.2. Utility of FRET-Based Assays with Camptothecin 
Cells were treated with various concentrations of CPT for 24 hours and lysates 
prepared in the provided buffer according to the manufacturer’s instructions (R&D 
Systems catalog number FP003), Lysates were combined with substrate in a black-96-
well plate and read on a BioTek plate reader using an excitation wavelength of 360 nm 
and reading at a wavelength of 460 nm.  The apparent β-secretase activity observed in 
this assay increases in a dose-responsive manner as shown in Figure 3.5A.  When cells 
are treated with 10 µM CPT for 0-24 hours, an interesting pattern is observed.  Cells 
which are not treated with CPT (the 0 hour time point), show very little apparent β-
secretase activity.  When CPT was added the maximal detection of apparent β-secretase 
activity occurred during the earliest time points, with intensity of the signal slowly fading 
over time (Figure 3.5B)   
It is worth noting that the data depicted in Figure 3.5 are presented as a fold 
change over background.  In calculating this change, a ratio is taken between the sample 
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Figure 3.5.  Apparent β-secretase activity increases with exposure to CPT.  (A) 
Exposure to increasing concentrations of CPT for 24 hours is associated with an 
apparent dose-dependent increase in β-secretase activity as measured by a 
commercially available FRET-based assay over three independent experiments.  
Asterisk indicates significant difference from untreated controls, p<0.01.  (B) 
Exposure to 10 μM CPT for 0-24 hours is associated with an increase in apparent β-
secretase activity at all time points where CPT is present. 
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of interest and the basal fluorescence present in a sample in which there is no substrate 
and only lysate is present.  For the dose response, the background sample utilized did not 
contain CPT, while in the time course the background sample did contain CPT.  Note that 
there is a 10-fold difference in the scale of the axis between Figure 3.5A and 3.5B.  In 
Figure 3.5B the untreated sample, which did not contain CPT, shows a reduction in the 
the apparent β-secretase activity as compared to a sample containing CPT but no 
substrate whatsoever, thereby yielding a fold change over background of less than one.  
This concerned us, as it suggested that the signal detected in the assay was not fully 
dependent on the presence of the substrate, though it did seem that, based on the dose 
response, the signal was dependent on the presence of CPT. 
A review of the literature on the CPT molecule revealed that CPT is actually 
fluorescent, with an excitation wavelength of approximately 370 nm and an emission 
wavelength of approximately 470 nm [13].  The excitation and emission wavelengths of 
EDANS, the reporter in this assay, are 336 nm and 490 nm, respectively, and the plate 
reader used in this assay used an excitation wavelength of 340 nm and read emitted light 
at 460 nm.  Due to the significant overlap between the spectra of EDANS and the spectra 
of CPT, we conclude that this particular assay is incompatible with the use of CPT.  
3.5.1.3. γ-Secretase Inhibition 
The finding that these secretase assays are unsuitable for determining CPT-
dependent changes in secretase activity forced us to find alternative ways to measure α- 
and β-secretase activity.  Given that (1) our goal was specifically to assess the relative 
activity of α- and β-secretase with APP as a substrate, (2) α- and β-secretase are the rate 
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Figure 3.6. C99 and C83 accumulate with γ-secretase inhibition by Compound E.  
Treatment with various concentrations of Compound E for 24 hours results in the 
accumulation of C-terminal fragments due to γ-secretase inhibition as detected by 
western blot.  Using a Licor Odyssey Infrared Imager, we are able to double-label the 
same protein at two epitopes.  In the top and bottom panels, the C-terminus of APP is 
labeled with a secondary antibody emitting light at a wavelength of 700 nm (red), 
while Aβ1-16 (the 6E10 epitope) is labeled using a secondary antibody emitting light at 
800 nm (green).  Bands representing fragments that contain both the C-terminus and 
the 6E10 epitope (full length APP in the top panel and C99 in the bottom panel) appear 
as yellow-orange.  A reprobe of the same blots with actin was also performed, and is 
shown in green in the middle panel. 
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limiting enzymatic steps in their respective proteolytic pathways, and (3) the activity of γ-
secretase during CPT-induced p53-dependent apoptosis had been previously assessed, we 
decided to utilize γ-secretase inhibition to prevent the turnover of C83 and C99 to p3 and 
Aβ (respectively) and AICD.  This would allow us to isolate the production of C83 and 
C99 in order to determine relative α- and β-secretase activity.  In order to inhibit γ-
secretase we used the potent, non-competitive γ-secretase inhibitor Compound E [14], 
which at a concentration of 1 nM effectively inhibited γ-secretase as evident by the 
accumulation of the α- and β- cleaved fragments C83 and C99 shown in Figure 3.6. 
The lack of a dose-dependent increase in C99 and C83 levels in this experiment 
suggests that concentrations lower than 1 nM may indeed be sufficient to inhibit γ-
secretase in our model.  It should be noted that concentrations of Compound E used in the 
literature range from 30 nM to 300 nM [14-16], though the IC50 of Compound E reported 
in the literature is 7 nM [17].  In spite of the lack of a dose response, we decided to use a 
concentration of 1 nM for further experimentation based on the fact that this 
concentration was below the reported IC50 for the compound, suggesting that it was 
within a range where we would not expect excessive off-target effects. 
3.5.1.4. Visualization of C-Terminal APP Fragments During P53-
Dependent Apoptosis 
In order to assess CPT-dependent changes in APP processing, we treated cell with 
1 nM Compound E for 24 hours, then treated with 10 µM CPT for 30 minutes to three 
hours or cells were left untreated. Cell lysates were then analyzed by western blot for 
APP and its proteolytic fragments using antibodies against the Aβ-region (6E10) (FL-
APP), the C-terminus of APP (C83 and C99), and β-actin (Actin).  A representative blot 
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Figure 3.7.  C99 generation is reduced and C83 production maintained with CPT 
treatment in the presence of Compound E.  (A) Treatment with 10 µM CPT for zero 
to three hours in the presence of Compound E leads to a decrease in full length APP, 
decreased levels of C99, and maintained levels of C83 in CPT treated cells as 
detected by western blot, with actin shown as a protein loading control. (B) 
Quantification of FL-APP detected after treatment with Compound E for 24 hours 
and CPT for 0-3 hours. Analysis by two way ANOVA revealed a significant effect 
of CPT treatment, with treated cells showing lower levels of FL-APP than untreated 
controls, F(1,29)=4.51,p=0.046. Histogram shows the mean of three independent 
experiments, ± SEM.  (C) Quantification of the ratio of C99 to FL-APP after 
treatment with compound E and CPT. No significant effect of treatment is observed. 
(D) Quantification of the ratio of C83 to FL-APP after treatment with compound E 
and CPT. A significant effect of treatment over time was observed as determined by 
two way ANOVA, F(4,29)=8.32, p=0.007, with the ratio of C83 to FL-APP 
increasing over time in CPT. Both histograms show the mean of three independent 
experiments, ± SEM.  
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shown in Figure 3.7A.  As expected, based on the literature indicating a decrease in the 
expression of APP during P53-dependent apoptosis [12], quantification of the levels of 
FL APP across three independent experiments showed a significant decrease in the levels 
of APP with CPT treatment (Figure 3.7B).  Since APP expression is known to decrease 
and a decrease in FL-APP was observed in our model, we took the ratio of the C-terminal 
fragments to FL-APP.  This provides us with some indication of secretase activity – 
maintained secretase activity would be indicated by a reduction in C-terminal fragment 
levels that paralleled the levels of FL-APP, leading to no change in the ratio of C-
terminal fragment to APP.  Indeed, this is exactly the pattern observed for C99 (Figure 
3.7A and C).  C83, on the other hand, is maintained in spite of decreasing availability of 
the substrate (Figure 3.7A and D), potentially indicating an increase in the activity of α-
secretase in spite of a decrease in the levels of FL-APP.  This upregulation of α-secretase 
activity may be a compensatory mechanism, allowing the production of sAPPα to be 
maintained in spite of decreasing APP, suggesting an important role of sAPPα in cellular 
function.  
3.5.1.5. Secretase Levels and Localization During P53-Dependent 
Apoptosis 
In order to assess the levels and localization of α-, β-, and γ-secretases, we 
performed immunostaining for ADAM-10, BACE, and PS1.  BACE was localized to the 
cell membrane as well as intracellular compartments morphologically consistent with the 
golgi apparatus.  PS1 was heavily colocalized with BACE in these same compartments in 
both treated and untreated cells.  Immunostaining for both BACE and PS1 showed no 
significant change in the levels or localization of either protein (Figure 3.8A). 
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Figure 3.8.  Immunocytochemistry of H4-APP cells with and without CPT treatment. 
Cells treated with 10 µM CPT and untreated controls were co-stained with BACE 
(green) and PS1 (red) antibodies, using Alexa Fluor 488 and 594 as secondary 
antibodies, respectively.  No significant changes in levels or localization of BACE or 
PS1 were observed.  (B) ADAM-10 levels and localization were also assessed, and 
there appeared to be an induction in the diffuse ADAM-10 staining in CPT treated 
cells.  (C) Quantification of ADAM-10 staining was performed using ImageJ.  Cell 
perimeters as well as areas of positive staining were identified, allowing us to 
determine the percentage of the area of the cell occupied by positive staining.  
Quantification across all images taken reveals a significant increase in the percent 
area of the cell occupied by ADAM-10, t=4.631, p<0.001. 
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ADAM-10 staining was more diffuse and increased when cells were treated with CPT 
(Figure 3.8B).  The area of the cell occupied by ADAM-10 stain was quantified using 
ImageJ, and showed a significant increase in cells treated with CPT (Figure 3.8C). 
3.5.1.6. Fragments of APP Secreted During P53-Dependent Apoptosis 
Based on the observation that C83 was maintained while C99 levels were 
reduced, along with immunostaining results which suggested that BACE and PS1 were 
unchanged while ADAM-10 seemed to increase, it appears that during p53-dependent 
apoptosis α-secretase activity is enhanced while β-secretase activity remains unchanged  
as total levels of APP are reduced.  We, therefore, hypothesized that Aβ levels would be 
reduced during p53-dependent apoptosis, while sAPPα levels would likely remain 
unchanged – both N-terminal fragments paralleling the changes observed within the C-
terminal fragments.   
In order to test this directly, we next measured the secretion of sAPPα and Aβ in 
apoptotic and non-apoptotic cells. H4-APP cells were treated with 10 μM CPT or left 
untreated and media was collected every hour for six hours. Media samples were 
analyzed by western blot using 6E10 antibody to determine the levels of secreted APP 
fragments.  A significant reduction in the levels of sAPPα was observed in the tissue 
culture supernatant from cells treated with CPT compared to the levels in media from 
untreated cells (Figure 3.9A and B).  This was surprising considering that C83 levels 
were maintained during apoptosis under γ-secretase inhibition as described in section 
3.5.1.4.  This raises the possibility that APP may be processed differently during 
apoptosis, and the likelihood of this is described in chapter 4.  
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Figure 3.9.  CPT treatment is associated with decreased production of sAPPα and 
Aβ. (A) H4-APP cells were treated with or without 10 µM CPT and tissue culture 
supernatants were collected at every hour for six hours. The supernatants were 
boiled with Laemmli sample buffer and analyzed by PAGE and western blot using 
6E10 antibodies.(B) Quantification of data from untreated and CPT treated cells 
after six hours of treatment with 10 µM CPT. (C) Tissue culture supernatant from 
H4-APP cells treated with or without CPT for one to six hours was 
immunoprecipitated using 6E10 antibody and western blotted using the same 
antibody. CPT treatment resulted in a decrease in the levels of sAPPα as well as Aβ 
in the tissue culture supernatant (representative of two independent experiments). 
 
 
 
 
 
 
 
 
116 
We also assessed Aβ levels by immunoprecipitation and western blot analysis 
using 6E10 antibody for both capture and detection. Like sAPPα, Aβ levels were reduced 
in the tissue culture supernatants from CPT treated cells compared to the untreated 
controls, and this reduction was visible at all the time points examined (Figure 3.9 C).  
This is consistent with the observation that C99 is reduced in the lysates of cells during 
p53-dependent apoptosis.   
3.6. Summary of Results 
In these experiments, we have shown that CPT induces apoptosis in H4-APP cells 
within three to six hours and that apoptosis is p53 dependent.  In our model, apoptosis is 
associated with an increase in ADAM-10 levels, but no change in BACE or PS1.  When 
cells are treated with CPT in the presence of the γ-secretase inhibitor Compound E, we 
see a decrease in the levels of C99 that parallels a decrease in the levels of full length 
APP.  Coupled with a decrease in the expression of full length APP previously described 
[12] this suggest that β-secretase activity is unchanged. Under these same conditions, 
however, we see that C83 levels are maintained in spite of decreased expression of the 
APP.  This is consistent with the observation that ADAM-10 is increased in cells and 
suggests that α-secretase activity may be increased in cells undergoing p53-dependent 
apoptosis. 
Aβ secretion is decreased in cells treated with CPT, which is consistent with the 
observation that full length APP and C99 levels are reduced.  Secreted sAPPα, on the 
other hand, is reduced during p53-dependent apoptosis in spite of maintained levels of 
C83 and decreased levels of sAPPα.  This may suggest that there is an alternative 
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cleavage happening within the ectodomain of APP, which precludes the production of 
sAPPα. 
3.7. Conclusions 
3.7.1. Aβ Production is Not Increased During P53-Dependent Apoptosis 
While the ability of Aβ to induce apoptosis has been well established, the effects 
of apoptosis on Aβ production are not yet clear.  To our knowledge, only one study has 
been performed in which Aβ levels were assessed during p53-dependent apoptosis.  This 
study was performed in HEK cells that overexpressed both APP with a Swedish mutation 
and, importantly, β-secretase [11].  The use of cells of non-neuronal origin, as well as the 
overexpression of β-secretase, may have contributed to higher levels of Aβ production 
than would occur in more neuronal cells that do not overexpress β-secretase. 
The apparent differences observed between our study and that of Jin et al may 
also be related to differences in endocytosis between HEK cells and our H4 cells.  One 
study has identified that the effects of endocytosis inhibitors are vastly different between 
HEK cells and C6 cells (a glioma cell line), suggesting perhaps that basal levels of 
endocytosis, and thus basal levels of amyloidogenic processing, are inherently different 
in HEK cells as compared to neuroglioma [18]. 
Apoptosis in neurons has been shown to be associated with caspase-3-mediated 
cleavage of APP at the C-terminus [19]. This cleavage of APP generates a 31 amino acid 
fragment from the C-terminus of APP, C31, which has been shown to be neurotoxic [20]. 
The effect of caspase cleavage on secretase processing of APP and Aβ production is not 
clearly understood. Co-localization of active caspase-3 with amyloid plaques and with 
caspase-cleaved APP has been observed in AD brain, which led to the hypothesis that 
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caspase activation may lead to enhanced Aβ generation and plaque formation [21, 22]. 
However, this correlation does not necessarily indicate that caspase cleavage of APP 
increases Aβ generation, especially given that truncation of APP at the C-terminus 
removes the endocytosis signal from APP and affects its internalization. If the 
internalization of APP is reduced by caspase-mediated truncation, this may in fact 
decrease Aβ production, as endocytosis is required for cleavage of APP via the 
amyloidogenic pathway [23]. 
Our findings in our neuroglioma cell line that Aβ levels are not, in fact, elevated 
during p53-dependent apoptosis is consistent with the observation that activation of 
caspase-3 results in the removal of C31, which includes the endocytosis signal.  In 
chapter 4, we will present evidence that the cleavage of APP to form C31 is occurring 
during CPT-induced p53 dependent apoptosis, which may contribute to the decreased 
production of Aβ observed in these cells during apoptosis. 
3.7.2. sAPPα is Decreased During P53-Dependent Apoptosis 
In addition to a decrease in the production of Aβ, we also observed a decrease in 
the production of sAPPα.  Changes in sAPPα are of particular interest, as sAPPα has been 
implicated in protecting neurons and synapses from apoptosis [24-26]. Our studies 
suggest that changes in APP processing associated with apoptosis could lead to decreased 
levels of sAPPα in the local microenvironment, making cells in that environment more 
prone to degeneration. 
3.7.2.1. Role of APP and sAPPα 
sAPPα is released from neurons in an activity-dependent manner and has been 
shown to have neurotropic effects, promoting long-term neuron survival, as well as 
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neurite outgrowth and synaptogenesis [For review, see 26].  During development, activity 
dependent survival, synaptogenesis, and synapse strengthening are vital to establishing 
the connectivity of the brain.  sAPPα, through its activity-dependent release and 
neurotrophic and neurotropic activity, may be involved in establishing and maintaining 
neural connections in an activity-dependent manner.  As the popular idiom “use it or lose 
it” suggests, active synapses are stable synapses, and it is these synapses that persist long 
term.  This may be achieved, at least in part, through the release and downstream effects 
of sAPPα. 
While the function of APP is not entirely clear3 – it was discovered and named for 
because it is the precursor of Aβ – it is not inconceivable that the function of APP is 
closely tied to the effects of sAPPα.  The structure of APP, with its large extracellular 
domain, one transmembrane pass, and modest intracellular domain, suggests that the 
extracellular portion, functionally, is the “business end” of the protein, with the 
membrane tether and intracellular domain important for trafficking to the surface of the 
cell.   
A loss of sAPPα, therefore, may negatively affect synapse formation, synaptic 
stability, and cell survival.  Even in the absence of Aβ, a loss of sAPPα production may 
contribute to memory loss and neuronal degeneration seen in AD. 
3.8. Closing Remarks 
In this chapter, we have assessed the effects of p53 dependent apoptosis, induced 
by the topoisomerase inhibitor CPT, on H4 cells overexpressing human, wild-type APP 
with regard to classical processing by secretases.  We present evidence that β-secretase 
                                                 
3 For more information regarding endogenous functions of APP, see section 6.4.3.1. 
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activity is not changed, and Aβ production is reduced, which could be due to a reduction 
in the expression of APP.  While we observe evidence for an increase in α-secretase 
activity including increased ADAM-10 levels and maintained levels of C83 in spite of 
decreased expression of APP, we actually see a decrease in the levels of the neurotrophic 
sAPPα fragment.   
The incongruity of the finding that C83 is maintained while sAPPα is reduced 
could be explained by alternative cleavage of APP in the extracellular domain.  The 
secretases are only a few examples of a number of different proteases that cleave APP at 
many sites along the peptide.  In the next chapter, we will explore the possibility of 
alternative cleavage of APP that precludes the formation of sAPPα, and present evidence 
for an apoptosis-dependent cleavage of APP within the near extracellular domain. 
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CHAPTER 4:  ALTERNATIVE PROCESSING OF APP DURING 
 
P53-DEPENDENT APOPTOSIS1 
 
 
 
4.1.Chapter Synopsis 
In the previous chapter, we discussed the effect of p53-dependent apoptosis on 
classical processing of APP, i.e. processing of APP by secretases.  This classical 
processing is particularly important with regard to the pathogenesis of AD, as according 
to the widely accepted amyloid cascade hypothesis Aβ, a proteolytic fragment of APP 
generated by amyloidogenic processing pathway, is central to disease pathogenesis.  Aβ 
can induce phosphorylation of tau and neurodegeneration.  Based on the anatomical 
progression of downstream pathology through the brain, we hypothesized that the 
intracellular pathways induced by Aβ exposure may help to stimulate the production of 
Aβ.  Evidence of p53-dependent apoptosis has been observed in the AD brain, and some 
evidence for upregulation of γ-secretase activity during p53-dependent apoptosis has 
been observed. 
In the previous chapter, we focused on determining whether p53-dependent 
apoptosis is associated with an increase in Aβ production.  The literature regarding 
production of Aβ during apoptosis is mixed, with some literature suggesting there is an 
increase in the production of Aβ and some literature suggesting that Aβ is reduced.  The 
latter view is more consistent with evidence that suggests that caspase cleavage of APP at 
                                                 
1 Portions of this chapter have been previously published (Fiorelli et al., 2013) and are utilized 
with the permission of the publisher.  See Appendices B and C. 
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the C-terminus results in the removal of the endocytosis domain, as endocytosis is 
required for Aβ production [2].  We find that during p53-dependent apoptosis Aβ 
production is decreased, with sAPPα production decreasing as well.  This decrease in the 
neurotrophic fragment may be detrimental to cells in the local microenvironment, as 
sAPPα is involved in cell survival and synaptic stability. 
Importantly, when we assessed levels of the C-terminal fragments of APP under 
γ-secretase inhibition, we saw no change in the levels of C83, the C-terminal fragment 
associated with α-secretase cleavage.  This is inconsistent with the observation that 
sAPPα levels are reduced, suggesting that there may be alternative cleavage of APP 
occurring during p53-dependent apoptosis.  
In the current chapter, we assess alternative cleavage of APP during p53-
dependent apoptosis.  Utilizing the model system presented in chapter 2, we provide 
evidence for the generation of novel proteolytic fragments approximately 25 kDa in size 
and immunoreactive to antibodies against the Aβ-region and the C-terminal caspase site. 
In vitro studies show the formation of one of these fragments in primary neurons, and 
both of these fragments in H4 neuroglioma cells undergoing apoptosis.  Inhibition of the 
generation of fragments with caspase inhibitors suggests that caspase-3 and/or caspase-7 
may play a role in the formation of these fragments. In vivo studies also suggest that 
production of a similar fragment occurs in transgenic mice overexpressing human APP. 
In addition, activation of the same proteases associated with generation of this proteolytic 
fragment in vitro is seen in the vicinity of Aβ plaques in vivo.  In vivo in our transgenic 
animals, the C-terminus appears to be retained in the ~25 kDa fragment.  Modeling of 
preoteolytic processing of APP suggests that this fragmentation may involve proteolysis 
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in the near extracellular domain.  Our studies using small peptide inhibitors of caspases, 
and shRNA to caspase-3 and caspase-7 show that the cleavage of APP during apoptosis is 
more specific to caspase-7 than caspase-3.  The production of these specific proteolytic 
fragments, as well as the involvement of caspase-7 in the cleavage of APP, suggest a 
potentially pathogenic role for this caspase in APP processing and neurodegeneration and 
warrant further investigation. 
4.2.Alternative Cleavage of APP 
In addition to cleavage by secretases, APP can also be cleaved by a number of 
different proteases, including proteases such as calpains and caspases [3-8].  In this 
section, we will review the literature regarding cleavage of APP by these other proteases. 
4.2.1. Cleavage of APP by Caspases 
In apoptotic cells APP is known to be cleaved by caspase-3 at three distinct sites 
[4, 9]. Two of these sites, DNVD*S198 and DYAD*G220, are located near the N-terminus 
of APP, while a third site, VEVD*A740, is located near the C-terminus. Since the 
cleavage at VEVD*A740 could be prevented with the small peptide inhibitor DEVD-
FMK, this cleavage has been attributed to caspase-3 [4].  Caspase-3 is known to be 
upregulated in neurons of the AD brain, especially late in the disease process [10].  
Cleavage at the C-terminal caspase site on APP by caspase-3 generates a 31 amino-acid 
C-terminal fragment referred to as C31. 
It has been shown that Aβ can induce apoptosis, involving activation of caspase-
3, and activation of caspase-3 can induce generation of the C31 fragment, which has been 
shown to induce apoptosis [11].  Aβ treatment of N2a cells results in enhanced apoptosis 
in cells that overexpress full length APP as compared to untransfected N2a cells, 
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indicating that Aβ-induced neurotoxicity is mediated by APP or a proteolytic fragment 
thereof.  In cells in which the VEVD*A740 site has been mutated to VEVAA740 [11], or in 
cells in which APP has been truncated such that the entire C31 peptide is removed, 
apoptosis is not enhanced.  This suggests that the C31 peptide is toxic and mediates Aβ-
induced cytotoxicity.  C31 is known to translocate to the nucleus, which may play a role 
in the induction of apoptosis, but the specific mechanism of C31-induced 
neurodegeneration is not yet clear, though it seems to involve a heterodimerization of 
C99 and C31 [12].  
While the importance of caspase cleavage of APP at the C-terminus, thought to be 
primary site of caspase cleavage on the APP protein, is beginning to be well understood, 
the cleavage of APP at other sites along the entire APP protein, such as the two N-
terminal sites, are not well understood. 
4.2.2. Cleavage of APP by Calpain 
In addition to cleavage of APP by caspases, early reports suggested that APP can 
also be cleaved primarily at the N-terminus by calpain-I, resulting in the generation of an 
~25 kDa N-terminal fragment of APP [5].  Calpain-I is a calcium-sensitive protease 
important for normal neuronal functions.  In neurodegenerative diseases, however, 
calcium homeostasis is disrupted, resulting in aberrant, pathological activation of 
calpains.  The excessive cleavage of calpain substrates that occurs with elevated levels of 
intracellular calcium can be detrimental to normal neuronal function [13]. 
Given that the primary calpain-I cleavage site is within the N-terminus of APP, 
calpain cleavage of APP prevents the production of full length neurotrophic sAPPα 
fragment, though the region of sAPPα required for its neuroprotective effects seems to be 
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located at the C-terminus of sAPPα, as the sAPPβ fragment does not show the same 
neuroprotective effects..  Like the caspase sites in the N-terminus of APP, the importance 
of this cleavage is not well understood. 
4.2.3. Cleavage of APP by MT-MMPs 
APP has also been shown to be cleaved by membrane type matrix 
metalloproteases (MT-MMPs).  These metalloprotease appear to be capable of cleaving 
APP at multiple sites in the extracellular domain in vitro, though it is not clear if all of the 
sites identified in this study are active in vivo [14].  It is, however, evident that MT-
MMPs do in fact cleave APP in vivo, and that this cleavage is enhanced in AD.  
Fragments generated by cleavage at the α-secretase site as well as one of the sites 
identified in vitro, SFGA*D626, has been isolated from the cerebral spinal fluid of patients 
with AD [1, 14]. 
While the functional role of metalloprotease cleavage of APP is not clear, it’s 
interesting to note that the fragments observed in the cerebrospinal fluid of AD patients 
are generated from α-secretase cleaved APP.  In order for α-secretase to confer its 
neuroprotective effects, the C-terminus of sAPPα, beyond the β-secretase site, must be 
present.  While sAPPα is neurotrophic, sAPPβ is 50- to 100- fold less so [15].  The 
cleavage of APP by MMPs at this site would remove the C-terminus of sAPPα, largely 
removing the neuroprotective potential of sAPPα.  It is not clear whether these MMP 
cleaved fragments are capable of providing neuroprotection in their own right. 
4.3.Proteolysis of APP During P53-Dependent Apoptosis  
It is evident from the literature reviewed in this chapter thus far that the 
alternative proteolysis of APP by enzymes other than secretases, though known to exist, 
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is vastly underappreciated and understudied.  In order to more fully characterize the 
proteolysis of APP during p53-dependent apoptosis, we assessed the proteolytic 
fragments of APP formed after H4-APP cells, as well as primary rat neurons, were 
subjected to DNA damage-induced apoptosis. 
4.3.1. Proteolysis in H4-APP Cells 
To assess the proteolytic processing of APP, we performed western blot analyses 
of lysates from H4-APP cells treated with CPT for different time periods using 6E10 and 
caspase-cleaved APP antibodies. The 6E10 antibody was raised against amino acids 1-16 
of the Aβ region in APP while caspase-cleaved APP antibody was raised using a 
synthetic peptide preceding the aspartic acid residue (APP739) in the C-terminal caspase-
cleavage site of APP, and affinity purified to specifically detect APP cleaved at this site 
[4].  
Western blot analysis of samples run on 10-20% Tricine gels using the 6E10 
antibody showed the appearance of novel cleaved APP fragments in lysates from cells 
undergoing apoptosis, but not in those from untreated samples (Figure 4.1A, top panel). 
CPT treatment was associated with a decrease in full length APP (Figure 4.1A top panel 
and second panel showing a lighter exposure of the full length APP). Together, these 
results suggest that the 6E10-binding domain of APP is cleaved from the full length 
protein during apoptosis. The blots also showed a decrease in a 6E10 reactive APP 
fragment migrating approximately at 12 kDa in cells treated with APP, which we believe 
corresponds to the β-secretase cleaved C-terminal fragment of APP, C99 of APP. 
Reprobe of the blots with caspase-cleaved APP antibody detected two bands, one 
running approximately at 78 kDa, which was not altered under apoptotic conditions, and 
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Figure 4.1. CPT-induced apoptosis of H4-APP cells is associated with the formation 
of novel APP fragments: (A) Lysates from H4-APP cells were separated on 10-20 % 
tricine gel and western blot analysis performed using 6E10. A time-dependent increase 
in the level of APP fragments is observed in the apoptotic cells. A short exposure of 
the blot shows a decrease in the levels of full length APP in a time-dependent manner 
in the CPT treated cells (second panel). The blot was reprobed with caspase-cleaved 
APP antibody, showing a time-dependent increase in the cleaved fragments in 
apoptotic cells (third panel). The lower panel shows the reprobe of the blot with an 
antibody against β-actin to show protein loading. (B) Lysates from H4-APP cells 
treated with CPT for one, three, and six hours were separated on a 15 % Tris-Glycine 
gel and analyzed by western blot using 6E10 and caspase-cleaved APP antibodies. 
6E10 antibody shows the appearance of the cleaved fragment (second panel) of APP 
with a concomitant decrease in the levels of full length APP after CPT treatment (top 
panel). Caspase-cleaved APP antibody shows much stronger immunoreactivity to the 
proteolytic fragments (third panel). Probing for β-actin showed equal amount of 
protein loading on the gels. (C) Quantification of the bottom band detected by 
caspase-cleaved APP antibody, with normalization to actin, revealed a significant 
induction in this band after six hours of CPT treatment, p=0.018. 
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a lower migrating band around 25 kDa which showed a time-dependent increase in 
lysates from apoptotic cells Figure 4.1A, third panel). Analysis of lysates from H4-APP 
cells after one, three, and six hours of treatments with CPT showed similar results on a 
15% Tris-glycine gel (Figure 4.1B, top and second panel). 
Reprobe of these blots with the caspase-cleaved APP antibody showed that two 
bands, which migrate between 25 and 37 kDa, are detected by this antibody (Figure 4.1B, 
third panel). This suggested to us that at least one of these bands could be similar or the 
same as that detected by 6E10 antibodies.  Quantification of the lower caspase-cleaved 
APP fragment from three independent experiments showed a significant increase in APP 
cleavage under apoptotic conditions (Figure 4.1C).  Because the detection of this 
fragment was most efficient with the caspase cleaved APP antibody, we used this 
antibody for most of our subsequent studies. 
4.4.Caspase Inhibition Prevents Production of Novel Proteolytic Fragments and 
Suggest Involvement of Group II Caspases 
In order to determine whether these fragments are formed by caspase cleavage of 
APP, H4-APP cells were pretreated with either the group II caspase inhibitor zDEVD-
FMK or the broad-spectrum caspase inhibitor zVAD-FMK for one hour, and then treated 
with or without CPT for six hours. Flow cytometric analysis of propidium iodide stained 
cells revealed that caspase inhibitors protected the cells against CPT-induced apoptosis  
(Figure 4.2A). Importantly, western blot analysis of the cell lysates revealed a significant 
reduction in CPT-induced generation of the novel fragments in the presence of zDEVD-
FMK and more significant inhibition with zVAD-FMK (Figure 4.2B).  This is quantified 
132 
 
 
Figure 4.2.  Formation of the ~25-35 kDa fragments is caspase-dependent.  (A) 
Quantification of the number of cells undergoing apoptosis in the presence and 
absence of caspase inhibitors and CPT, as analyzed by flow cytometry with propidium 
iodide staining. Asterisks indicate a significant difference between groups, p<0.05. (B) 
Western blot analysis of the H4-APP cells showed a strong reduction in the formation 
of the new fragments in the presence of zDEVD-FMK. In the presence of zVAD-
FMK, the formation of these bands was completely abolished. Reprobe of these blots 
with an antibody against β-actin shows protein loading on gels. (C) Quantification of 
the bottom band detected by the caspase-cleaved APP antibody, normalized to actin, 
from three independent experiments, reveals significant attenuation in the formation of 
the fragments by caspase inhibitors, with the six hour CPT treated sample showing a 
significant difference from all other groups, p<0.05. Note that a logarithmic scale is 
used in this panel. 
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in Figure 4.2C – note that given the magnitude of these changes a logarithmic scale is 
used in this figure.   
A similar effect is seen in H4 cells that are not overexpressing APP as well, with 
inhibition of caspases abolishing the formation of this fragment as detected by both 
caspase cleaved APP antibodies and, though the detection is weak, 6E10 (Figure 4.3), 
suggesting that the formation of this fragment is not a consequence of overexpression of 
APP.  Taken together, these data suggest that these fragments are generated in a caspase-
dependent manner, and the strong inhibition of generation of this fragment with the 
group-II caspase inhibitor zDEVD-FMK suggests that caspase-3 and/or caspase-7 may be 
involved in this cleavage. 
4.5.Group II Caspase Activation is Associated with Fragment Formation in H4-
APP cells 
 In order to determine whether caspase-3 and/or caspase-7 may be responsible for 
the cleavage of APP in our model, we assessed levels and localization of cleaved and 
potentially active caspases in cells undergoing apoptosis in response to CPT. Both 
cleaved caspase-3 and cleaved caspase-7 were significantly induced following a six hour 
treatment with CPT (Figure 4.4A). We observed a slight mobility shift in cleaved 
caspase-7 in cells treated with zDEVD-FMK, the reason for which is unclear at this point 
(Figure 4.4A, second panel). When compared to cleavage of caspase-3, cleavage of 
caspase-7 seemed to correlate more closely with the formation of these novel fragments 
(Figure 4.4A, third panel), suggesting that activation of caspase-7 may be associated with 
proteolytic cleavage of APP and generation of these fragments. Induction of cleaved 
caspase-3 and cleaved caspase-7 were also evident by immunocytochemistry after CPT 
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Figure 4.3. Inhibition of APP cleavage by caspase inhibitors. Treatment of H4 glioma 
cells with caspase inhibitors show inhibition of APP processing: H4 glioma cells were 
left untreated or treated with CPT for one, two, three or six hours or pre-treated for 
one hour with Z-DEVD-FMK or ZVAD-FMK and treated with CPT for six hours and 
cell lysates were prepared and separated on a 15% Tris-glycine gel and analyzed by 
western blot using 6E10 (A) and caspase-cleaved APP (B & C) antibodies. 6E10 
antibody (A) shows the appearance of the cleaved fragment of APP with a 
concomitant decrease in the levels of full length APP (top panel) after CPT treatment. 
The formation of the fragment is inhibited by treatment of the cells with Z-DEVD-
FMK and Z-VAD-FMK, which was associated with slight increase in full length APP. 
Caspase-cleaved APP antibody shows a much stronger immunoreactivity to the 
proteolytic fragments (C, long exposure). The short exposure (B) from the caspase-
cleaved APP blot shows inhibition of band formation by z-DEVD-FMK and Z-VAD-
FMK, the long exposure shows that the inhibition was more efficient in cells treated 
with Z-VAD-FMK. Probing for β-actin (D) showed equal amount of protein loading 
on the gels. 
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treatment  (Figure 4.4B and 4.4C, respectively). Both cleaved caspase-3 and cleaved 
caspase-7 co-localized with 6E10 staining in H4-APP cells, suggesting that this close 
proximity of APP with active caspases in apoptotic cells may facilitate APP proteolysis. 
The levels of APP in caspase-positive cells were lower compared to non-apoptotic cells. 
4.6.Group II Caspase Cleavage is Also Associated with Fragment Formation in 
Neurons 
 Caspase-3 and caspase-7 up-regulation and activation have been observed in AD 
brains [10]. Although caspase-3 activation has been associated with apoptosis in neurons 
[16], the role of caspase-7 in this process has not been established. To assess whether 
caspase-7 activation occurs in neurons undergoing apoptosis, we analyzed rat cortical 
neurons treated with CPT. Neurons were treated with CPT for 12 hours and 
immunostained using antibodies against cleaved caspase-3 or -7. MAP2 was used as a 
neuronal marker. Analysis of the cells under a fluorescent microscope showed a 
significant induction in the levels of cleaved caspase-3 and cleaved caspase-7 in neurons 
undergoing apoptosis (Figure 4.5A and 4.5B). In cells that showed substantial caspase 
activation, staining with the neuronal marker MAP2 was diminished, though MAP2 
staining in the distal neurites (not shown) persisted. Together with cell morphology, this 
suggests that despite decreased MAP2 immunoreactivity these cells are indeed dying 
neurons. Western blot analysis of neuronal lysates treated with CPT for 12 hours also 
showed induction of both cleaved caspase-3 and cleaved caspase-7 in CPT treated cells  
(Figure 4.5C). This could be partially inhibited by the group II caspase inhibitor zDEVD-
FMK and the pan-caspase inhibitor zVAD-FMK. Analysis of the cell lysate with caspase-
cleaved APP antibody revealed the formation of an ~25 kDa fragment under apoptotic 
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Figure 4.4. Activation of caspase-3 and -7 is associated with APP proteolysis in 
apoptotic cells: (A) H4-APP cells were treated with CPT in the presence and absence 
of caspase inhibitors for six hours and analyzed by western blot using antibodies 
directed against cleaved caspase-3 or cleaved caspase-7. Cleavage of caspase-3 
(topmost panel) and caspase-7 (second panel) was observed in cells treated with CPT. 
The cleavage of these caspases was associated with an induction in the formation of 
the fragments detected by caspase-cleaved APP antibody (third panel). Blots were 
probed for β-actin as a loading control (bottom panel). Immunocytochemical analysis 
of H4-APP cells also showed significant induction in cleaved caspase-3 (B) and 
cleaved caspase-7 (C) after one and six hours of exposure to CPT. Cells were co-
immunostained with 6E10 antibody (green) to show colocalization of both active 
caspase-3 and active caspase-7 (red) with APP (green) (Magnification: 63X). Cells 
showing increased levels of cleaved caspases also showed a reduction in the level of 
APP signal intensity, consistent with the decrease in full length APP observed by 
western blot in Figure 4.1 A and 4.1 B. Hoechst was used to visualize the nuclei of the 
cells. 
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Figure 4.5. Apoptosis is associated with induction of cleaved caspase-3 and cleaved 
caspase-7 in primary cortical neurons: Primary neurons were cultured from E18 
embryonic rat cortices for seven days, followed by treatment with 10 µM CPT to 
induce apoptosis. A and B show immunocytochemistry with MAP2 as a neuronal 
marker (green) and cleaved caspase-7 (A) or cleaved caspase-3 (B) antibodies (red) 
(Magnification: 63X). Hoechst staining, shown to the right of panels A and B, shows 
condensed or fragmented nuclei (indicative of apoptosis) in cells positive for cleaved 
caspases, whereas MAP2 positive neurons in the untreated samples show intact nuclei. 
(C) Western blot analysis of the lysates from neurons treated with CPT for 12 hours 
showed a significant induction in cleaved caspase-3 (top panel) and cleaved caspase-7 
(second panel) levels. Activation of caspases was partially attenuated in the presence 
of 10 µM zDEVD-FMK and zVAD-FMK. Analysis of the lysates with an antibody 
generated against caspase-cleaved APP detected a single band of ~25 kDa size. The 
level of this fragment was attenuated slightly in the presence of caspase inhibitors 
(third panel). A reprobe of this blot using an antibody against β-Actin was performed 
as a control for protein loading (bottom panel). 
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conditions, the levels of which were attenuated in the presence of caspase inhibitors. This 
suggests that both caspase-3 and caspase-7 are present in neurons and are activated under 
apoptotic conditions.  
4.7.Proteolysis of APP In Vivo in Transgenic Mice 
In order to assess the various proteolytic fragments generated in a transgenic 
mouse model of amyloid deposition, PS-APP mice overexpressing mutant forms of 
human APP(V717F) and presenilin-1 (PS1) were used.  These mice show plaque 
deposition at approximately 8-10 months of age [17, 18].  Brains from 10 month old PS-
APP mice were homogenized in RIPA lysis buffer and the various proteolytic fragments 
assessed by western blot as shown in Figure 4.6.  Prominent bands observed with 6E10 
included full-length APP, C99, Aβ, and an ~25 kDa band (Figure 4.6A), similar in size to 
the fragment observed in vitro during p53-dependent apoptosis. A similar ~25 kDa band 
has been observed in human AD tissue with 6E10, where it has been described as a 
hexamer of Aβ [19].  However, as seen in Figure 4.6B, a similar sized fragment from the 
transgenic mice expressing human APP is also detected by a C-terminal antibody, 
suggesting that this fragment contains the C-terminus of APP. One would not expect a C-
terminal antibody to detect a hexamer of Aβ, as Aβ oligomers should not contain the C-
terminus of APP. 
Quantification of the gels showed that full length APP is elevated 2 fold in PS-
APP animals as detected by the C-APP antibody, while the C-terminal fragments are 
increased approximately 4-fold. In contrast, the ~25 kDa fragment was elevated 7-fold in 
the PS-APP mice (Figure 4.6 C). This significant increase in the ~25 kDa fragment over 
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Figure 4.6.  Characterization of APP proteolytic fragments from 10 month old PS-
APP mice.  (A) Western immunoblot analysis performed using 6E10, an antibody 
directed against the Aβ region of human APP.  This antibody is specific to human 
APP, so no banding is observed in nontransgenic (Ntg) mice.  The brain extracts from 
the transgenic mice show the full length APP, Aβ, a band corresponding to the β-
secretase cleaved C-terminal fragment of APP, C99, as well as a ~25 kDa band of 
unknown origin.  (B) Western blotting performed using an antibody directed against 
the C-terminus of APP.  The C-terminal antibody is raised against 9 aa from the C-
terminus of APP and, unlike 6E10 antibody, detects both mouse and human APP. The 
blots show bands corresponding to full length APP, α- and β- secretase cleaved C-
terminal fragments of APP, C83 and C99 respectively, as well as the ~25 kDa band 
observed with 6E10 antibody in both Ntg and PS/APP brain extracts. (C) 
Quantification of the blots shown in B reveals an approximately 2 fold increase in full 
length APP in PS-APP mice and an approximately 4 fold increase in the C-terminal 
fragments compared to the Ntg mice.  Levels of the ~25 kDa band, however, are 7 
times higher in PS/APP mice than in Ntg.  Asterisks indicate significant difference 
from Ntg, p<0.01. 
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the full length APP, along with the fact that the PS/APP mice develop pathology while  
nontransgenic mice do not, warrant an investigation on the significance of this 
intermediate proteolytic fragment in development of AD pathology. 
4.7.1. Caspase Cleavage In Vivo in Transgenic Mice 
Since the proteolytic fragment observed in vitro was dependent on the activation 
of caspase-3 and/or -7, we set out to determine whether  the ~25 kDa fragment in the 
brain extracts of PS/APP mice is associated with activation of caspases -3 and -7.  We 
performed immunostaining analysis using antibodies towards the cleaved forms of these 
caspases on the brains of PS/APP mice. We observed an increase in the levels of both 
active caspase-3 and -7 proximal to amyloid deposits as detected by co-staining with the 
6E10 and the corresponding cleaved caspase antibodies (Figure 4.7A and B). Confocal 
analysis of the co-stained sections showed colocalization of APP with both cleaved 
caspase-7 and cleaved caspase-3 in the vicinity of the plaques (Figure 4.7A and B 
respectively and the corresponding insets).  This suggests that these caspases may cleave 
APP in vivo at the novel site reported here, and potentially contribute to the 
neurodegeneration associated with AD via production of the ~25 kDa fragment or via a 
reduction in the levels of sAPPα, which has been shown to have a protective anti-
apoptotic effect on neurons.  
4.8.Modeling of APP and Identification of a Potential Caspase Site 
The novel APP fragments observed in lysates from cells undergoing apoptosis 
immunoreacted with 6E10 and the C-terminal caspase cleavage site-specific antibodies. 
The only fragment generated by secretase cleavage of APP that would immunoreact with 
both of these antibodies would be the C99 fragment that is truncated by cleavage at 
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Figure 4.7.  Active caspase-3 and -7 are observed in the vicinity of Aβ plaques in PS-
APP transgenic mice.  (A) Brain tissue from 10 month old PS-APP transgenic mice 
were stained with antibodies to APP (6E10, green), and cleaved caspase-7 (red), and 
the nuclei were counterstained with Hoechst.  Co-localization of cleaved caspase-7 
(red) and 6E10 (green) was observed in the vicinity of Aβ plaques.  The inset shows a 
closer view of one area of colocalization.  (B) Similarly, co-localization of cleaved 
caspase-3 (red) and 6E10 (green) was also observed in the vicinity of Aβ plaques. 
Samples were visualized using a confocal imager and analyzed using the Fluoview 2.0 
software.  Images are shown at 14x magnification (10x objective with 1.4x digital 
zoom).  Confocal microscopy was performed with the kind assistance of Dr. Beyong 
Cha at the USF Health microscopy core. 
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VEVD*A740. Such a fragment would have a predicted molecular weight of ~8 kDa. As 
this is considerably smaller than the molecular weight of the fragments generated under 
apoptotic conditions, we scanned APP for other known proteolytic sites, such as those 
cleaved by calpains, caspases, and MT-MMPs, to determine whether APP fragments with 
molecular weights similar to those we observed could be generated by proteases other 
than the secretases. Figure 4.8 shows a ball-and-chain model of APP with various 
proteolytic sites numbered. The grid towards the right of Figure 4.8 shows the predicted 
molecular weight of fragments generated by cleavage at a single site (light gray boxes, 
showing molecular weight of N-terminal and C-terminal fragments, respectively), or the 
internal fragment generated by cleavage at two sites identified by the intersection of a 
row and column. For example, cleavage at the β-secretase site (row 5) and the γ-secretase 
site (column 7) generates a fragment with a predicted molecular weight of ~4.5 kDa, Aβ. 
These estimated molecular weights are based on the amino acid structure at neutral pH 
with no post-translational modifications and are calculated using the APP770 isoform. For 
fragments containing the 6E10 epitope, the molecular weight is bolded and underlined.  
Since we suspected that the cleavage may be caspase-dependent, based upon the 
response to inhibitors, we also utilized a support vector machine (SVM)-based predictive 
model to detect potential caspase cleavage sites in APP [20]. We identified a potential 
group II caspase site, DEVD*E563, approximately 25 kDa from the C-terminal end of 
APP, indicated by the asterisk in Figure 4.8. Based upon the predicted molecular weight 
of the fragments identified by bioinformatic analysis, we suspect that the fragments 
observed in this study are generated by cleavage at either this novel caspase site, or by 
sequential cleavage by MT-MMPs in the extracellular domain and caspases at 
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Figure 4.8.  Bioinformatic prediction of potential proteolytic sites involved in 
generation of the novel APP fragments. The figure shows a schematic depicting 
known proteolytic sites on APP, and table identifying these various sites on APP770 
isoform. Each site is assigned a number starting from the N-terminus, with a putative 
caspase cleavage site (DEVD*E563) identified by a support vector machine-based 
caspase substrate predictive model identified using an asterisk. The right side of the 
table is a grid illustrating the predicted molecular weights of fragments generated by 
cleavage at one or two of the sites identified. Each cell contains the predicted 
molecular weight for a fragment generated by cleavages at the site identified in the left 
side of the table and by number in the top row of the grid. The light gray cells on the 
diagonal, those where both row and column represent the same site, indicate cleavage 
at a single site with predicted molecular weight of the N-terminal and C-terminal 
fragments listed, respectively. The white cells show the molecular weight of the 
internal fragment generated by cleavage at two different sites. The molecular weights 
of fragments containing the 6E10 epitope (Aβ1-16) are bolded and underlined. Note 
that sites in the near extracellular domain, specifically the putative caspase site and the 
MT-MMP site, could potentially generate fragments similar in size and 
immunoreactivity to the fragments we observed. 
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VEVD*A740. Interestingly, cleavage in this manner would not preclude amyloidogenic or 
nonamyloidogenic processing of APP. It would, however, prevent the generation of the 
α-secretase-cleaved N-terminal fragment of APP, sAPPα, which has neuroprotective and 
anti-apoptotic properties and therefore a depletion of this fragment may have deleterious 
effect on cell survival. 
4.9.MMP-Dependent Changes in APP Processing 
Based on the bioinformatic analysis of APP it is possible that the ~ 25 kD C-
terminal fragment observed during p53-dependent apoptosis may be generated by 
cleavage by either MT-MMPs or group II caspases in the extracellular domain and 
caspase-3 in the C-terminal domain.  In order to assess whether APP is being cleaved by 
MMPs in our H4-APP cells, we treated H4-APP cells with 25 µM GM6001, an MMP-
inhibitor (Figure 4.9).  Even in the absence of CPT, treatment with GM6001 resulted in a 
significant induction of the β-cleaved C-terminal fragment C99.  These changes are 
quantified in Figure 4.9B.  This suggests that MMP inhibition has unanticipated effects 
on classical processing APP.  While we would have liked to assess the effect of MMP 
inhibition in the CPT-treated condition, the increased pronounced enhancement of β-
cleaved fragments with GM6001 is potentially confounding.  If the ~25 kDa fragment is 
MMP-dependent, we would expect to see a decrease in the levels of this fragment when 
cells are pretreated with GM6001.  However, the large induction in β-secretase 
processing seen with GM6001 would also result in a decrease in this fragment, as the 
fragment does contain the β-secretase site.  Given these potential confounds, we decided 
to not pursue the MMP-mediated processing of APP at this point, and instead focus on 
caspase- dependent cleavage of APP.  
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Figure 4.9.  MMP-dependent changes in APP processing.   H4-APP cells were treated 
with 25 µM GM6001 for seven hours and protein lysates collected.  Equal amounts of 
protein were loaded onto 12% tris-glycine gels and electrophoresed for analysis by 
western blot.  (A) Two representative, independent experiements showing an increase 
in the levels of C99 after treatment with GM6001 is shown.  MMP-16, an MMP 
predicted to cleave APP in the near extracellular domain [1], increases slightly upon 
treatment with 25 µM GM6001. (B) Quantification of the levels of C99 over 3 
independent experiments show a nearly 3-fold increase in C99 with GM6001 
treatment.  Asterisks indicate significant difference, P<0.05.  Error bars show ± 
standard deviation. 
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4.10. Studies with shRNA Suggest a Role for Caspase-7 in APP Proteolysis 
The similarity in substrate specificity and lack of specific inhibitors capable of 
discriminating between group II caspases make it challenging to determine whether a 
specific proteolytic event is attributable to caspase-3, caspase-7, or both. Although it is 
classically difficult, we attempted to down-regulate each specific caspase using shRNA to 
caspase-3 and caspase-7 in order to examine whether down-regulation of these caspases 
have any effect on cleavage of APP to generate the fragments we have observed. Sets of 
four shRNA clones each to caspase-3 and caspase-7 were obtained from OriGene 
(Rockville, MD) and were transiently transfected into H4-APP cells using Turbofectin 
8.0 (OriGene) according to the manufacturer’s protocol. Initial studies showed that 
maximum down-regulation was obtained with clones one and four of each shRNA set, 
and we decided to use clone four of each shRNA set in our studies. Western blot analysis 
showed no down-regulation with a control shRNA (Figure 4.10A, lane 2 top and middle 
panel), while cells transiently transfected with shRNA to caspase-7 showed down-
regulation predominately of caspase-7 (Figure 4.10A, lane 4). Cells transiently 
transfected with shRNA to caspase-3 showed down-regulation of both caspase-3 and 
caspase-7, indicating that the shRNA to caspases-3 was not specific for this caspase 
(Figure 4.10A, lane 3). Cells transfected with shRNA to caspase-7 showed down-
regulation of two bands around 25-35 kDa on the western blots, which could be splice 
variants of procaspase-7 [21]. From the transient transfection experiments, we conclude 
that: (1) the effect of shRNA transfection are sequence dependent, as the control shRNA 
showed no effects, (2) shRNA to caspase-7 down-regulates caspase-7, and (3) the shRNA 
to caspase-3 used down-regulates both caspase-3 and caspase-7. 
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Figure 4.10.  Down-regulation of caspase-3 and caspase-7 reduces the generation of 
~25-35 kDa caspase-cleaved APP fragments in CPT treated H4-APP cells. (A) H4-
APP cells were transiently transfected with shRNA to caspase-3 or shRNA to caspase-
7 and the down-regulation of the respective caspases analyzed after 48 hours using 
antibodies against caspase-3 (top panel) and caspase-7 (second panel). The lower 
panel in (A) shows the actin probe of the blot to show protein loading. (B) H4-APP 
cells stably transfected with shRNA to caspase-3 or caspase-7 were analyzed using the 
respective caspase antibodies. Reprobing of the blot with β-actin antibody shows 
protein levels on the blot (bottom panel). (C) Quantification of the levels of caspase-3 
and caspase-7 in stably transfected cells from three independent experiments (as 
represented in B), normalized to β-actin. An approximately 86% decrease in full-
length caspase-3 levels were observed in cells transfected with shRNA to caspase-3 or 
shRNA to caspase-7. Similarly, an approximately 49 % decrease in caspase-3 levels 
was observed with shRNA to caspase-3, and a 56 % decrease in caspase-7 levels was 
observed with shRNA to caspase-7. Induction of cleaved caspase-3 was observed with 
shRNA to caspase-7, but no induction of cleaved caspase-7 was observed with shRNA 
to caspase-3. (D) Western blot analysis of the lysates with antibody to caspase-cleaved 
APP showed a reduction in the levels of the cleaved fragment in the shRNA 
transfected cells after three hours of treatment with 10 µM CPT. The figure shows 
data from two experiments treated with CPT (E) Quantification of data from three 
independent experiments (representative figure is shown in panel D), normalized to 
actin, shows a 31% reduction in caspase-cleaved APP with shRNA to caspase-3 and a 
90% reduction in cells transfected with shRNA to caspase-7. Asterisks indicate 
significant differences, p<0.05. 
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We also performed stable transfections of these same shRNAs into H4-APP cells 
(Figure 4.10B and C) and detected a significant reduction in full length caspase-3 and -7 
with both shRNA clones (Figure 4.10B, top panel and third panel). Interestingly, in 
addition to inhibiting the expression of caspase-7, cells stably transfected with shRNA to 
caspase-7 showed an increase in cleaved caspase-3 (Figure 4.10B, second panel). Cells 
transfected with shRNA to caspase-3 did not show any up-regulation of cleaved caspase-
7. This is not surprising as caspase-3, which is involved in the cleavage of caspase-7, was 
downregulated in these cells. Figure 4.10B shows a representative blot from one of three 
independent experiments; the results from these experiments were quantified and are 
presented in Figure 4.10C. Data from the stable shRNA transfection studies suggest that: 
(1) Similar to transient transfections, shRNA to caspase-3 resulted in down-regulation of 
both caspase-3 and caspase-7, (2) as with transient transfection, shRNA to caspase-7 was 
specific for caspase-7, and (3) stable knockdown of caspase-7 leads to an increase in 
cleavage of caspase-3 to the active form.  
We next examined APP fragment formation in stably transfected cells treated 
with or without CPT by western blot analysis using the caspase-cleaved APP antibody 
(Figure 4.10D and E).  Cells stably transfected with shRNA to caspase-3 showed a partial 
reduction in the levels of the cleaved fragments, while shRNA to caspase-7, which 
downregulated caspase-7 and induced cleavage of caspase-3, resulted in a substantial 
decrease in the levels of the fragments. This suggests that, although both caspase-3 and -7 
may be capable of cleaving APP, caspase-7 is more directly associated with the formation 
of the fragments, as substantial down-regulation of these fragments was observed with 
shRNA to caspase-7, even in the presence of increased levels of cleaved caspase-3. 
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4.11. Conclusions 
In this chapter, we present our findings that under apoptotic conditions, APP is 
processed alternatively to generate fragments that are detected by antibodies directed 
towards Aβ region and C-terminal caspase cleavage site on APP.  Similar fragments are 
observed in an APP-expressing transgenic mouse model as well.  Based upon the size and 
immunoreactivity we conclude that the generation of these fragments involves cleavage 
within the ectodomain of APP, beyond the β-secretase cleaving site. Experiments with 
small peptide inhibitors of caspases and shRNA to caspases-3 and -7 suggest that these 
fragments are generated by a mechanism involving group-II caspases, and preferentially 
involving caspase-7.  Based upon fragment size, immunoreactivity, and bioinformatic 
analysis of the APP sequence, we hypothesize that these fragments may be generated by 
cleavage of APP within the near ectodomain, potentially by MT-MMPs or caspases, and 
at the C-terminal domain by caspases. Cleavage within the near ectodomain prevents the 
production of sAPPα, which is neuroprotective and anti-apoptotic. 
We used H4 neuroglioma cells overexpressing APP as a model system where 
apoptosis was induced using the DNA damaging agent CPT. Although the levels of 
apoptosis is higher in our in vitro system as compared to the human condition, a near-
homogeneous population of APP expressing apoptotic cells allows us to study changes in 
potentially intermediate proteolytic fragments of APP generated during apoptosis. In the 
human condition, even small changes in APP processing, over the decades-long disease 
process, may have significant impact on pathology development. Changes in sAPPα are 
of particular interest, as sAPPα has been implicated in protecting neurons and synapses 
from apoptosis [22]. Our studies suggest that changes in APP processing associated with 
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apoptosis could lead to decreased levels of sAPPα in the local microenvironment, making 
cells in that environment more prone to degeneration. Whether the altered processing of 
APP described here occurs in vivo in human AD brains needs to be established. However, 
analysis of brain extracts from mice overexpressing human APP [23-25] and human AD 
patients [19] have shown generation of similarly sized proteolytic products detected by 
6E10 antibody. These APP metabolites are often interpreted as oligomeric Aβ, though 
they may in fact be other proteolytic fragments of APP that contain the 6E10 epitope. 
Further, proteomic analysis of cerebrospinal fluid from AD patients has resulted in the 
identification of 11 short peptides that vary in N-terminal start site but end just before the 
α-secretase cleavage site. The N-termini of these fragments are formed by cleavages that 
occur in the near extracellular domain of APP [14]. The precise origin of these fragments 
and the proteases that generate them are not clear, but their existence suggests that there 
is active proteolysis in the ectodomain region, beyond the β-secretase site, of APP in 
human AD brains. These data, as well as our results presented here thus suggest that, 
APP undergoes altered processing under degenerative and apoptotic conditions and a 
detailed analysis of the APP proteolysis may identify hitherto unknown intermediates as 
well as the importance of these cleavages in pathology development. 
Apoptosis in neurons has been shown to be associated with caspase-3-mediated 
cleavage of APP at the C-terminus [11]. This cleavage of APP generates a 31 amino acid 
fragment from the C-terminus of APP, C31, which has been shown to be neurotoxic [26]. 
The effect of caspase cleavage on secretase processing of APP and Aβ production is not 
clearly understood. Co-localization of active caspase-3 with amyloid plaques and with 
caspase-cleaved APP has been observed in AD brain, which led to the hypothesis that 
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caspase activation may lead to enhanced Aβ generation and plaque formation [4, 27]. 
However, this correlation does not necessarily indicate that caspase-dependent cleavage 
of APP increases Aβ generation, especially given that truncation of APP at the C-
terminus removes the endocytosis signal from APP and affects its internalization. If the 
internalization of APP is reduced by caspase-mediated truncation, this may in fact 
decrease Aβ production, as endocytosis is required for cleavage of APP via the 
amyloidogenic pathway [2]. Our results support this hypothesis and are consistent with 
the findings presented in chapter 3, showing that apoptosis is associated with a decrease 
in generation of Aβ and sAPPα, as well as an increase in the formation of alternatively 
processed APP fragments. 
Further, our data also suggest that in addition to cleavage by caspase-3, APP can 
be cleaved by caspase-7, and that caspase-7 may cleave APP at a novel site in the 
ectodomain. Such a cleavage would generate a C-terminal fragment of ~25 kDa. This 
cleavage would likely occur after endocytosis of APP, within a luminal space, as 
DEVD*E563 (based on APP770) lies in the extracellular domain of APP. Interestingly, 
caspase-7, but not caspase-3, has been shown to translocate to an endosomal-lysosomal 
compartment under inflammatory and apoptotic conditions [28]. This would allow 
caspase-7, but not caspase-3, access to DEVD*E563, explaining the apparent preference 
for caspase-7 over caspase-3 observed in our studies.  
Once APP is cleaved at this novel site, the fragment generated could undergo 
further proteolysis. We observed a decrease in the levels of secreted Aβ and the C99 
fragments in cells undergoing apoptosis, and this paralleled with a decrease in full-length 
APP as well as sAPPα. While changes in the levels of these fragments may be indicative 
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of decreased expression of APP [29], the concomitant increase in the ~25-35 kDa 
fragments observed here suggests that these changes are at least partially due to altered 
proteolysis. Formation of these fragments precludes the production of sAPPα, and the 
fragments themselves could be further processed by secretases and caspases, including 
cleavage by caspase-3 to generate the neurotoxic fragment C31. Further analysis of 
ectodomain cleavage of APP and the functions of the fragments generated is certainly 
warranted, as any alterations in APP processing may have important implications for 
pathology development in AD.  
Studies in individuals with an increased risk for developing AD (those with a 
Clinical Dementia Rating of 0.5) show up-regulation of caspase-1 and caspase-7 in the 
entorhinal cortex [10]. Caspase-1, also known as interleukin converting enzyme, is 
associated with neuroinflammation and has been shown to cleave and activate caspase-7 
in vitro [30]. The up-regulation of both of these caspases early in the disease process 
suggests that neuroinflammation may induce activation of caspase-7 and alternative 
processing of APP. Up-regulation of caspase-1 and caspase-7, but not TUNEL-positive 
cells, have been reported in the brains of patients with a Clinical Dementia Rating of 0.5. 
Patients with more advanced dementia, Clinical Dementia Rating of 5, show upregulation 
of other caspases, including caspase-3, and a massive increase in TUNEL-positive cells 
[10]. This indicates that, despite its traditional role as an executioner caspase, caspase-7 
may actually be acting early in the disease process, prior to the onset of apoptosis, and 
may play a physiological role in neurons outside of the apoptotic pathway. This is 
supported by our shRNA experiments, in which caspase-3 cleavage was observed in cells 
stably transfected with shRNA to caspase-7, even under non-apoptotic conditions (Figure 
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4.10B). The compensatory up-regulation of cleaved caspase-3, the closest homologue to 
caspase-7, under non-apoptotic conditions suggests an important physiological role for 
caspase-7 outside of apoptosis. While the role of caspase-3 in APP cleavage is beginning 
to be well understood, the role of caspase-7 in neuronal function, as well as caspase-7 
mediated cleavage of APP, warrants further investigation. 
The notion that caspase activation has a physiological role outside of apoptosis is 
not new. Caspases are thought to play an important role in modulating synaptic plasticity 
and long term memory [31-34]. APP and its proteolytic fragments have also been 
implicated in synaptic plasticity and neurite outgrowth [for review, see 35]. sAPPα has 
been shown to have substantial trophic effects on synaptic plasticity [36]. At low 
concentrations, even Aβ appears to have a positive effect on synaptic plasticity [37], 
though at high concentrations Aβ aggregates and induces neurodegeneration [38]. The 
alternative APP processing events described in the studies presented here preclude the 
generation of the neurotrophic sAPPα fragment. This is confirmed by the observation that 
sAPPα levels are decreased under apoptotic conditions. They do not, however, preclude 
the formation of the neurotoxic Aβ and C31 fragments. It is possible that the fragments 
generated under apoptotic conditions are intermediate fragments of APP which may be 
further processed by secretases to generate Aβ and/or C31. The cleavage of APP that 
generates these fragments may, therefore, enhance neurodegeneration by decreasing the 
availability of sAPPα to provide neuroprotection while still allowing the production of 
the toxic fragments. This suggests that neuroinflammation-induced caspase-7 activation 
could shift APP into an alternative cleavage pathway that is potentially cytotoxic, and 
inhibition of this pathway may protect neurons against cytotoxicity.  
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4.12. Closing Remarks 
In the previous chapter, we presented the finding that p53-dependent apoptosis 
was associated with a decrease in the Aβ and sAPPα.  This could be due to a decrease in 
expression of the substrate or a decrease in the relative activity of the enzymes.  Using γ-
secretase inhibition, we determined that there was likely no change in β-secretase 
activity, but α-secretase activity was sustained.  In this chapter, we present the finding 
that during p53-depedent apoptosis, alternative, caspase-dependent processing of APP 
occurs, including an apparent cleavage in the near extracellular domain.  While this 
cleavage precludes the production of sAPPα, it does not preclude the production of Aβ.  
Nevertheless, as discussed in Chapter 3, there is no increase in Aβ during p53-dependent 
apoptosis.  Therefore, our hypothesis that Aβ production may propagate through the brain 
due to APP processing during p53-dependent apoptosis is not supported by our data. 
Models of p53-dependent apoptosis rely on the induction of DNA damage.  In the 
case of CPT-dependent apoptosis, this is achieved by damaging DNA during its 
synthesis.  Therefore, the changes we see during p53-dependent apoptosis in our model 
could also reflect cell cycle dependent changes that occur during S-phase.  In the next 
chapter, we will focus cell cycle dependent changes in APP and its processing.  
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CHAPTER 5:  PROCESSING OF APP DURING CELL CYCLE1  
 
 
 
5.1. Chapter Synopsis 
In the previous chapters, we have discussed the hypothesis that Aβ production 
may propagate through the brain in an anatomical fashion, similar to that seen in tau, and 
have discussed two potential mechanisms by which this could occur – p53-dependent 
apoptosis and./or aberrant cell cycle activation.  We have explored the possibility that 
p53-dependent apoptosis may result in increased production of Aβ, and found that in fact 
there is no increase in Aβ production during p53-dependent apoptosis.  There is instead a 
decrease in both Aβ and sAPPα.  Further, there is an increase in an ~25 proteolytic 
fragment that is caspase-dependent and appears to involve cleavage of APP in the near 
ectodomain.  This cleavage precludes the production of the neurotrophic sAPPα 
fragment, but does not preclude the production of Aβ. 
In p53-dependent apoptosis, apoptosis is induced primarily in S-phase.  In this 
chapter, we assess S-phase dependent processing of APP.  Further, we discuss the 
evidence in the literature from our lab and others that indicates that cell-cycle related 
events, such as the phosphorylation of APP, can affect downstream processing.  Finally, 
we will present evidence that mitotic phosphorylation of APP is associated with 
amyloidogenesis and discuss the potential mechanistic relationship between APP 
phosphorylation and amyloidogenic processing. 
                                                 
1 Some results in this chapter have been previously published (Judge et al., 2011) and are utilized 
with the permission of the publisher.  See Appendix B. 
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5.2. Cell Cycle Dependent Processing of APP 
Our findings regarding decreased levels and processing of APP during p53-
dependent apoptosis raised the question as to whether these effects were due specifically 
to apoptotic processes or if these changes are related to cells in S-phase.  P53, as 
discussed in Chapter 3, transcriptionally regulates genes involved in cell cycle arrest and 
apoptotic cell death [2].  This confers the ability of p53 to gauge whether a replicating 
cell’s DNA is in sufficiently healthy condition to be replicated, and transcriptionally halt 
cell growth to allow for repair.  In our model of CPT-dependent apoptosis, DNA-damage 
occurs due to topoisomerase inhibition and therefore accumulates during S-phase.  As 
shown in Figure 3.2 (see Chapter 3), the number of cells in S-phase increases when cells 
are undergoing CPT-dependent apoptosis.  This accumulation of cells in S-phase is 
indicative of an S-phase block, suggesting that any changes observed at these time points 
could be indicative of changes in processing dependent on cell cycle, and more 
specifically S-phase. 
5.2.1. Modeling Cell Cycle with Aphidicolin 
In order to obtain a synchronous population of cells in S-phase, we arrested cells using 
the DNA polymerase inhibitor aphidicolin.  Because in an asynchronous population the 
vast majority of cells are in G0/G1, and because in our experience doubling of a culture 
of H4-APP cells takes approximately 18 hours, treatment of H4-APP cells with 5 µg/mL 
aphidicolin for 18 hours results in cells that are arrested late in early S-phase.  When 
aphidicolin, and therefore DNA polymerase inhibition, is removed the cells begin to 
replicate their DNA.  This process can be visualized using propidium iodide to stain the 
DNA content of cells.  When these cells are stained with propidium iodide and 
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Figure 5.1.  Effectiveness of aphidicolin block and release in H4-APP cells. H4-APP 
cells were arrested with 5 µg/mL aphidicolin for 18 hours, then aphidicolin removed 
and cells were allowed to continue to grow in normal growth media for 1-6 hours. 
Cells were fixed and stained with propidium iodide (PI) and analyzed via flow 
cytometry. DNA content indicates that cells progress synchronously into S-phase 
following aphidicolin release. 
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collected at each hour post-stimulation, the DNA content of these cells steadily increases 
(Figure 5.1).  This allows us to model cells as they progress through S-phase and 
potentially into G2/M-phase, though the longer the duration post-aphidicolin block, the 
more asynchronous these cells become.  
5.2.2. Cell Cycle Dependent Changes in APP Processing 
When cells are treated with aphidicolin and not released, they are arrested in early 
S-phase.  As is evident in Figure 5.1, cells are approximately halfway through S-phase 
after 4 hours post-aphidicolin.  We treated cells with 5 µg/mL aphidicolin for 18 hours, 
then allowed them to cycle for 12 hours post release. H4-APP cells treated with 100 
ng/mL nocodazole for 18 hours served as positive control for an M-phase specific 
population.  Nocodazole is a microtubule depolymerizing agent that results in the arrest 
of cells primarily in M-phase. 
Cells were lysed and equal amounts of protein run on a 12% Tris-Glycine gel for 
analysis by western blot.  Using 6E10 and a C-terminal APP antibody, we can detect both 
full length APP and the C83/C99 C-terminal fragments.  We see a reduction in both full 
length APP and a decrease in the levels of C-terminal fragments with aphidicolin 
treatment that is sustained until 12 hours post release, at which point APP levels begin to 
increase again.  Nocodazole treatment suggests that APP levels, both full length and 
processed forms, are higher during M-phase.  Therefore, the increase observed in the full 
length form of APP after 12 hours of serum stimulation after aphidicolin block may be 
indicative of cells beginning to enter M-phase.  Temporally, the processed forms of APP 
appear to lag behind that of the full length forms – aphidicolin treatment alone decreases  
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Figure 5.2.  Aphidicolin block and release and nocodazole arrest reveal cell cycle 
dependent processing of APP. Cells were treated with 5 µg/mL aphidicolin for 18 
hours, after which aphidicolin was removed, the cells washed twice with PBS, and 
serum containing media added.  Additionally, another sample was arrested in M-phase 
using 100 ng/mL nocodazole for 18 hours as a positive control for M-phase cells.  
Lysates were analyzed by western blot using 6E10 and C-terminal APP antibodies 
(cAPP). Full length APP was reduced as cells went through S-phase (aphidicolin 
treatment, 4 hour release, and 8 hour release conditions), with processed forms reduced 
in the 4 hour and 8 hour release conditions.  Full length APP and processed forms were 
increased during M-phase. 
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full length APP, but a reduction in C-terminal fragments is not seen until the 4 hour time 
point.  Similarly, an increase in full length APP is observed at the 12 hour time point, but 
an increase in the C-terminal fragments is not yet observed, though nocodazole treatment 
indicates that the C-terminal fragments are somewhat higher during M-phase.   
5.3. Cell Cycle Dependent Phosphorylation of APP 
M-phase dependent changes in APP are not limited to expression and proteolysis.  
Our lab and others have previously described cell-cycle dependent phosphorylation of 
APP at threonine 668.  The first report of cell-cycle dependent phosphorylation, from 
Suzuki and colleagues, showed that in vitro purified cdc2/cyclin B complex, a cell cycle 
dependent kinase complex active during M-phase, could phosphorylate a synthetic 
peptide consisting of APP645-694 as well as APP663-676 [3].  The latter peptide contains only 
one threonine, suggesting the residue phosphorylated was threonine 668.  Subsequent 
work from Li-Huei Tsai’s laboratory identified elevated levels of P-APPT668 in the brains 
of AD patients, which appeared to colocolize with BACE1 in the endosomes.  Further, 
the β-secretase cleaved fragment C-terminal fragment C99 had a higher propensity to be 
phosphorylated than the corresponding α-secretase cleaved fragment C83, suggesting that 
the phosphorylation of APP at threonine 668 may be associated with amyloidogenic 
processing [4]. 
Further, PC12 cells arrested at the G2/M-phase with nocodazole in the presence 
of [32P]-orthophosphate results in labeling of both full length and C-terminal fragments of 
APP.  There was also an increase in the relative level of C-terminal fragments as 
compared to full length APP, suggesting that there may be an increase in processing in a 
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Figure 5.3.  Phosphorylation of APP is elevated during M-phase. Asynchronously 
growing H4-APP cells were fixed by PIPES fixation and stained using an antibody 
against phosphorylated APP (P-APP), along with α-tubulin and Hoechst to visualize 
mitotic spindles. Cells undergoing mitosis, which secreted more Aβ as shown in Figure 
5.4, also had elevated levels of P-APP. 
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Figure 5.4.  Mitosis-specific phosphorylation of APP. H4-APP cells were growth 
arrested by serum starvation for 48 hr and serum stimulated with and without 
roscovitine, olomoucine, or aphidicolin for 12 hr, and 100 ng/mL nocodazole, 10 µM 
vinblastine, or 100 ng/mL taxol for 16 hr. Cell extracts were prepared and equal 
amounts of proteins were immunoprecipitated using 6E10 antibody and western 
blotted using P-APP antibody (A). B) APP levels in total lysate analyzed using 6E10 
antibody. Panel C shows reprobe of blot B (without stripping) with actin antibody 
showing equal amount of proteins on gel. The histogram in panel D shows the percent 
of P-APP in cells under the different treatment conditions. The data represent the mean 
of three independent experiments with standard deviation shown. Cells arrested in 
metaphase showed significantly higher levels of P-APP (P< 0.05). Panel E shows the 
FACS analysis data from cells treated with cell cycle inhibitors. Cells were treated 
with roscovitine or aphidicolin for 12 hr or nocodazole or taxol for 16 hr and fixed and 
stained using propidium iodide before analysis on a FACS machine. Mean percent of 
cells in different phases of the cell cycle from three independent experiments is shown.  
Reprinted from Judge, M., et al., Mitosis-specific phosphorylation of amyloid 
precursor protein at threonine 668 leads to its altered processing and association with 
centrosomes. Mol Neurodegener, 2011. 6: p. 80. [1]. 
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cell cycle and/or phosphorylation dependent manner [3].  In fact, APP phosphorylation 
does appear to occur in a cell-cycle dependent manner when analyzed in asynchronously 
growing cells.  Mitotic spindles can be easily visualized using antibodies against α-
tubulin along with staining of chromatin with Hoechst.  When cells stained in this manner 
are also stained with an antibody specifically recognizing APP phosphorylated at 
threonine 668, we see that phosphorylated APP levels are elevated specifically in cells 
undergoing mitosis (Figure 5.3). 
Subsequent research in our own laboratory has shown an upregulation of both cell 
cycle regulatory proteins, including cyclin D1, cyclin E, and P-cdc2, as well as elevated 
levels of APP phosphorylated at threonine 668, in transgenic mice overexpressing APP, 
as well as in double transgenic mice overexpressing PS1 and APP, as compared to 
nontransgenic littermate controls [1].  Further, we have previously reported that in H4-
APP cells treated with cell cycle inhibitors such as taxol, nocodazole, and vinblastine 
have elevated levels of P-APP as compared to cells treated with inhibitors that act at the 
G1/S checkpoint in cell cycle or early in S-phase, such as aphidicolin, roscovitine, and 
olomoucine.  Levels of C-terminal fragments are also elevated during M-phase as 
compared to G1/S-phase, suggesting that APP processing may be enhanced by the 
phosphorylation of APP.  Two figures from this study, performed by Judge et al., are 
reproduced here in figures 5.4 and 5.5 [1].2 
 In order to assess whether Aβ levels were elevated during M-phase, cells were 
serum starved and stimulated or treated with various cell cycle inhibitors. 
Immunoprecipitation using 6E10 antibody was performed on both the media (for secreted 
Aβ) and the lysates (for intracellular Aβ) and the results are shown in Figure 5.4.  
                                                 
2 For copyright permissions regarding the use of this work see Appendix B. 
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Figure 5.5.  Aβ generation is altered in a cell cycle-dependent manner.  H4-APP cells 
were synchronized by serum starvation and stimulated with serum containing media 
plus or minus 50 µM olomoucine, 20 µM roscovitine, 5 µg/mL aphidicolin, 100 ng/mL 
nocodazole, 10 µM vinblastine, or 100 ng/mL taxol. Cell culture supernatants (A and 
C) and cell extracts (B and D) were immunoprecipitated and western blotted using 
6E10 antibody. Control was performed similarly to the rest of the samples, except no 
primary antibody was used in immunoprecipitation assay. Cell culture supernatant 
showed a time dependent increase in Aβ generation upon serum stimulation (A and C). 
The extracts showed similar results, which was visible only after longer exposure of 
the blot (D). Panels C and D represent longer exposure of the bottom part of the blots 
shown in A and B to show the Aβ levels in cell extracts. In both the cases roscovitine 
treatment was associated with a decrease in the level of secreted and cellular Aβ. 
Secreted APP was not altered in the supernatant although the level of APP and C-APP 
fragments are increased in the extracts prepared from nocodazole and vinblastine-
arrested cells. Panel E and F show mean percent of Aβ (compared to secreted and full 
length APP) from three independent experiments under different treatment conditions. 
Data that showed significant changes are marked using a star (P < 0.05).  Reprinted 
from Judge, M., et al., Mitosis-specific phosphorylation of amyloid precursor protein 
at threonine 668 leads to its altered processing and association with centrosomes. Mol 
Neurodegener, 2011. 6: p. 80 [1]. 
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Levels of Aβ were higher in cells that had been stimulated with serum for 14 hours or 
longer, i.e. cells that had been cycling long enough to have entered M-phase.  Treatment 
with taxol, a microtubule stabilizing agent that yields a moderately effective M-phase 
block, results in a significant induction in Aβ levels in the media, while treatment with 
nocodazole or vinblastine, microtubule destabilizing agents which result in a more potent 
M-phase block, resulted in elevated levels of intracellular Aβ.  This may be indicative of 
a failure of Aβ secretion, potentially due to the microtubule destabilization caused by 
these agents.  Regardless of whether the Aβ was detected extracellularly or 
intracellularly, it appears that Aβ generation is indeed enhanced during M-phase. 
 Roscovitine treatment, interestingly, sharply reduced Aβ production below 
baseline levels.  Roscovitine is an inhibitor of cdk2, cdc2, and cdk5.  As discussed in 
section 5.3, cdc2, when complexed with cyclin B, is capable of phosphorylating APP [3].  
Cdk5 has also been shown to mediate phosphorylation of APP [5].  Prevention of Aβ 
production by inhibition of these specific APP-phosphorylating kinases strongly suggests 
that phosphorylation of APP by cdc2 and/or cdk5 contributes to its processing via the 
amyloidogenic pathway.  In the section that follows, we will discuss evidence from the 
literature that further supports this notion and present a mechanism by which Aβ-
production may be mediated in a cell-cycle dependent manner. 
5.4. Function of APP Phosphorylation 
The functional importance of phosphorylation of APP is not entirely clear.  In 
addition to being mediated by cdc2 and cdk5, APP can also be phosphorylated at 
threonine 668 by c-Jun N-terminal kinase 3 (JNK3) and glycogen synthase kinase 3β 
(GSK3β) [6, 7], Phosphorylation of APP seems to affect its localization, as APP 
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phosphorylation has been shown to induce its localization to nerve terminals and that this 
localization requires kinesin-1 [8], and studies in our own lab have illustrated that during 
mitosis phosphorylated APP localizes to the centrosome [1].  Both of these observations 
strongly suggest that not only is phosphorylation of APP important for regulating the 
subcellular localization of this protein, but suggest that this localization may be mediated 
by interactions between APP and kinesin-1, as kinesin is localized to the spindle poles 
during mitosis and is also a major motor protein responsible for anterograde transport 
along the axon.  Importantly, APP can directly bind to the light chain of kinesin-1, and it 
has been hypothesized that one of APP’s normal functions may be to mediate the 
interaction between kinesin-1 and other cargo molecules [9].3 
Fourteen amino acids away from the threonine-668 site in APP is a YENPTY 
motif, which appears to be vital for the endocytosis of APP.  This region is also important 
for interaction with various other proteins, including Fe65 and Mint family of proteins.  
The phosphorylation of APP at threonine 668 induces a conformational change in the C-
terminal domain that can affect the binding to these interacting proteins.  Blocking the 
interaction of APP with Fe65 results in a shift toward non-amyloidogenic processing 
[10], suggesting that Fe65 binding to APP promotes amyloidogenic processing. 
5.4.1. Phosphorylation and Endocytosis 
Fe65 is known to modulate the endocytosis of both APP and LRP, promoting 
clatherin-mediated endocytosis and internalization of the APP peptide [11].  
Phosphorylation can result in the induction of a conformational change in APP, which 
appears to be mediated by the prolyl isomerase Pin1 [12], inducing a conformational 
                                                 
3 For further discussion of the endogenous function of APP, see section 6.4.3.1. 
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change in APP that negatively affects the binding of Fe65 [13].  Nevertheless, 
phosphorylated APP is also known to be enriched in endocytic fractions [4].  This 
suggests that binding of Fe65 and interaction of the Fe65/APP complex with LRP 
promotes endocytosis, and phosphorylation of APP may occur within the endocytic 
pathway.  This in turn may have implications for the processing of APP.   
5.4.2. Phosphorylation and APP Processing 
The endocytosis of APP is thought to contribute to its amyloidogenic processing 
as BACE1 and APP colocalize in endosomal compartments [4].  In hippocampal neurons 
in the AD brain, colocalization of phosphorylated APP and BACE is seen in large 
vesicular bodies that also colocalize with endosomal markers [4].  Further, 
phosphorylated APP cofractionates with BACE1 and endosomal markers, suggesting that 
these proteins are indeed colocalized in the endosomes.  Importantly, C-terminal 
fragments generated by β-secretase cleavage (i.e. C99) are preferentially phosphorylated 
as compared to their α-secretase generated counterparts (i.e. C83), suggesting that 
phosphorylation is associated with an increased propensity for APP to be processed via 
an amyloidogenic pathway [4].  Preventing APP phosphorylation by inhibition of kinases 
or mutation of the threonine 668 site also prevents generation of Aβ, strongly suggesting 
that the phosphorylation of APP contributes to its amyloidogenic processing [4]  
It’s also important to note that the phosphorylation of APP at threonine 668 
renders APP less likely to be cleaved by caspases at the C-terminus, which occurs at 
aspartate 664 [14].  The notion that this phosphorylation is associated with increased 
amyloidogenesis, but is incompatable with caspase cleavage, is consistent with the 
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observations we presented in Chapter 3, suggesting that caspase activation is associated 
with decreased amyloidogenic processing of APP. 
5.5. Endocytosis and APP Processing 
Obviously, APP can only be cleaved by β-secretase when it is in the same 
subcellular compartment as the secretase.  The finding that both β-secretase and APP, and 
significantly phosphorylated APP, colocalize to endosomes strongly suggests that both 
phosphorylation and endocytosis are important for amyloidogenic processing.  While it 
has long been suggested that endocytosis is a requirement for Aβ generation, the specific 
compartment in which Aβ is generated has been a matter of some debate, with candidate 
organelles including the endoplasmic reticulum, trans-golgi network, early and late 
endosomes, and lysosomes having been recognized as sites.   
A recent study elegantly assessed this question using an siRNA approach to 
inhibit various proteins along the endosomal sorting pathway to determine where Aβ is 
generated.  Three different endosomal sorting complexes required for transport (ESCRT) 
were targeted:  ESCRT-0, which mediates sorting of endosomal cargoes, ESCRT-I, 
important for membrane budding, ESCRT-III, important for fusion with multivesicular 
bodies, and VPS4, required for the breakdown of the ESCRT-III complex to allow 
recycling and continuation of the process.  Blocking each of these steps in the endosomal 
pathway allowed these investigators to isolate where in the pathway Aβ was being 
produced [15].  Knockdown of components of the ESCRT-0 and ESCRT-II complexes 
resulted in retention of APP in the early endosomes and a decrease in Aβ production, 
while depletion of components of the ESCRT-III pathway and/or VPS4 results in 
accumulation of APP in the trans-golgi network and increased APP processing and 
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generation of Aβ. [15].  This suggests that APP, which is endocytosed and recycled to the 
trans-golgi network is processed in an amyloidogenic fashion from an endocytosed pool. 
5.6. Cell Cycle Dependent Production of Aβ 
The data we presented earlier in this chapter suggest that APP is phosphorylated 
in a cell cycle dependent manner.  The phosphorylation of APP seems to be associated 
with its localization within the endosomes, suggesting that either APP phosphorylation 
enhances the endocytosis of APP or that APP is phosphorylated within endocytic 
vesicles.  Regardless of the specific compartment in which the phosphorylation occurs, it 
is evident from the literature that APP which is endocytosed and recycled to the trans-
golgi network tends to be processed via an amyloidogenic pathway, and that C-terminal 
fragments generated during amyloidogenic processing of APP tend to be phosphorylated 
at threonine 668.   
The evidence that suggests that phosphorylation of APP is associated with 
enhanced amyloidogenic processing is consistent with the observations from our 
laboratory that (1) cells undergoing mitosis have elevated levels of phosphorylated APP 
and (2) arrest of cells in mitosis is associated with an increase in the production of Aβ.  
Taken together, we can conclude that mitosis-dependent APP phosphorylation 
contributes to increased Aβ generation during mitosis. 
5.7. Conclusions 
From the data presented and evidence from the literature presented in this chapter, 
we can begin to draw together a mechanism for mitotic generation of Aβ.  APP can be 
endocytosed via clathrin-mediated endocytosis, likely associated with interaction with 
Fe65 and LRP.  If the cell is undergoing mitosis, the presence of cyclin B-cdc2 
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complexes result in elevated phosphorylation of APP.  Outside of mitosis this 
phosphorylation may be mediated by other kinases, but the enhancement of this 
processing is likely mediated by cdc2-dependent phosphorylation.  
While it is not clear whether phosphorylation of APP has a direct effect on the 
propensity of APP to be endocytosed or whether APP is phosphorylated after 
endocytosis, it does appear that the phosphorylation of APP can mediate its further 
interactions and downstream processing. Following phosphorylation, the prolyl-
isomerase Pin1 can induce isomerization of APP, which results in decreased 
amyloidogenic processing.  In the disease condition, however, Pin1 levels are reduced, 
and thus isomerization of APP is reduced.  This allows APP, now localized in the 
endocytic compartment and phosphorylated, to be cleaved in an amyloidogenic manner.  
The enhancement of phosphorylation of APP, occurring during mitosis, is therefore 
associated with an increase in amyloidogenic processing. 
Given that isomerization of phosphorylated APP by Pin1 can act as a switch, 
shuttling APP towards non-amyloidogenic processing when isomerization occurs and 
allowing amyloidogenic processing to occur if isomerization does not occur, increasing 
the function of Pin1 may be of great benefit in preventing amyloid production.  
Interestingly, Pin1 can also mediate conformational changes in tau, making it a very 
attractive target to curb disease progression. 
5.8. Closing Remarks 
In these experiments, we have investigated the role of cell-cycle dependent 
changes on amyloidogenic processing.  Our broad working hypothesis, as presented in 
chapter 2, suggests that Aβ can induce cell cycle activation and p53 dependent apoptosis 
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in cells.  Given the fact that AD pathology tends to spread through the brain, we tested 
the hypothesis that p53-dependent apoptosis and/or cell cycle activation may induce 
amyloidogenesis, establishing a feed-forward process and allowing pathology to 
propagate through the brain.   
While our experiments regarding p53-dependent apoptosis did not support this 
hypothesis, as Aβ levels were decreased during p53-dependent apoptosis, we did find that 
p53-dependent apoptosis was associated with a decrease in the production of sAPPα, 
likely due to ectodomain cleavage of APP.  The experiments presented in this chapter, 
however, do suggest that aberrant cell cycle activation can induce the phosphorylation of 
APP, and that this phosphorylation of APP is associated with enhanced amyloidogenic 
processing. 
Therefore, while our hypothesis that the p53-dependent apoptosis may increase 
Aβ production and allow propagation of Aβ through the brain is not supported, the 
hypothesis that aberrant cell-cycle activation may lead to amyloidogenesis is supported 
by the evidence.  Together, with the literature suggesting that Aβ can elicit aberrant cell-
cycle related events, this suggests that Aβ can induce cell cycle activation, which in turn 
results in mitotic phosphorylation of APP and increased processing of APP via an 
amyloidogenic pathway.  The cell-cycle related increase in amyloidogenic processing 
results in an increase in secreted Aβ in the local microenvironment, which may result in 
the induction of aberrant cell cycle related events in surrounding cells.   
Importantly, in addition to APP, tau is also heavily phosphorylated during mitosis 
– the same epitopes on tau that are phosphorylated during AD are phosphorylated during 
mitosis.  The intracellular phosphorylation of tau leads to the formation of paired helical 
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filaments and ultimately neurofibrillary tangles, impairing intracellular trafficking and 
metabolism and contributing to the demise of the cell.  Thus, Aβ, in inducing aberrant 
cell cycle entry, leads to both the phosphorylation of tau and an increase in the generation 
of Aβ, allowing disease pathology to spread through the brain.  The implications of this 
research for our understanding of disease pathogenesis and disease treatment will be 
further discussed in the next chapter. 
Interestingly, recent studies have suggested that, in addition to its apparent 
position downstream of amyloid in disease pathogenesis, phosphorylated tau can also be 
transferred transynaptically, allowing tau pathology to spread from one region to another 
directly through the neuronal circuitry.  This presents an alternative mechanism by which 
tau pathology, at least, may propogate through the brain.  This alternative mechanism, 
will also be discussed further in the next and final chapter.   
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CHAPTER 6:  DISCUSSION 
 
 
 
6.1. Chapter Synopsis 
In the preceding chapters, we have discussed the hypothesis that Aβ production 
induces cell cycle activation and p53-dependent apoptosis, and have explored the 
possibility that changes in APP processing associated with p53-dependent apoptosis and 
cell cycle activation may result in increased generation of Aβ.  In chapter 3, we presented 
our evidence suggesting that in our apoptosis model there is no increase in Aβ 
production; rather we see a decrease in the levels of both Aβ and sAPPα.  P53-dependent 
apoptosis was, however, associated with an increase in formation of a ~25 kDa protein 
fragments which appears to involve cleavage by group II caspases, and show some 
preference for caspase-7 over caspase-3.   
Although our model of apoptosis was not associated with an increase in the 
production of Aβ, we did see an increase in the production of Aβ occurring in a cell cycle 
dependent manner, with a decrease in APP levels and processing during S-phase and an 
increase in APP levels and processing during M-phase.  Our lab and others have reported 
that the phosphorylation of APP occurs in a cell cycle dependent manner, and the same 
phase associated with APP phosphorylation were also associated with an increase in Aβ 
production.  This is consistent with findings from other laboratories, which suggest that 
APP, and the BACE-cleaved fragment C99, colocalize with BACE in the endocytic 
compartment both colocalizes with BACE1 and tend to be phosphorylated. 
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In the current chapter, we will discuss the significance of our findings regarding 
classical processing of APP, in particular the decrease in sAPPα, as well as discuss 
findings from others regarding amyloidogenic processing in other models of cell death.  
We will also review the literature regarding alternative processing of APP in the near 
extracellular domain.  We will then discuss the relative importance of cell cycle 
dependent changes in APP, focusing on changes related to APP phosphorylation, 
including interactions with the APP binding protein Fe65. 
Next, we will discuss the implications of our work on the anatomical cascade 
hypothesis, as well as an alternative explanation of propogation of pathology that stems 
from some recent literature regarding direct transmission to misfolded tau across the 
synapse.  Finally, we will discuss the implications of this research for the treatment of 
AD. 
6.2. Classical Processing of APP During Apoptosis 
In chapter 3, we presented our findings regarding secretase-mediated processing 
of APP in cells undergoing p53-dependent apoptosis following CPT treatment.  We 
found that, with regard to the C-terminal fragments, C83 levels were maintained while 
C99 levels were reduced.  This was seen during γ-secretase inhibition, which allowed us 
both to isolate the α- and β- processing steps and account for the possibility of increased 
γ-secretase activity described in the literature [1].  This would suggest that α-mediated 
proteolysis is increased while β-mediated proteolysis is decreased.  Immunoprecipitation 
of the media for secreted fragments, however, revealed a decrease in both Aβ and sAPPα.  
The decrease in Aβ is consistent with the finding that C99 production is decreased.  The 
decrease in sAPPα levels observed, however, seemed initially to be inconsistent with the 
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finding that C83 production was sustained.  However, our findings presented in chapter 4 
provide evidence for increased cleavage of APP within the near ectodomain in cells 
undergoing apoptosis.  This would preclude the production of sAPPα, and explains why, 
though C83 levels are maintained, sAPPα levels are reduced. 
6.2.1. Significance of a Decrease in sAPPα 
The reduction in the levels of sAPPα are of particular significance because sAPPα 
is known to be neurotrophic.  sAPPα has been shown to inhibit calcium currents and 
increase potassium currents, stabilizing membrane potentials and protecting cells against 
excitotocity [2-4].  Importantly, sAPPα is released from neurons in an activity-dependent 
manner [5], suggesting that it may play a role in buffering depolarizing currents, for 
example dampening post-synaptic responses in response to high-frequency stimulation.  
A decrease in the levels of sAPPα may, therefore, leave cells vulnerable to excitotoxic 
stress due to impaired calcium homeostasis.   
In addition to these neuroprotective effects, sAPPα also appears to be capable of 
enhancing memory.  Intracerebroventricular sAPPα administration in rats has been shown 
to result in enhanced learning and memory performance, increased long-term 
potentiation, and enhanced N-methyl D-aspartate receptor mediated currents [6].  Further, 
sAPPα can increase the proliferation rates of neural stem cells, promote neurite 
outgrowth, and lead to increased synaptogenesis [5, 7].  A decrease in sAPPα, as is 
observed during p53-dependent apoptosis, may therefore result in memory impairment 
even when the production of Aβ is reduced.   
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6.2.2. Results From Other Models of Apoptosis 
While we do not observe an increase in the levels of Aβ in cells undergoing p53-
dependent apoptosis, other laboratories have seen increases in Aβ production in cells 
undergoing this type of apoptosis as well as in cells undergoing cell death by other 
means.  Jin et al. reported increases in Aβ production in cells undergoing p53-dependent 
apoptosis using CPT treatment of HEK cells overexpressing APP with the Swedish 
mutation and BACE1 [1].  The most significant differences between their study and ours 
is the overexpression of BACE1 and use of mutant APP, as well as the duration of 
treatment with the DNA-damaging agents, which at 24-48 hours is much longer than our 
treatments.  In our experience and in our cell lines, treatment for that duration results in a 
completely dead culture, while treatment for 3-6 hours allows us to measure things 
occurring during the apoptotic process.  Together with the overexpression of BACE1, this 
suggests that the increase in Aβ production observed in the Jin et al. study [1] may be a 
consequence of colocalization of high levels of BACE1 and APPSwe in apoptotic bodies, 
and not necessarily indicative of processing occurring while the cells are in the process of 
undergoing apoptosis. 
Beyond p53-dependent apoptosis, other forms of cell death have been shown to 
be associated with increased production of Aβ.  For example, induction of apoptosis 
using the staurosporine in a murine neuroblastoma cell line (N2a cells) has been shown to 
increase Aβ production nearly 3-fold, with the majority of this Aβ accumulating 
intracellularly in the endoplasmic reticulum [8].  In PC12 cells, staurosporine treatment 
results in an approximately 2.5 fold increase in the secretion of Aβ [9]. Interestingly, in 
serum free conditions this increase can be inhibited using a selective ERK inhibitor, 
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while in the presence of serum the same ERK inhibitor does not inhibit staurosporine-
induced Aβ secretion.  A similar pattern is observed with respect to the phosphorylation 
of APP, with P-APP detected in each condition where Aβ is produced.  This suggests that 
in non-cycling cells, phosphorylation of APP is mediated by ERK, whereas in cycling 
cells this phosphorylation is mediated by other kinases, such as cdc2/cyclin B. 
Trophic factor deprivation has also been shown to elicit caspase-6 dependent 
degeneration of axons and neuronal death.  This appears to involve the death receptor 
DR6, which can act upstream of caspase-6.  Importantly sAPPβ has been shown to be a 
ligand for DR6, and growth factor deprivation is also associated with an increase in the 
production of sAPPβ.  This suggests that trophic factor deprivation can result in enhanced 
amyloidogenic processing of APP, which can lead to DR6 mediated cell death in 
surrounding neurons [10]. 
In CPT-dependent apoptosis, cells are most stressed as they enter into S-phase, 
and do not progress into M-phase, where cell cycle dependent phosphorylation occurs.  
This explains why, in the case of CPT-induced apoptosis, an increase in Aβ is not seen, 
whereas in staurosporine-induced apoptosis an increase in Aβ generation is observed.  
This suggests that the phosphorylation of APP, by ERK or cyclin-dependent kinases, is 
necessary for Aβ generation, even during apoptosis. 
6.3. Alternative Processing of APP During Apoptosis 
In addition to processing by secretases, APP can also be cleaved by many 
different proteases, including caspases, calpains, and matrix metalloproteases.  In chapter 
4, we presented evidence of a caspase-dependent proteolytic event which results in the 
formation of fragments of APP that is detected at ~25 kDa.  The size and 
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immunoreactivity of the fragments suggests that they are generated by cleavage of APP 
in the near ectodomain.  While there have been a few reports of evidence of proteolysis in 
this region, the specifics of the proteolysis in this region are not well understood. 
6.3.1. MMP-Dependent Cleavage of APP 
One important study isolated cerebrospinal fluid from AD patients and control 
individuals and performed proteomic analysis by mass spectrometry, identifying 11 novel 
fragments, seven of which were upregulated in AD[11].  One of these fragments, called -
45 to 15 in this study, would result from cleavage by α-secretase at the C-terminus of the 
fragment and by cleavage at SFGA*D626.  This same site was also identified in a study in 
which various membrane-type matrix metalloproteases (MT-MMPs) were overexpressed 
along with APP.  In this study, the C-terminal fragment resulting from this cleavage was 
detectable in the cell lysates, by western blot on a 12% SDS-PAGE gel, and seemed to 
run much smaller than the molecular weight predicted for a peptide containing the entire 
C-terminus from this site onwards.  However, only the N-terminus of these fragments 
were sequenced, leaving the possibility that this peptide is also cleaved somewhere 
towards the C-terminus, perhaps at the γ-secretase site [12].   
6.3.2. ST101-Dependent Cleavage of APP 
In addition to cleavage by MMPs, a recent study from Frank Laferla’s laboratory 
has described a proteolytic fragment generated from APP that is approximately 17 kDa in 
size and generated in the presence of the azaindolizinone derivative spiro[imidazo[1,2-
s]pyridine-3,2-idan]-2(3H)-one (ST101).  While the protease responsible for the 
generation of this fragment is not clear, it does appear that it involves a proteolytic event 
approximately 150 amino acids from the C-terminus, within the range of the 11 sites 
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identified from the cerebrospinal fluid of patients [11, 13].  Perhaps the most interesting 
feature of this particular proteolytic event is the fact that it is associated with a decrease 
in the production of Aβ, despite the fact that the C-terminal fragment resulting from this 
cleavage contains both the β- and γ-secretase sites.  This suggests that the proteolytic 
event that generates this fragment is somehow incompatible with amyloidogenic 
processing, through mechanisms that are as yet unclear.   
6.3.3. Caspase Cleavage of APP 
The work we have presented in chapter 4 focused on the caspase-dependent 
generation of a ~25 kDa proteolytic fragment during CPT-induced apoptosis.  Caspase 
cleavage of APP has been described at three distinct sites along the APP peptide – two at 
the N-terminus and one at the C-terminus [14].  The C-terminal caspase site is by far the 
most studied, and cleavage of APP at this site generates a 31 amino acid fragment from 
the C-terminus of APP, C31, which has been shown to be neurotoxic [15].  This cleavage 
has been attributed to cleavage by caspase-3, -6, and -8 [14, 16, 17].  Our studies further 
suggest that caspase-7 may also be involved in the cleavage of APP, as shRNA to 
caspase-7 decreases the production of the ~25 kDa fragment even in the presence of 
increased levels of cleaved caspase-3. 
6.3.3.1. Inflammation and Activation of Caspase-7 
Although few studies have investigated the importance of caspase-7 activation in 
AD, the few that have suggest that caspase-7 activation occurs relatively early in the 
disease process.  Studies in individuals with an increased risk for developing AD (those 
with a Clinical Dementia Rating of 0.5) show up-regulation of caspase-1 and caspase-7 in 
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the entorhinal cortex [18], one of the first areas affected in AD.  TgCRND8 mice show 
activation of caspase-7, but not caspase-3, in the vicinity of Aβ plaques [19]. 
 Caspase-1, also known as interleukin converting enzyme, is associated with 
neuroinflammation and has been shown to cleave and activate caspase-7 in vitro [20].  
The upregulation of caspase-1 in AD is well established, and it is thought to contribute to 
neurodegeneration via activation of interleukin-1β, a proinflammatory cytokine which is 
also elevated in AD and is considered to be fundamental to the inflammatory state of the 
AD brain [21]. 
The upregulation of both caspase-1 (interleukin converting enzyme) and 
mediation of inflammation by IL-1β strongly suggest that active caspase-1 is an 
important player in mediating the inflammatory response in AD.  Caspase-1 can activate 
both caspase-3 and caspase-7, and caspase-7 and caspase-1 mRNA levels are increased 
early in the disease process.  Taken together, this suggests that caspase-7 may be active 
early in the disease process, and may be related to neuroinflammation through regulation 
by caspase-1.  
6.3.3.1.1. Caspase-3 vs. Caspase-7 
Caspase-3 and caspase-7 are often thought of as largely homologous caspases, 
and indeed a large number of substrates can be cleaved by both caspases.  However, 
caspase-3 knockout is typically embryonically lethal, with gross abnormalities in brain 
development due to decreased apoptosis, caspase-7 knockout mice are viable.  This 
suggests that apoptotic functions may be largely mediated by caspase-3, which is further 
supported by the fact that caspase-7 appears to be more specific and caspase-3 more 
promiscuous [22].  Importantly, caspase-3 is also more effective than caspase-7 in 
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cleaving caspase-6, -9, and -2, which may provide a positive feedback loop promoting 
apoptosis.  This implies that, compared to caspase-3, caspase-7 is less effective as an 
executioner caspase.  Importantly, it also appears that caspase-3 and caspase-7 may 
localize to different cellular compartments, as caspase-7 has been identified in endosomal 
structures, while caspase-3 has not [23]. 
Our data using shRNA suggests that caspase-7 may have alternative functions 
outside of apoptosis, as stable knockdown of caspase-7 using shRNA resulted in the 
activation of caspase-3, the closest homologous caspase.  This was not seen in transient 
transfections, suggesting that cells which have decreased levels of caspase-7 for an 
extended period of time compensate for the loss of the enzyme by upregulating cleaved 
caspase-3.  It has been suggested that caspases may play an important role in synaptic 
plasticity, cell survival, proliferation, and differentiation [24], but non-apoptotic functions 
of caspases are not well understood and warrant further investigation. 
6.3.3.2. Caspase Cleavage of Tau 
While we have focused primarily on the cleavage of APP, it should be noted that 
tau can also be cleaved by caspases at aspartate 421.  Caspase-cleaved tau has been 
observed in the AD brain.  Cleaved tau is especially prone to aggregation, serve as a seed 
for aggregation of tau in vitro.  Cleaved tau rapidly adopts an MC1 conformation – so 
named for the conformation-specific antibody used to detect it – a conformation 
associated with the early stages of neurofibrillary tangle formation [For review, see 25].  
This cleavage can be performed by caspase-3, but can also be performed by other 
caspases including caspase-1, -6, -7, and -8 [25].  Interestingly, TgCRND8, which as 
mentioned above showed activation of caspase-7 but not caspase-3, show both cleavage 
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of tau and MC1 staining.  Caspase-7, MC1, and cleaved tau staining were reduced by 
treatment with the caspase inhibitor Q-VD-OPh, suggesting that caspase inhibition may 
be beneficial for modulation of tau pathology in vivo [19]. 
6.4. Cell Cycle Dependent Processing of APP 
In addition to investigating caspase related cleavages of APP, we also discussed 
the regulation of APP during cell cycle.  During S-phase, expression and processing of 
APP are reduced and phosphorylation of APP is not detected, however during M-phase 
expression, phosphorylation, and amyloidogenic processing of APP are all increased.  
This suggests that aberrant cell cycle activation may play a role in amyloid production. 
6.4.1. “Mitosis” in Neurons 
The expression of cell cycle related proteins, including cyclins D, A, B, and E, 
cdks 1, 2, 4, and 5, in neurons even in normal brain suggest non-canonical roles for these 
proteins in the brain [26].  However, the sequential activation of cell cycle related 
proteins observed in the entorhinal cortex and the dentate gyrus in response to excitotoxic 
damage to the hippocampus suggest that excitotoxic stress may induce aberrant cell cycle 
re-entry.  Markers of the G1/S phase of cell cycle are present in the brains of mice after 
excitotoxic injury, and shortly after the increase in G1/S markers an increase in PHF-1 
and APP are observed.  An increase in cyclin B is also observed in these brains [27].  The 
increase in PHF-1 may be due to upregulation of cyclin B, which along with its binding 
partner cdc2 has been shown to induce phosphorylation of tau.  We have observed an 
increase in APP expression and phosphorylation associated with M-phase as well.   
While it is clear that neurons can express markers of cell cycle and that there is 
some functional activity of these proteins, neurons are not entirely capable of mitosis due 
190 
to their complex cytoarchitecture.  Mitosis involves the reorganization of the cytoskeleton 
to form the mitotic spindle.  In order to reorganize microtubules, microtubule stabilizing 
proteins dissociate from microtubules, allowing their break-down.  Tau is one of these 
proteins, and in order to dissociate from the microtubules tau is phosphorylated.  The 
same epitopes that are phosphorylated on tau to induce its dissociation from the 
microtubules during mitosis are the epitopes phosphorylated during AD – antibodies 
raised against paired helical filaments isolated using the antibody Alz50 from brain 
homogenates from AD patients (specifically the TG and MC series of antibodies created 
in the laboratory of Peter Davies) stain cells in mitosis.   
The notion of “mitosis” in neurons is somewhat controversial, as neurons are 
generally thought of as post-mitotic and incapable of cell division.  Although this is 
almost certainly the case, the aberrant activation of proteins associated with mitosis, 
which may well result from sequential activation of proteins associated with earlier 
phases of the cell cycle and deregulation of cell cycle checkpoints, could still occur.  The 
phosphorylation of tau during mitosis can induce reorganization of microtubules and in 
neurons cause microtubule destabilization, impaired trafficking, and proteosomal stress 
resulting in the formation of neurofibrillary tangles. 
6.4.2. Cell Cycle Dependent Phosphorylation of APP 
Beyond the phosphorylation of tau, the phosphorylation of APP also occurs 
during mitosis.  Suzuki et al. first described mitosis-specific phosphorylation of APP in 
1994 and showed that in vitro purified cdc2/cyclin B complex, a cell cycle dependent 
kinase complex active during M-phase, could phosphorylate a synthetic peptide 
consisting of APP645-694 as well as APP663-676 [28].  The latter peptide contains only one 
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threonine, suggesting the residue phosphorylated was threonine 668.  Subsequent work 
from Li-Huei Tsai’s laboratory identified elevated levels of P-APPT668 in the brains of 
AD patients, which appeared to colocolize with BACE1 in the endosomes, suggesting 
that the phosphorylation of APP at threonine 668 may be associated with amyloidogenic 
processing [29]. 
Work from our own laboratory has identified an increase in cell cycle markers 
cyclin D1 and cyclin E as well as phosphorylation of APP in the brains of transgenic 
mice overexpressing human APP and PS1, with animals expressing APP showing 
elevated levels compared to nontransgenic animals and PS/APP animals expressing even 
higher levels.  Staining for phosphorylated APP was also colocalized with phospho-
neurofilament staining with NFH antibody, in the vicinity of plaques, suggesting that 
conditions in the vicinity of Aβ plaques lead to both phosphorylation of APP and neurite 
degeneration.  We also reported that inhibition of cell cycle progression was associated 
with changes in both the phosphorylation status of APP and changes in APP processing, 
where a block at the G1/S transition results in a decrease in APP phosphorylation and 
processing and a block in M-phase results in increase phosphorylation of APP and 
amyloidogenic processing [30].  This is consistent with the observation from other labs, 
which suggest that the phosphorylation of APP is increased in endocytic vesicles, and 
that endocytosis of APP is associated with its amyloidogenic processing. 
6.4.3. Phosphorylation and Interaction with Fe65 
The specific mechanism by which phosphorylation of APP, mitotic or otherwise, 
is associated with endocytosis and increased APP processing is not entirely clear.  
Phosphorylation of APP seems to decrease the association of APP with the adaptor 
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protein Fe65.  APP serves to tether Fe65 to the cell membrane, and the phosphorylation 
of APP blocks the interaction of Fe65 with APP, essentially “liberating” Fe65 from its 
membrane association [31].  This allows Fe65 to be translocated to the nucleus, where it 
can modulate AICD-dependent gene transcription. 
AICD, after cleavage by γ-secretase, translocates to the nucleus and modulate 
gene transcription.  Somewhat paradoxically, it is predominately phosphorylated AICD 
that localizes to the nucleus, and the phosphorylation of AICD seems to be vital for its 
interaction with Fe65 [32].  Fe65, therefore, seems to bind phosphorylated AICD in the 
nucleus, but not phosphorylated APP in the cytoplasm. 
Phosphorylation of APP is associated with increased binding of Pin1, a peptidyl-
prolyl cis-trans isomerase which, when APP is phosphorylated Pin1 converts the peptide 
to a trans conformation.  A loss of Pin1 (and therefore a decrease in the isomerization of 
phosphorylated APP) results in an increase in the production of Aβ [33].  This suggests 
that it may be the isomerization of surface APP, and not phosphorylation per se, that 
results in a decrease in Fe65 binding.  Fe65 appears to form a complex with APP and low 
density lipoprotein receptor-related protein (LRP), and this interaction appears to 
promote the endocytosis of APP and consequent amyloidogenic processing [34].  It is 
reasonable to suggest that the decrease in Pin1 seen in AD may result in decreased 
isomerization of APP, increased association of Fe65 with APP and LRP, increased 
endocytosis of APP, and increased amyloidogenic processing 
6.4.3.1. Reflections on the Function of APP 
APP was identified and named for its role in the production of Aβ, and as such the 
vast majority of research aimed at understanding APP has focused on its proteolysis to 
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the extent that the actual raison d’être for APP has never been entirely clear.  
Structurally, the protein resembles a cell surface receptor – the extracellular domain of 
APP is complex, folding upon itself with many loops for interacting with other proteins.  
There is a single transmembrane domain that tethers it to the membrane, and a rather 
short and indescript intracellular domain known to be involved in trafficking and 
interactions with adaptor proteins.  This structure is consistent with a proposed function 
of APP as a receptor which modulates intracellular signaling through binding interactions 
at the C-terminus.  A number of proteins have been shown to interact with the 
extracellular domain of APP, including Aβ, F-spondin, Netrin-1, and BRI2 [For review, 
see 35].  While it is evident that the APP extracellular domain can interact with various 
proteins, the function of these interactions are still not clear, and the functional role of 
APP as a receptor is still questionable. 
Another potential function of APP is in cell and synaptic adhesion, as the 
extracellular domain, importantly, interacts with matrix proteins and heparin sulfate 
proteoglycans.  Indeed, in our own laboratory we have consistently noticed a qualitative 
difference in the adhesion of cells expressing APP versus those that do not, with APP 
expressing cells adhering more strongly.  Interestingly, APP can also form parallel or 
antiparallel dimers, possibly playing a role in cell-cell adhesion.  This seems to be 
particularly important in modulating synaptic strength [For review, see 35].  Importantly, 
secretion of α-cleaved forms of APP is activity dependent and enhances synaptic 
stability.  The importance of APP in regulating synaptic adhesion and stability certainly 
warrants further investigation. 
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6.5. Anatomical Cascade Hypothesis 
Throughout this text, we have referred to the anatomical cascade hypothesis.  This 
hypothesis serves to bridge the apparent gap between the amyloid cascade hypothesis, 
which has become widely accepted, and the fact that intraneuronal tau pathology follows 
a predictable progression through the brain.  The amyloid cascade hypothesis is strongly 
supported and in fact historically rooted in the genetics of familial AD.  The entirety of 
AD pathology – plaques, neurofibrillary tangles, and neurodegeneration – can and does 
occur with duplication or mutation of APP or with gain-of function mutations to PS1.  
This strongly suggests that the processing of APP into Aβ is paramount for all aspects of 
pathology to occur, and that Aβ lies upstream of tau in the pathogenesis of AD.  
However, Aβ-associated pathology, namely amyloid plaques, are found throughout the 
cortex and, though they increase in number and often become more dense as the disease 
progresses, they do not follow a particular anatomic course through the brain.  Tau 
pathology, on the other hand, does progress in a predictable fashion, following the same 
anatomical course in each patient.  There is somewhat of a dichotomy here – if amyloid 
does indeed lie upstream of tau, and tau follows this progression through the brain, does 
amyloid also follow this progression?  It is clear that the deposition of plaques does not, 
however the specific pathological species of Aβ, which mediates tau pathology, is not the 
plaque but small oligomers.  These small, soluble oligomers do not persist for staining by 
immunohistochemical techniques.  Therefore, while the formation of plaques does not 
progress predictably through the brain the production of amyloid and its small, soluble 
oligomers may. 
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6.5.1. The Anatomical Cascade via Cell Cycle Activation 
We have in this work assessed whether p53-dependent apoptosis or cell cycle 
activation may provide a mechanism by which Aβ produced and secreted from one cell 
may induce Aβ production in anatomically adjacent regions.  Aβ has been shown to 
induce both cell cycle activation and apoptosis, so we isolated each process to assess 
whether Aβ production is altered.  While we did not observe an increase in the production 
of Aβ from cells undergoing p53-dependent apoptosis in our model, we do see an 
increase in the production of Aβ from cells during mitosis.  The schematic presented in 
figure 2.1 has been modified to include these findings and is presented in figure 6.1. 
Importantly, Aβ has been shown to elicit cell cycle activation.  As discussed at 
length in chapter 2, Aβ can induce cell cycle related events, including activation of 
mitogen-activated protein kinase (MAPK) pathways, cyclin D1 expression, cyclin B1 
expression, and Rb phosphorylation.  This induction includes the activation of 
cdc2/cyclin B, which can phosphorylate many intracellular proteins including tau and 
APP.  The phosphorylation of APP has been associated with colocalization of APP and 
BACE1 in AD brain, connecting APP phosphorylation with its amyloidogenic processing 
[29].  Indeed, as presented in chapter 5, in the same conditions we observe 
phosphorylation of APP (namely arrest of cells in M-phase) we observe an increase in 
amyloidogenic processing. 
Taken together, this suggests that Aβ can induce cell cycle activation and that 
cells cycle activation, provided cells get far enough into the cell cycle for mitotic 
phosphorylations to occur, can in turn result in an increase in the production of Aβ.  This 
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Figure 6.1.  Schematic of our findings as they apply to the anatomical cascade 
hypothesis.  As presented in figure 2.1, Aβ has been proposed to act as a mitogenic 
signal, and phosphorylation of tau can occur in a cell cycle dependent manner.  Since 
tau pathology propagates through the brain in a predictable manner and Aβ is 
upstream of tau, we hypothesized that Aβ production may also propagate through the 
brain in a similar fashion. In this schematic, we illustrate that Aβ elicits cell-cycle 
reentry in the cell on the left.  If DNA damage is extensive, cells may undergo p53-
dependent apoptosis.  Our findings suggest that p53 dependent apoptosis is 
associated with a decrease in sAPPα as well as production of a novel caspase 
cleaved proteolytic fragment of APP.  If DNA is not sufficiently damaged or if p53 
is deficient, cells may advance further in the cycle.  Progression of cells into mitosis 
is associated with an increase in the phosphorylation of APP and an increase in the 
production of Aβ which may then affect surrounding cells, allowing pathology to 
propagate through the brain. 
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may occur in cells which either have insufficient DNA damage to enter apoptosis at the 
p53 checkpoint or in cells in which p53 is deficient or mutated.  Since Aβ is secreted, this 
would induce cell cycle activation in cells in the local microenvironment, allowing AD 
pathology to spread through the brain. 
6.5.2. Direct Transmission of Tau Across the Neuronal Synapse 
While our data suggests that the propagation of tau pathology through the brain 
can be explained by cell cycle activation mediated by Aβ secretion, it should be noted 
that recently a more direct explanation of the propagation of tau pathology has emerged.  
Interestingly, and rather surprisingly, the microtubule-associated protein tau has been 
shown to directly spread from one neuron to the next, across the synapse [36-38]. 
In 2012, two important studies were reported of tau pathology spreading from the 
entorhinal cortex to adjacent brain regions.  One study from the laboratory of Karen Duff 
used a mouse with inducible expression of human tau with the P301L mutation (Tg4510 
mice) and crossed these with mice expressing a tetracycline transactivator under the 
neuropsin promoter, which drives the expression of the transgene in the entorhinal cortex.  
They found that in young mice, tau pathology was isolated to the entorhinal cortex, but in 
older mice pathology was found in other structures, including the CA1 region of the 
hippocampus and granule cells of the dentate gyrus.  This suggests that tau may be 
moving from one cell to the next across the synapse [36]. 
One caveat of this studies is the observation of human tau mRNA in cells of the 
dentate gyrus, harvested by laser capture microdissection.  Though the authors suggest 
that due to the sensitivity of PCR for detection of mRNA it is possible that very few of 
the many cells pooled actually express the RNA, they did observe higher levels of human 
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tau mRNA in the dentate gyrus of old animals than in young animals, even in cells that 
did not have positive staining for tau protein [36].  This suggests that it is possible that 
the tetracycline transactivator may be present in these cells and driving the expression of 
tau, and that the effects are mediated by “leakage” of the transactivator transgene rather 
than by tau protein actually making the trans-synaptic “leap”.  
In a separate study from Brad Hyman’s laboratory reported largely similar results 
in a mouse model generated independently but using an identical approach (Tg4510 mice 
crossed with mice expressing a tetracycline transactivator under the neuropsin promoter).  
In this study, they show tau expression in the dentate gyrus but, instead of laser capture 
microdissection, use fluorescence in situ hybridization (FISH) to determine whether tau-
positive cells of the dentate are expressing the transgene or are the recipients of trans-
synaptic transmission of tau.  Importantly, in cells that are positive for human tau protein, 
they do not detect the expression of tau mRNA.  This suggests that the tau protein 
observed in these cells was not expressed by the cells, and instead was expressed in other 
cells (presumably in the entorhinal cortex) and taken up by cells of the dentate [37]. 
Another study from the laboratory of Virginia Lee shows that aggregated tau can 
propagate to adjacent regions.  In this study, synthetic, preformed tangles were injected 
into young PS19 transgenic mice.  These mice typically develop tau pathology at 8-9 
months of age, but in this study 2-3 month old mice were used.  Preformed tangles were 
injected unilaterally into a specific location in the hippocampus, and tau pathology was 
observed in regions of the hippocampus distal to the injection site, including 
contralaterally, and later was observed in other structures including the entorhinal cortex.  
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This suggests that the injected tau can be taken up by neurons, and act as “seeds” for the 
aggregation of misfolded tau in the brains of these mice [38]. 
These studies suggest that misfolded tau can be transferred from one cell to the 
next, and that this misfolded tau could seed the aggregation of tau in the post-synaptic 
cell.  Importantly, phosphorylated tau, associated with exosomes, has been reported in the 
cerebrospinal fluid of AD patients, suggesting that tau transmission could be occurring in 
the human condition.  This present an alternative explanation for the anatomical 
progression of tau pathology that is independent of the induction of phosphorylated tau 
induced by Aβ.  It is possible that both mechanisms work in tandem, with Aβ-inducing 
tau phosphorylation and synaptic transmission providing a seed of misfolded tau that 
allows phospho-tau native to the postsynaptic cells to aggregate into filaments and 
ultimately form tangles. 
6.6. Implications for the Treatment of Alzheimer’s Disease 
In this chapter, as in the rest of this work, many interrelated pathways of AD 
pathogenesis have been presented.  Caspase-mediated cleavage of APP and tau have been 
discussed, and while caspase-mediated cleavage of APP does not seem to modify 
pathology, caspase cleavage of tau results in tau adopting an MC1 configuration and 
makes tau prone to aggregation.  Because caspases are typically thought of as proteases 
involved in the more final stages of cell death, caspase inhibition is generally regarded as 
“too little too late.”  However, the upregulation of caspase-1 and caspase-7, both of 
which are capable of cleaving tau, early in the disease process suggests that these 
proteases may have disease-modifying abilities far earlier than neurodegeneration, and 
that caspase inhibition, such as with Q-VD-OPh, may provide some benefit. In fact, 
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intranasal administration of a caspase-9 inhibitor has been shown to be effective in 
preventing axon loss and neurodegeneration following stroke [39]. 
Our research also strongly implicates cell cycle activation in the pathological 
development of AD.   Inhibition of cell cycle progression, especially at the G1/S 
transition, would likely effectively inhibit cell cycle related phosphorylation of both tau 
and APP, leading to a decrease in amyloid production and tau pathology.  Of course, 
targeting such therapy to neurons may present a technical challenge, and the targeting of 
cell cycle inhibition to neurons would also impede neurogenesis, which is also important 
for memory.  It would take further investigation to determine whether the benefits of cell 
cycle inhibition, with regard to Aβ and tau pathology, would outweigh the risk of 
impaired neurogenesis, and whether or not this would ultimately have a positive or 
negative effect on memory. 
Our work also echoes the work of others in illustrating the apparent importance of 
the phosphorylation of APP in amyloidogenic processing.  This seems to be related to the 
trafficking of APP, though the details of this mechanism, likely involving APP 
interacting proteins like Fe65, are still being elucidated.  The phosphorylation-dependent 
isomerization of APP by Pin1 may be an important means of altering APP endocytosis 
and preventing amyloidogenic processing.  The activity of Pin1 is known to be decreased 
in AD – increasing Pin1-mediated isomerization of APP, or potentially disrupting the 
interaction between APP, adaptor proteins, and LRP, to prevent endocytosis of APP and 
amyloidogenic processing, may also be of significant therapeutic benefit.   
The therapeutic approaches presented here focus primarily on early phases of the 
disease process.  However, the brain is resilient, and disease progression, pathologically, 
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is typically quite advanced before patients present with symptoms.  Approaches focused 
on removing Aβ in patients with moderate to advanced AD using immunotherapy, though 
successful in mice, have shown little benefit.  Similarly, approaches involving secretase 
inhibition have also shown little benefit in clinical trials, though treatment in these cases 
may have simply begun too late for a drug that acts on processes that are important early 
in disease progression.  The approaches presented here, which, like secretase inhibition, 
also focus on Aβ production, would be best used early in the disease process.   
Therefore, the early detection of AD is paramount in order for these treatment 
approaches to be viable.  Fortunately, recent advances in the detection of AD pathology, 
especially early amyloid deposition, will allow for early detection of disease onset – 
provided patients are actually imaged, likely on at least two occasions to determine if 
pathology is increasing.  Since memory problems are often imperceptible while amyloid 
production and deposition is steadily increasing, it may be necessary for imaging to be 
done on a prophylactic basis.  At the present time this is cost-prohibitive, but now that the 
technology has already been developed it is possible that cost will, over the next decade 
or so, drop significantly and potentially allow for routine amyloid imaging in a clinical 
setting for early detection of AD.  The early detection of AD will ultimately broaden the 
possibilities for therapeutic intervention. 
6.7. Final Remarks 
In this chapter, we have discussed the implications of our findings in the context 
of the literature and related these findings to our original hypothesis.  The broader goal of 
this work was to determine whether cell cycle activation or p53-dependent apoptosis 
might provide a mechanism for the spread of AD pathology through the brain. While we 
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found no evidence to support the role of p53-dependent apoptosis in this processs, we did 
find that phosphorylation of APP and amyloidogenic processing was increased in cells 
undergoing mitosis.  Since Aβ has been shown to induce cell cycle activation, and our 
data suggest that cell cycle activation can, in turn, increase the production of Aβ, we 
believe that the Aβ-dependent induction of aberrant cell cycle related events in AD could 
serve as a driving force in the spread of AD pathology.   
The cell cycle dependent increase in Aβ production is directly correlated with the 
mitotic phosphorylation of APP, consistent with the literature that suggests that 
phosphorylation of APP is associated with its amyloidogenic processing.  This strongly 
implicates kinases capable of phosphorylating APP as central to the disease process.  
Many of the kinases involved in the mitotic phosphorylation of APP are also capable of 
phosphorylating tau, suggesting that aberrant cell cycle reentry could drive both Aβ and 
tau pathology.  It is important to note that misfolded tau appears to be capable of 
spreading from cell to cell within the neuronal network, directly across the synapse.  The 
presence of this misfolded tau may act as a seed for the aggregation of phosphorylated 
tau, allowing pathology to spread in a prion-like manner. 
The results presented here suggest various treatment approaches, including 
caspase and/or kinase inhibition to prevent the misfolding of tau (as caspase-cleaved and 
phosphorylated tau has a strong propensity for aggregation), cell cycle inhibition, or 
disruption of APP endocytosis to decrease amyloidogenic processing.  All of these 
approaches intercede rather early in the disease process, making early detection of AD 
vital to treatment development.  Continued research into these potential approaches 
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coupled with earlier detection of the disease process could lead to promising treatments 
for early stage Alzheimer’s disease. 
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Appendix A:  Materials and Methods 
Ethics Statement 
 Studies involving animals (primary neuronal culture) were done in accordance 
with the rules and regulations set forth by the University of South Florida's Institutional 
Animal Care and Use Committee (IACUC). This specific study was approved by the 
University’s IACUC committee (Protocol # R3758). Timed pregnant rats at E14 were 
purchased from Harlan and cared for by the well-established animal care facility at 
University of South Florida (USF), which is accredited by the American Association of 
Laboratory Animal Care (AALAC).  
 
Cell Culture and Drug Treatment 
 Cortical neurons were cultured following published protocols [1]. Somnasol 
solution was diluted 1:10 in normal saline and pregnant rats were anaesthetized with 0.7 
mL diluted solution to collect embryos at E18.  Embryos were removed and brains 
collected and placed in a dissecting solution until trituration.  500 mL of dissecting 
solution was prepared by combining 25 mL of buffered saline (137 mM NaCl, 5.4 mM 
KCl, 0.17 mM Na2HPO4, and 0.22 mM KH2PO4) with 14 mL 9.9 mM Hepes, along with 
3 g glucose, and 7.5 g sucrose and adjusting the pH to 7.4 using 1N NaOH.  The volume 
was brought to 500 mL with ddH2O and filter sterilized. After removal of the meninges 
embryonic brains were minced in dissecting solution and placed in 0.25% trypsin for 5 
minutes (Life Technologies).  Trypsin was removed by centrifugation at 500 x g for 5 
minutes and tissue fragments placed back in dissection solution, where they were 
triturated by passing through firepolished Pasteur pipettes of three different diameters in  
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decreasing order. Dissociated cells were centrifuged at 500 x g and resuspended in 
neurobasal media (Life Technologies) containing B27 supplement and plated onto poly-
L-lysine coated culture plates at a density of approximately 200,000 cells/cm2. Cells were 
cultured for seven days prior to initiation of experiments. Apoptosis in neurons was 
induced by treatment with 10 µM camptothecin for 12-24 hours (CPT, Sigma) [2-4]. For 
experiments involving caspase inhibition, neurons were pretreated  with group II caspase 
inhibitor zDEVD-FMK or the broad-spectrum caspase inhibitor zVAD-FMK (R&D 
Systems, Minneapolis, MN) at 10-20 µM concentrations for 1 hour prior to the addition 
of CPT.  Caspase inhibitors were present for the entire duration of CPT treatment. 
Samples were then collected for western blot analysis as described below[1, 5]. 
 H4 cells expressing APP (H4-APP) were a kind gift from Dr. Todd Golde (Mayo 
Clinic, Jacksonville, FL). The generation of this cell line has been previously described 
[6]. These cells were cultured in “normal growth media” consisting of Opti-MEM (Life 
Technologies) media containing 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1% 
penicillin/streptomycin (Life Technologies), and 50 µg/ml hygromycin (Life 
Technologies) until they reached 60% confluency. For experiments involving serum 
deprivation, cells were rinsed twice with DPBS (Fisher) and cultured in DMEM (Life 
Technologies) containing penicillin/streptomycin with no serum for 48 hours. After 48 
hours, cells were rinsed with DPBS twice more before adding the appropriate treatment 
media. For experiments involving caspase inhibition, cells were cultured in 10-20 µM 
zDEVD-FMK or zVAD-FMK in normal growth media for one hour prior to induction of  
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apoptosis. Cells were then exposed to 10 µM CPT for indicated time periods in the 
presence and absence of inhibitors. 
 
Lysate Preparation 
 After treatment for the indicated times, cells were scraped into culture media, and 
pelleted by centrifugation at 500 x g for five minutes at 4°C. Pellets were washed three 
times in ice cold PBS (spinning at 500 x g for five minutes at 4°C between washes) and 
resuspended in ice cold RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, and 50 mM Tris (pH 8.0)) containing protease inhibitors (1 
mM PMSF, 1 mM NaVO4, 1 mM NaF, and one Complete Mini protease inhibitor tablet 
per 10 mL (Roche Applied Science, Indianapolis, IN)). Cells were lysed by sonication 
using a sonic dismembranator (Thermo Fisher Scientific) on setting 6 for 10 seconds on 
ice and the insoluble fraction separated by high-speed centrifugation (20800 x g for 15 
min at 4°C). The supernatant containing soluble proteins was retained and analyzed for 
total protein content using a Bradford or bicinchoninic assay (BCA) (Thermo Fisher 
Scientific, Rockford, IL) following the manufacturer’s protocol.  Samples containing 
equal amounts of protein were prepared by dilution in 1xRIPA.  For loading onto western 
blots, samples were prepared in Laemmli sample buffer (4x stock consisting of 200 mM 
Tris pH 6.8,  40% v/v glycerol, 50 mM EDTA, 8% SDS, 20% β-mercaptoethanol, and 
0.02% bromophenol blue) or Tricine Sample Buffer (Life Technologies) depending on 
gel for polyacrylamide gel electrophoresis (PAGE) and western blot analysis. 
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Western Blot Analysis 
 Western blot analyses were performed following established protocols [1, 5]. 
Briefly, samples were separated by PAGE on either 10-20% tricine (Life Technologies) 
or 15% tris-glycine mini gels at 90-125 V.  15% Tris-glycine gels were casted using a 
solution of 15% acrylamide, 375 mM Tris (pH8,8), 0.1% SDS, 0.1% APS, and 0.0008% 
TEMED (resolving gel), with the stacking gel containing 5% acrylamide, 125 mM tris 
pH 6.8, 0.1% SDS, 0.1% APS, and 0.001% TEMED.  For running buffer, 1x tricine 
running buffer (Life Technologies) was used for 10-20% tricine gels and 1x tris-glycine 
running buffer (14.4 g glycine, 2.9 g Tris, and 1 g SDS per liter in ddH2O) was used for 
tris-glycine gels. Molecular weight markers used were either SeeBlue Plus 2 (Life 
Technologies) or Precision Plus Dual Xtra (BioRad). Proteins were transferred to 0.1 or 
0.2 µm nitrocellulose membranes using the XCell SureLock mini-blotting module 
(Invitrogen) at 30 V for two hours.  Transfer buffer contained 14.4 g glycine and 2.9 g 
tris base per liter in ddH2O.  The membranes that were used for detection of Aβ were 
boiled in PBS for five minutes prior to blocking non-specific binding. Membranes were 
blocked in 5% non-fat dry milk prepared in TBS for one hour prior to probing with 
primary antibodies overnight. Primary antibodies were diluted in a solution of 3% bovine 
serum albumin (BSA) in TBS containing 0.02% sodium azide and included p53 (1:1000, 
Cell Signaling) , caspase-3 (1:500, Cell Signaling), caspase-7 (1:500, Cell Signaling), 
cleaved caspase-3 (1:500, Cell Signaling), cleaved caspase-7 (1:500, Cell Signaling), 
poly ADP-ribose polymerase (PARP) (1:500, Cell Signaling), 6E10 (1:1000, Covance), 
caspase-cleaved APP (1:4000, Millipore), and β-actin (1:7000, Sigma). Blots were  
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washed four times in PBS containing 0.05% Tween-20 and probed with appropriate 
secondary antibodies, either goat anti-mouse or donkey anti-rabbit IgG conjugated to 
horseradish peroxidase (both diluted at 1:5000, Thermo Fisher Scientific), for two hours 
at room temperature. After further washes, blots were developed using Super Signal West 
Pico Enhanced Chemiluminescence (ECL) Substrate (Thermo Fisher Scientific). Images 
captured on autoradiography films (MidSci) were scanned for digitization using a flatbed 
scanner, and densitometric analysis was performed using ImageJ, image processing and 
analysis tool.  
 
Immunoprecipitation 
 Equal number of cells were plated onto 100 mm tissue culture dishes and cultured 
for 24 hours, after which point cells were treated with fresh growth medium in the 
absence or presence of CPT (10 µM) for different time periods. At each time point, tissue 
culture supernatant from each culture dish was collected and spun down at 1,000 rpm for 
five minutes to remove cell debris. The supernatants were subjected to 
immunoprecipitation analysis for secreted APP and Aβ following established protocols 
[5]. Briefly, the tissue culture supernatants were incubated with two µl of 6E10 antibody 
for two hours at 4oC by end-over-end rotation. 30 µl (packed volume) of protein G 
sepharose beads (GE Healthcare) were added, and incubation continued overnight. A 
sample incubated with no primary antibody and only protein G sepharose beads served as 
control for the immunoprecipitation experiments. At the end of the incubation beads were 
collected by centrifugation at 6,000 rpm for 30 seconds and washed with RIPA lysis   
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buffer (described above) four times. The pelleted beads were boiled with Laemmli 
sample buffer (described above) to solubilize the antigen-antibody complex, separated on 
a 10-20 % tris-glycine gel, and western blot analysis performed as described above using 
6E10 antibody to determine secreted levels of APP and Aβ. 
 
Immunostaining Analyses 
 Cells were plated in eight-chamber slides (Nunc) coated with poly-L-lysine 
(Sigma). After the indicated treatments, cells were fixed with 4% para-formaldehyde and 
immunostaining analysis was performed following established protocols [1, 5, 7]. Slides 
were washed with PBS and blocked with 1% BSA in TBS containing 0.1% Triton X-100 
for one hour. Slides were then incubated overnight at 4°C in primary antibodies diluted in 
blocking buffer which included 6E10 (1:500, Covance), cleaved caspase-3 (1:250, Cell 
Signaling), cleaved caspase-7 (1:250, Cell Signaling), and MAP2 (1:1000, Abcam). 
Following incubation, slides were washed four times with PBS for five minutes per wash 
and incubated with secondary antibodies (goat anti-mouse AlexaFluor 488 (1:1000, Life 
Technologies) and goat anti-Rabbit AlexaFluor 594 (1:4000, Life Technologies)) for two 
hours in the dark. Slides were then washed twice, counterstained with 1 µg/mL Hoechst 
stain (Sigma) diluted in PBS for five minutes, and washed thrice more before 
coverslipping using Fluorogel (Electron Microscopy Sciences). Stained cells were 
visualized using a Zeiss Imager.Z1 microscope and analyzed using AxioVision Rel 4.6.3 
software.  
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Flow Cytometry 
 Cells were lifted using 0.05% trypsin/EDTA (Life Technologies) for two to three 
minutes, followed by neutralization of trypsin using normal growth media. Cells were 
pelleted by centrifugation at 500 x g for five minutes at 4°C and pellets washed with PBS 
twice, centrifuging at 500 x g for five minutes at 4°C between washes. Pelleted cells were 
resuspended in one part PBS and fixed by adding nine parts ice cold 70% ethanol, added 
drop-wise while vortexing at a low speed. Fixed cells were stored at -20°C for no more 
than one week before analysis. Fixed cells were pelleted by centrifugation at 200 x g for 
five minutes and washed twice with PBS. Cells were then resuspended in staining 
solution containing 5 µg/mL propidium iodide, 0.1% Triton X-100, and RNaseA in TBS 
and incubated at room temperature for 45 minutes. Samples characterizing apoptosis in 
H4-APP cells were then analyzed using a BD LSR II flow cytometer. Results were 
modeled for cell cycle progression and apoptosis using ModFit LT. Samples involving 
caspase inhibitors were analyzed using an AccuriC6 cytometer with CFlow Plus analysis 
software.  
 
shRNA Knockdown of Caspases 
 Four different shRNA clones to both human caspase-3 and caspase-7 in pGFP-V-
RS vector (TG305638) were obtained from Origene Technologies  and transfected into 
H4-APP cells using Turbofectin 8.0 transfection reagent (Origene Technologies) 
following the manufacturer’s protocol. Since these plasmids allow expression of GFP by 
a CMV promoter, the transfection efficiency could be verified by analyzing the cells for  
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GFP expression using a Zeiss Observer.A1 inverted microscope with fluorescence 
capabilities. Down-regulation of the corresponding caspases was verified by western blot 
analysis using caspase-3 and caspase-7 antibodies prior to using these cells for CPT 
treatment. An empty vector and a scrambled non-effective shRNA-containing vector 
were used as controls in transfection studies. 
 
PS-APP Tissue Processing 
Ten month old PS-APP mice were anaesthetized with 0.5 mL of a 1:10 dilution of 
SomnaSol in normal saline and transcardially perfused with normal saline.  Brains were 
harvested and one hemisphere homogenized in RIPA lysis buffer (described above).  
After homogenization, proteins were extracted by high speed centrifugation.  (20800 x g 
for 15 min at 4°C) and the resulting supernatents analyzed by western blot as described 
above.  The other hemisphere was fixed with 4% paraformaldehyde, and cryoprotected 
by incubation in increasing concentrations of sucrose – 10%, 20%, then 30%.  Tissue was 
transferred into the next highest concentration of sucrose after 24 hours or when the 
tissue sank to the bottom of the container.  Tissue was then sectioned into 25 µm 
sections, and mounted onto Colorfrost Plus slides (Fisher) for immunohistochemical 
analysis as described above. 
 
Statistical Analyses 
 Experiments involving time courses with CPT were analyzed using a two-way 
ANOVA (time and treatment). shRNA and inhibitor effects were analyzed with a one-  
217 
Appendix A:  Materials and Methods (continued) 
way ANOVA when CPT was not present and a two-way ANOVA in the presence of 
CPT. All post-hoc analyses were done using the Tukey-Kramer method.  Any 
comparisons involving only two conditions were assessed using a student’s t-test.  All 
statistical analyses were performed using NCSS-PASS. 
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 Dr. Agi M. Thomson 
 Editor in Chief, Alfomine 
 Pala, India 686574. 
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Copyright permissions for: 
 
Judge, M., et al., Mitosis-specific phosphorylation of amyloid precursor protein at 
threonine 668 leads to its altered processing and association with centrosomes. Mol 
Neurodegener, 2011. 6: p. 80. 
 
AND  
 
Fiorelli, T., L. Kirouac, and J. Padmanabhan, Altered processing of amyloid precursor 
protein in cells undergoing apoptosis. PLoS One, 2013. 8(2): p. e57979. 
 
These works are open access under the BioMed Central Open Access License agreement 
and Creative Commons Public License, respectively.  As such, any user is granted the 
right to “reproduce the Work, to incorporate the Work into one or more Collective 
Works, and to reproduce the Work as incorporated in the Collective Works, or to create 
and reproduce Derivative Works” as outlined in the Creative Commons Attribution 
License, which is identical to the BioMed Central Open Access License provided in the 
next pages. 
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License 
 
THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS OF THIS 
CREATIVE COMMONS PUBLIC LICENSE ("CCPL" OR "LICENSE"). THE WORK 
IS PROTECTED BY COPYRIGHT AND/OR OTHER APPLICABLE LAW. ANY USE 
OF THE WORK OTHER THAN AS AUTHORIZED UNDER THIS LICENSE OR 
COPYRIGHT LAW IS PROHIBITED. 
 
BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU ACCEPT 
AND AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE. THE 
LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE IN 
CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS AND 
CONDITIONS. 
 
1. Definitions 
a. "Collective Work" means a work, such as a periodical issue, anthology or 
encyclopedia, in which the Work in its entirety in unmodified form, along with a 
number of other contributions, constituting separate and independent works in 
themselves, are assembled into a collective whole. A work that constitutes a 
Collective Work will not be considered a Derivative Work (as defined below) for 
the purposes of this License. 
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b. "Derivative Work" means a work based upon the Work or upon the Work and 
other pre-existing works, such as a translation, musical arrangement, 
dramatization, fictionalization, motion picture version, sound recording, art 
reproduction, abridgment, condensation, or any other form in which the Work 
may be recast, transformed, or adapted, except that a work that constitutes a 
Collective Work will not be considered a Derivative Work for the purpose of this 
License. For the avoidance of doubt, where the Work is a musical composition or 
sound recording, the synchronization of the Work in timed-relation with a moving 
image ("synching") will be considered a Derivative Work for the purpose of this 
License. 
c. "Licensor" means the individual or entity that offers the Work under the terms of 
this License. 
d. "Original Author" means the individual or entity who created the Work. 
e. "Work" means the copyrightable work of authorship offered under the terms of 
this License. 
f. "You" means an individual or entity exercising rights under this License who has 
not previously violated the terms of this License with respect to the Work, or who 
has received express permission from the Licensor to exercise rights under this 
License despite a previous violation. 
2. Fair Use Rights. Nothing in this license is intended to reduce, limit, or restrict any 
rights arising from fair use, first sale or other limitations on the exclusive rights of the 
copyright owner under copyright law or other applicable laws. 
226 
Appendix B:  Copyright Permissions (continued) 
3. License Grant. Subject to the terms and conditions of this License, Licensor hereby 
grants You a worldwide, royalty-free, non-exclusive, perpetual (for the duration of the 
applicable copyright) license to exercise the rights in the Work as stated below: 
a. to reproduce the Work, to incorporate the Work into one or more Collective 
Works, and to reproduce the Work as incorporated in the Collective Works; 
b. to create and reproduce Derivative Works; 
c. to distribute copies or phonorecords of, display publicly, perform publicly, and 
perform publicly by means of a digital audio transmission the Work including as 
incorporated in Collective Works; 
d. to distribute copies or phonorecords of, display publicly, perform publicly, and 
perform publicly by means of a digital audio transmission Derivative Works. 
e. For the avoidance of doubt, where the work is a musical composition: 
i. Performance Royalties Under Blanket Licenses. Licensor waives the 
exclusive right to collect, whether individually or via a performance rights 
society (e.g. ASCAP, BMI, SESAC), royalties for the public performance 
or public digital performance (e.g. webcast) of the Work. 
ii. Mechanical Rights and Statutory Royalties. Licensor waives the 
exclusive right to collect, whether individually or via a music rights 
agency or designated agent (e.g. Harry Fox Agency), royalties for any 
phonorecord You create from the Work ("cover version") and distribute, 
subject to the compulsory license created by 17 USC Section 115 of the 
US Copyright Act (or the equivalent in other jurisdictions). 
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f. Webcasting Rights and Statutory Royalties. For the avoidance of doubt, where 
the Work is a sound recording, Licensor waives the exclusive right to collect, 
whether individually or via a performance-rights society (e.g. SoundExchange), 
royalties for the public digital performance (e.g. webcast) of the Work, subject to 
the compulsory license created by 17 USC Section 114 of the US Copyright Act 
(or the equivalent in other jurisdictions). 
The above rights may be exercised in all media and formats whether now known or 
hereafter devised. The above rights include the right to make such modifications as are 
technically necessary to exercise the rights in other media and formats. All rights not 
expressly granted by Licensor are hereby reserved. 
4. Restrictions.The license granted in Section 3 above is expressly made subject to and 
limited by the following restrictions: 
a. You may distribute, publicly display, publicly perform, or publicly 
digitally perform the Work only under the terms of this License, and You must 
include a copy of, or the Uniform Resource Identifier for, this License with every 
copy or phonorecord of the Work You distribute, publicly display, publicly 
perform, or publicly digitally perform. You may not offer or impose any terms on 
the Work that alter or restrict the terms of this License or the recipients' exercise 
of the rights granted hereunder. You may not sublicense the Work. You must 
keep intact all notices that refer to this License and to the disclaimer of 
warranties. You may not distribute, publicly display, publicly perform, or publicly 
digitally perform the Work with any technological measures that control access or  
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use of the Work in a manner inconsistent with the terms of this License 
Agreement. The above applies to the Work as incorporated in a Collective Work, 
but this does not require the Collective Work apart from the Work itself to be 
made subject to the terms of this License. If You create a Collective Work, upon 
notice from any Licensor You must, to the extent practicable, remove from the 
Collective Work any credit as required by clause 4(b), as requested. If You create 
a Derivative Work, upon notice from any Licensor You must, to the extent 
practicable, remove from the Derivative Work any credit as required by clause 
4(b), as requested. 
b. If you distribute, publicly display, publicly perform, or publicly digitally perform 
the Work or any Derivative Works or Collective Works, You must keep intact all 
copyright notices for the Work and provide, reasonable to the medium or means 
You are utilizing: (i) the name of the Original Author (or pseudonym, if 
applicable) if supplied, and/or (ii) if the Original Author and/or Licensor 
designate another party or parties (e.g. a sponsor institute, publishing entity, 
journal) for attribution in Licensor's copyright notice, terms of service or by other 
reasonable means, the name of such party or parties; the title of the Work if 
supplied; to the extent reasonably practicable, the Uniform Resource Identifier, if 
any, that Licensor specifies to be associated with the Work, unless such URI does 
not refer to the copyright notice or licensing information for the Work; and in the 
case of a Derivative Work, a credit identifying the use of the Work in the 
Derivative Work (e.g., "French translation of the Work by Original Author," or  
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"Screenplay based on original Work by Original Author"). Such credit may be 
implemented in any reasonable manner; provided, however, that in the case of a 
Derivative Work or Collective Work, at a minimum such credit will appear where 
any other comparable authorship credit appears and in a manner at least as 
prominent as such other comparable authorship credit. 
5. Representations, Warranties and Disclaimer 
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING, 
LICENSOR OFFERS THE WORK AS-IS AND MAKES NO REPRESENTATIONS 
OR WARRANTIES OF ANY KIND CONCERNING THE WORK, EXPRESS, 
IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, 
WARRANTIES OF TITLE, MERCHANTIBILITY, FITNESS FOR A PARTICULAR 
PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER 
DEFECTS, ACCURACY, OR THE PRESENCE OF ABSENCE OF ERRORS, 
WHETHER OR NOT DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW 
THE EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY NOT 
APPLY TO YOU. 
6. Limitation on Liability. EXCEPT TO THE EXTENT REQUIRED BY 
APPLICABLE LAW, IN NO EVENT WILL LICENSOR BE LIABLE TO YOU ON 
ANY LEGAL THEORY FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, 
PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF THIS LICENSE OR 
THE USE OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGES. 
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7. Termination 
a. This License and the rights granted hereunder will terminate automatically upon 
any breach by You of the terms of this License. Individuals or entities who have 
received Derivative Works or Collective Works from You under this License, 
however, will not have their licenses terminated provided such individuals or 
entities remain in full compliance with those licenses. Sections 1, 2, 5, 6, 7, and 8 
will survive any termination of this License. 
b. Subject to the above terms and conditions, the license granted here is perpetual 
(for the duration of the applicable copyright in the Work). Notwithstanding the 
above, Licensor reserves the right to release the Work under different license 
terms or to stop distributing the Work at any time; provided, however that any 
such election will not serve to withdraw this License (or any other license that has 
been, or is required to be, granted under the terms of this License), and this 
License will continue in full force and effect unless terminated as stated above. 
 
8. Miscellaneous 
a. Each time You distribute or publicly digitally perform the Work or a Collective 
Work, the Licensor offers to the recipient a license to the Work on the same terms 
and conditions as the license granted to You under this License. 
b. Each time You distribute or publicly digitally perform a Derivative Work, 
Licensor offers to the recipient a license to the original Work on the same terms 
and conditions as the license granted to You under this License. 
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c. If any provision of this License is invalid or unenforceable under applicable law, 
it shall not affect the validity or enforceability of the remainder of the terms of 
this License, and without further action by the parties to this agreement, such 
provision shall be reformed to the minimum extent necessary to make such 
provision valid and enforceable. 
 
d. No term or provision of this License shall be deemed waived and no breach 
consented to unless such waiver or consent shall be in writing and signed by the 
party to be charged with such waiver or consent. 
e. This License constitutes the entire agreement between the parties with respect to 
the Work licensed here. There are no understandings, agreements or 
representations with respect to the Work not specified here. Licensor shall not be 
bound by any additional provisions that may appear in any communication from 
You. This License may not be modified without the mutual written agreement of 
the Licensor and You. 
Creative Commons is not a party to this License, and makes no warranty whatsoever in 
connection with the Work. Creative Commons will not be liable to You or any party on 
any legal theory for any damages whatsoever, including without limitation any general, 
special, incidental or consequential damages arising in connection to this license. 
Notwithstanding the foregoing two (2) sentences, if Creative Commons has expressly 
identified itself as the Licensor hereunder, it shall have all rights and obligations of 
Licensor. 
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Except for the limited purpose of indicating to the public that the Work is licensed under 
the CCPL, neither party will use the trademark "Creative Commons" or any related 
trademark or logo of Creative Commons without the prior written consent of Creative 
Commons. Any permitted use will be in compliance with Creative Commons' then-
current trademark usage guidelines, as may be published on its website or otherwise 
made available upon request from time to time. 
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